{
  "symbol": "LIXTW",
  "company_name": "Lixte Biotechnology Holdings Inc WT",
  "ir_website": "https://ir.lixte.com/",
  "structured_data": [
    {
      "section_name": "Latest News",
      "links": [
        {
          "title": "LIXTE Receives U.S. Patent Issue Notification for Immune Oncology",
          "url": "https://ir.lixte.com/news-events/press-releases/detail/116/lixte-receives-u-s-patent-issue-notification-for-immune-oncology",
          "content": "[Skip to main content](#mainContent) [Skip to section navigation](#sectionNav) [Skip to footer](#Footer)\n\n[ ![LIXTE-logo-web-horz-black-190](https://d1io3yog0oux5.cloudfront.net/_dc5892ca2b7f04aeb93d8225863bdadd/lixte/files/theme/site-files/20231127/lixte.com/wp-content/uploads/2023/10/LIXTE-logo-web-horz-black-190.png#763) ](https://lixte.com)\n\n  * [Our Approach](https://lixte.com)\n  * [Science](https://lixte.com/science/)\n  * [Programs](https://lixte.com/programs/)\n  * [Team](https://lixte.com/team/)\n  * [Investor Information](https://ir.lixte.com)\n\n\n\n[ ](#)\n\n✕\n\n  * [Our Approach](https://lixte.com)\n  * [Science](https://lixte.com/science/)\n  * [Programs](https://lixte.com/programs/)\n  * [Team](https://lixte.com/team/)\n  * [Investor Information](https://ir.lixte.com)\n\n\n\nPress Releases\n\n# LIXTE Receives U.S. Patent Issue Notification for Immune Oncology\n\nSeptember 04, 2024 8:30 am EDT  [ Download as PDF ](https://d1io3yog0oux5.cloudfront.net/_dc5892ca2b7f04aeb93d8225863bdadd/lixte/news/2024-09-04_LIXTE_Receives_U_S_Patent_Issue_Notification_for_116.pdf \"PDF: LIXTE Receives U.S. Patent Issue Notification for Immune Oncology\")\n\n**Patent Covers Combining LIXTE’s LB-100****with Various Innovative Cancer Immunotherapies**\n\n**PASADENA, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) --**[LIXTE Biotechnology Holdings, Inc](https://www.globenewswire.com/Tracker?data=4y1a9Fo_zQ09sZC3b-J5lbSqVqCYMT89_Q7TPZafQrOS7Z0kLQ83mb1YxUsKApY-mpe-Uz1aKarWbAZRpaze7gXD5JdAzqZJtau_9j3Dzos= \"Opens in a new window\"). (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent application number 16/467,721, titled, \"Oxabicycloheptanes for Modulation of Immune Response,” for combining the Company’s LB-100 compound with various innovative cancer immunotherapies.\n\n“The patent award further bolsters LIXTE’s existing intellectual property portfolio and underscores the Company’s commitment to pioneering research and delivering innovative solutions to patients battling cancer,” said Bas van der Baan, LIXTE’s Chief Executive Officer.\n\nLIXTE is developing its first-in-class lead clinical PP2A inhibitor, LB-100, as a potentiator of cancer immunotherapy. The Company is testing LB-100 in combination with immunotherapies in clinical trials at the Netherlands Cancer Institute (NKI) in Amsterdam and at The University of Texas MD Anderson Cancer Center in Houston.\n\nAt NKI, LIXTE is providing LB-100, and F. Hoffmann-La Roche Ltd. (“Roche”) is providing atezolizumab (Tecentriq®, a PD-L1 inhibitor) through the imCORE Network as part of a new clinical trial in immune therapy for unresponsive (MSI Low) metastatic colon cancer. The imCORE Network is an academic-industry collaboration that aims to accelerate cancer immunotherapy research through institution-sponsored studies\n\nA second trial underway at MD Anderson is testing the combination of LB-100 and GSK’s dostarlimab-gxly for the treatment of ovarian clear cell carcinoma (OCCC).\n\nThe new patent award follows the signing of an exclusive patent license agreement earlier this year between LIXTE and the National Institute of Neurological Disorders and Stroke (NINDS) and National Cancer Institute (NCI), each a component of the National Institute of Health (NIH). The agreement provides LIXTE with an opportunity to explore and develop novel combination therapies that can potentially transform the landscape of cancer treatment.\n\n**About LIXTE Biotechnology Holdings, Inc.**\n\n[LIXTE Biotechnology Holdings, Inc](https://www.globenewswire.com/Tracker?data=4y1a9Fo_zQ09sZC3b-J5lbSqVqCYMT89_Q7TPZafQrPVp3CdX6sq2HyrR-zjRzyU4z2q-GjVTNE4PnudfonvXB3ATgOhLc3Kr5UVdpvZL9z0EOpvLrNGvrQ-rGDpgaYHvL-BI0mgr_SKtt-HNV9fX4HhmhBnyrutXlQMVtuJ0lnAQiW3vAsFEPNzhMjB0FpyaEE_sML_-1t969cDUKFqRzEgIMl3h_DZgVFoyb5BDzAvk9iCHIprX8N3IH8zML9yRLEwlr9_ohtMNO_l59a_0g== \"Opens in a new window\"). is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see [www.lixte.com](https://www.globenewswire.com/Tracker?data=Ajice8JGtyUzfnXDZeoC2yq6pb4k9tS_ADkMiV8i0e_9VVe_BqDfrA-g3ZdS35V3P9R2C26O_g4xR4TR4RLolMkTdUUYXx9M77eMjgSoQvmoa4MAAKystnuun99VcWYYqA_L_EdfQuJPoW_zPr8-4BpD6oJwgjo9U24FBIwXlgY8db1A9XmBfhkPL6EHARearsUi-nz2VCu69L0dhhmY9S7PfdsmlUBd5RW7bCpplwE= \"Opens in a new window\")), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.\n\nLIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for colon, ovarian, and sarcoma cancers. Additional information about LIXTE can be found at [www.lixte.com](https://www.globenewswire.com/Tracker?data=Ajice8JGtyUzfnXDZeoC218lhvI8nZyj5MTfwYLoU9l7iTItGDNWrnGc8Cq908ejdyu7T4OFEo40Q_Pt4A_G2Xy3cOjXCyKtRvNIBsJxaUGkM3Bmo91Wn_rEVoutIcjAD-56qPewZi6_B2JObmstRrE4qtUrRUulveKtXpVV-P9KEgQb9QJ6-YQc6hOBogL--JTNBKHHRBUJPf6v-W3d5wKGN3e85dc03HbhpAGpNms= \"Opens in a new window\").\n\n**Forward-Looking Statement Disclaimer**\n\nThis announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company’s ability to obtain and maintain compliance with Nasdaq’s continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as \"intend,\" anticipate,\" \"believe,\" \"estimate,\" \"potential(ly),\" \"continue,\" \"forecast,\" \"predict,\" \"plan,\" \"may,\" \"will,\" \"could,\" \"would,\" \"should,\" \"expect\" or the negative of such terms or other comparable terminology.\n\nThe Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.\n\nReaders are urged to read the risk factors set forth in the Company’s filings with the United States Securities and Exchange Commission at [https://www.sec.gov](https://www.globenewswire.com/Tracker?data=8YgB03ZP9UWFFIaxi-ys-CnRa_aWdkZqQqZV7LYThvdKcVvBqcBXsTmvtu196zRrTJKb0-m2Y9B2UL7cutu82Q== \"Opens in a new window\"). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.\n\n**For more information about LIXTE, Contact:**[info@lixte.com](https://www.globenewswire.com/Tracker?data=VoCvYlOejmsR-u2FZvcxVRVKJBLBpJcXCv3GRJxC2lfO9c_3eiHjy5FjtAXciQWJG7A7QTvONIMmJerpbe8CEg== \"Opens in a new window\")General Phone: (631) 830-7092; Investor Phone: (888) 289-5533\n\nor\n\nPondelWilkinson Inc. Investor Relations [pwinvestor@pondel.com](https://www.globenewswire.com/Tracker?data=0dfASMx1Ecb2QABQPU2LtThNflgTegnEp9xOSZrtNxKg8I_i1r5iJZqhCi5TpqsQ_ZkOtL1AJ4TiRV4rfs63jBzhWvVtcCRhT2KY1KYW6mg= \"Opens in a new window\")Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962\n\n[![Primary Logo](https://ml.globenewswire.com/media/7e828ef4-6c8f-4c94-b376-4e3749530fba/small/logo-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/7e828ef4-6c8f-4c94-b376-4e3749530fba)\n\nSource: Lixte Biotechnology Holdings, Inc. \n\nReleased September 4, 2024\n\n  * [emailEmail Alerts](/news-events/email-alerts)\n  * [location_cityCompany Profile](/company-information)\n  * [contact_pageContacts](/company-information/contacts)\n  * [rss_feedRSS News Feed](https://ir.lixte.com/news-events/press-releases/rss \"Opens in a new window\")\n  * [account_treeSitemap](/sitemap)\n\n\n"
        },
        {
          "title": "First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company",
          "url": "https://ir.lixte.com/news-events/press-releases/detail/115/first-patient-dosed-with-lixtes-lb-100-in-new-clinical-trial-to-treat-colorectal-cancer-collaborating-with-nki-supported-by-major-pharma-company",
          "content": "[Skip to main content](#mainContent) [Skip to section navigation](#sectionNav) [Skip to footer](#Footer)\n\n[ ![LIXTE-logo-web-horz-black-190](https://d1io3yog0oux5.cloudfront.net/_dc5892ca2b7f04aeb93d8225863bdadd/lixte/files/theme/site-files/20231127/lixte.com/wp-content/uploads/2023/10/LIXTE-logo-web-horz-black-190.png#763) ](https://lixte.com)\n\n  * [Our Approach](https://lixte.com)\n  * [Science](https://lixte.com/science/)\n  * [Programs](https://lixte.com/programs/)\n  * [Team](https://lixte.com/team/)\n  * [Investor Information](https://ir.lixte.com)\n\n\n\n[ ](#)\n\n✕\n\n  * [Our Approach](https://lixte.com)\n  * [Science](https://lixte.com/science/)\n  * [Programs](https://lixte.com/programs/)\n  * [Team](https://lixte.com/team/)\n  * [Investor Information](https://ir.lixte.com)\n\n\n\nPress Releases\n\n# First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company\n\nAugust 26, 2024 8:30 am EDT  [ Download as PDF ](https://d1io3yog0oux5.cloudfront.net/_dc5892ca2b7f04aeb93d8225863bdadd/lixte/news/2024-08-26_First_Patient_Dosed_with_LIXTE_s_LB_100_in_New_115.pdf \"PDF: First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company\")\n\n**PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) --**[LIXTE Biotechnology Holdings, Inc.](https://www.globenewswire.com/Tracker?data=26rbpwfCjin-dbpjJ0A1NBKqmhN5Xgt30Cj29nHOzF_qEq2DtZLQ0YD3o1pA3mSFtAw5igbZeYLeeN1snVt0piYEycJWnHEnB-LQkelJ4pc= \"Opens in a new window\") (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer Institute (NKI) and supported by F. Hoffmann-La Roche Ltd. (“Roche”) for treatment of unresponsive (MSI Low) metastatic colorectal cancer.\n\nAs part of the clinical trial ([NCT06012734, clinicaltrials.gov](https://www.globenewswire.com/Tracker?data=n6oMi-aQJw7l07ZPGnRB1_WhitohrSSNTAbun0HtJ_h6VqL52xzKLEe-ooid5pPHDruvjJyiepc9m8zbLXo7GoNG-I5VHT36gQlS544t31dJhBVHh03TlzE-Wnk6fYV67R9MbI_xFZnLOmqch5aD0g== \"Opens in a new window\")), LIXTE is providing its lead compound, LB-100, and Roche is providing atezolizumab (Tecentriq ®, a PDL1 inhibitor) through the imCORE Network, a global academic-industry partnership that aims to accelerate cancer immunotherapy research through institution-sponsored studies.\n\n“Our objective with this trial is to bring immunotherapy as an effective treatment option to approximately 85 percent of all colorectal cancer patients, who thus far have not been responsive to traditional protocols,” said Neeltje Steeghs, M.D., Ph.D., medical oncologist at NKI.\n\nBas van der Baan, LIXTE’s Chief Executive Officer, said, “We are pleased to begin this important trial, which is being funded by Roche. This is the second recent clinical trial combining LB-100 with immunotherapy that is funded by a major pharmaceutical company, following the start of a clinical trial earlier this year with GSK for treatment of clear cell ovarian cancer.”\n\n**About LIXTE Biotechnology Holdings, Inc.**\n\n[LIXTE Biotechnology Holdings, Inc](https://www.globenewswire.com/Tracker?data=26rbpwfCjin-dbpjJ0A1NBKqmhN5Xgt30Cj29nHOzF-Su-DHWS1rhdqI8UcXh8ZHO3g_LMaMhk-VDe4aXo4xOaYPJuuPv7hAr-PjARHDpT8HcPletH6pNOPJ4QNrJiIHAH1m8ApwfQYA0CPWACeI8zR_D_5ushCGyL1mv_cJD-jlwC5bQ0A_GDn5-7V_9ngye4W5NhIOmBKOnkVJjtD7ee_Mn3niSgp5Cq_vTAcEgsOf0zlH94Pgi0F43OCjAPZko7ZkEOiVVb5kx4k5Z-Jr8g== \"Opens in a new window\"). is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see [www.lixte.com](https://www.globenewswire.com/Tracker?data=VX26RQ72jpo8g-0OvWD5yLFS9lHvAY6Ki4h9Zpby_ZtNseo8huywqUvRalSEQnlk-t-2WRmGri1lR19cddpm1UzT5BQ80fSuOhOFaQL9iqbP0xQdObI4jzQua8v8AxLtsTY7Q4Kuk7AM_5VnW5E8Ywy0_XPETNg5a1DbSgFMrZXamgbDx3KCcLXxC0RG-8t6pU72RnLKYBp4M7j51Lf9bUCu3_kYY-3KSwhNHgL2ykA= \"Opens in a new window\")), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.\n\nLIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for colorectal, ovarian and sarcoma cancers. Additional information about LIXTE can be found at [www.lixte.com](https://www.globenewswire.com/Tracker?data=VX26RQ72jpo8g-0OvWD5yIfnpy70V3NZalgstACc-RnELUdng8dk1_1vNLV-IcNM5GDdmq4EGyhTk_c1cHPlds1mKSgzR3EIEbdT82yEFk9UZzHmbBlB3ncqKBi28CTIGsOA64dhzIFEy7vwSzpbtLnS_5Clj3NIzc0W-n-zysANhrE4djrpmQoo2Fht-5yOtmXbxca5HwGgGWTKtoealhLa22xLuqRZMCzGIwKMSnE= \"Opens in a new window\").\n\n**Forward-Looking Statement Disclaimer**\n\nThis announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company’s ability to obtain and maintain compliance with Nasdaq’s continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as \"intend,\" anticipate,\" \"believe,\" \"estimate,\" \"potential(ly),\" \"continue,\" \"forecast,\" \"predict,\" \"plan,\" \"may,\" \"will,\" \"could,\" \"would,\" \"should,\" \"expect\" or the negative of such terms or other comparable terminology.\n\nThe Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.\n\nReaders are urged to read the risk factors set forth in the Company’s filings with the United States Securities and Exchange Commission at [https://www.sec.gov](https://www.globenewswire.com/Tracker?data=VzFAgKZahmpPe-wmwmTrXchJuJ5w3oaRaxIH6RaVlogwkOSrTaIDdDUfLS4nednXnBFza84QYoPhrmQN0gT2sedCDRYB0-YKNY1dMGTLEhjgjAq6LmBu9-_TBQgswDaL8C3XU0IwCS7-o1diJZ3H_xY6Q7NQJmAv5cXKXFJW7FeFj_wg2JOYgGvrEBPMs3UMJMc3tkcxVetjbkIINkoNg77JhAiKfzivLUCshrdrVCQ= \"Opens in a new window\"). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.\n\n**For more information about LIXTE, Contact:**[info@lixte.com](https://www.globenewswire.com/Tracker?data=_KSQuKKC-XUIzPWKPqfnPTRpEynairfRBlWw4ET5WZffHVlbGa-ujl9iPrp7aMs4phcVsScpDpJIxva3biCYJw== \"Opens in a new window\")General Phone: (631) 830-7092; Investor Phone: (888) 289-5533\n\nor\n\nPondelWilkinson Inc. Investor Relations [pwinvestor@pondel.com](https://www.globenewswire.com/Tracker?data=H3wef2uDKEJnp41peDfcm9RYxUQ0byk3ysG-gwME-BEfY-mJPSgbg4FcTx2mYryHwcWILIWC9xp90bwKXVFRNe-HFYwq6Ema7Eha_pIDfEo= \"Opens in a new window\")Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962\n\n[![Primary Logo](https://ml.globenewswire.com/media/7e828ef4-6c8f-4c94-b376-4e3749530fba/small/logo-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/7e828ef4-6c8f-4c94-b376-4e3749530fba)\n\nSource: Lixte Biotechnology Holdings, Inc. \n\nReleased August 26, 2024\n\n  * [emailEmail Alerts](/news-events/email-alerts)\n  * [location_cityCompany Profile](/company-information)\n  * [contact_pageContacts](/company-information/contacts)\n  * [rss_feedRSS News Feed](https://ir.lixte.com/news-events/press-releases/rss \"Opens in a new window\")\n  * [account_treeSitemap](/sitemap)\n\n\n"
        },
        {
          "title": "LIXTE Biotechnology Provides Update On Recent Activities and Developments",
          "url": "https://ir.lixte.com/news-events/press-releases/detail/114/lixte-biotechnology-provides-update-on-recent-activities-and-developments",
          "content": "[Skip to main content](#mainContent) [Skip to section navigation](#sectionNav) [Skip to footer](#Footer)\n\n[ ![LIXTE-logo-web-horz-black-190](https://d1io3yog0oux5.cloudfront.net/_dc5892ca2b7f04aeb93d8225863bdadd/lixte/files/theme/site-files/20231127/lixte.com/wp-content/uploads/2023/10/LIXTE-logo-web-horz-black-190.png#763) ](https://lixte.com)\n\n  * [Our Approach](https://lixte.com)\n  * [Science](https://lixte.com/science/)\n  * [Programs](https://lixte.com/programs/)\n  * [Team](https://lixte.com/team/)\n  * [Investor Information](https://ir.lixte.com)\n\n\n\n[ ](#)\n\n✕\n\n  * [Our Approach](https://lixte.com)\n  * [Science](https://lixte.com/science/)\n  * [Programs](https://lixte.com/programs/)\n  * [Team](https://lixte.com/team/)\n  * [Investor Information](https://ir.lixte.com)\n\n\n\nPress Releases\n\n# LIXTE Biotechnology Provides Update On Recent Activities and Developments\n\nAugust 19, 2024 8:30 am EDT  [ Download as PDF ](https://d1io3yog0oux5.cloudfront.net/_dc5892ca2b7f04aeb93d8225863bdadd/lixte/news/2024-08-19_LIXTE_Biotechnology_Provides_Update_On_Recent_114.pdf \"PDF: LIXTE Biotechnology Provides Update On Recent Activities and Developments\")\n\n**_-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial_**** _by Major Pharma Company-_**\n\n**_-Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer-_**\n\n**_-Preclinical Data Published in Journal_**** _EMBO Reports_**** _Shows LB-100_**** _as Potentially Enhancing the Benefit of Immunotherapy-_**\n\n**_-LIXTE to Present at Two Upcoming Investor Conferences-_**\n\n**PASADENA, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) --**[LIXTE Biotechnology Holdings, Inc](https://www.globenewswire.com/Tracker?data=Zqe9twZeYhXQfdglRnCNPtZ4FLKZNOoSgV9MJ1TLYafHbByWiIiOM7LjNIYojNHYs9iE0sCZyqtcENw55jDQCmc-0FEvVVD1r7sQl2hI0o4aJiXGHrB7hr6kzHuvQvvgmOmx_blk3MzwdhAnfkANR171mHkkD6s2d7JIpuP5r-DqNsPvhMvX7xbW0IliG6V0Z_1uOAq2-ebJ1ZEbn-cidUWQMuF7RG1czfoc1mvHPrjhCtvU_iF_GeT6kS2OeJb81NF1FR1S3el3_Ro6fGQSOw== \"Opens in a new window\"). (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company’s recent activities.\n\n“We are encouraged by the growing interest shown by major pharmaceutical companies in our proprietary compound, LB-100, as demonstrated by their support in clinical trial collaborations,” said Bas van der Baan, LIXTE’s President and Chief Executive Officer.\n\n“Highlighting the Company’s recent progress is our new agreement with The Netherlands Cancer Institute, supported by F. Hoffmann- La Roche Ltd. (“Roche”), which is funding the clinical trial in metastatic colorectal cancer and providing atezolizumab (Tecentriq®, a PD-L1 inhibitor) through the imCORE network, an academic industry collaboration that aims at accelerating cancer immunotherapy research through institution sponsored studies. Already underway is a proof-of-concept trial, funded by GSK, of LB-100 plus GSK’s dostarlimab-gxly in ovarian clear cell cancer.\n\n“We are seeing encouraging results in the first phase of our clinical trial to determine appropriate dosing and toxicity for treating advanced soft tissue sarcomas with a combination of LB-100 and standard-of-care chemotherapy and expect to see the data from this first phase early in 2025. We are exploring alternative sites, including international locations, for our small cell lung cancer trial, following termination of that clinical trial at City of Hope due to limited patient accrual,” Mr. van der Baan added.\n\n**Recent Company Highlights:**\n\n  * Collaboration with the Netherlands Cancer Institute, supported by Roche, to conduct a new clinical trial ([NCT06012734 in clinicaltrials.gov](https://classic.clinicaltrials.gov/ct2/show/NCT06012734 \"Opens in a new window\")) in immune therapy for unresponsive (MSI Low) metastatic colorectal cancer. LIXTE is providing its lead compound, LB-100, and Roche will provide atezolizumab (Tecentriq®,a PD-L1 inhibitor). The clinical trial will test recent findings that indicate that LB-100 increases recognition of colorectal cancer cells by the immune system. \n  * [Jan Schellens, M.D., Ph.D., joined LIXTE as Chief Medical Officer effective August 1, 2024](https://ir.lixte.com/news-events/press-releases/detail/108/lixte-biotechnology-holdings-names-distinguished-oncologist-jan-schellens-as-chief-medical-officer \"Opens in a new window\"). Dr. Schellens brings to the Company more than 25 years of clinical experience as a medical oncologist, pharmacologist and clinical pharmacologist, including more than two decades developing and bringing new drugs to market. Co-author of more 900 publications in peer-reviewed scientific journals, Dr. Schellens has held leadership positions at the Netherlands Cancer Institute in Amsterdam and the Dr. Daniel den Hoed Clinic-Erasmus University in Rotterdam. He was professor of clinical pharmacology at Utrecht University in the Netherlands, where he earned his M.D. degree, and he served as a board member and Chief Medical Officer of Byondis B.V. in Nijmegen, Netherlands. Dr. Schellens also earned a Ph.D. degree in Pharmaceutical Sciences from Leiden University in Leiden, Netherlands. \n  * New pre-clinical data in the journal  _EMBO Reports_ shows that LIXTE’s lead compound, LB-100, can turn immunologically “cold” tumors “hot,” potentially enhancing the benefit of immunotherapy. In a paper titled, “[The Phosphatase Inhibitor LB-100 Creates Neoantigens in Colon Cancer Cells through Perturbation of mRNA Splicing](https://www.embopress.org/doi/full/10.1038/s44319-024-00128-3 \"Opens in a new window\"),” the article reported that LIXTE’s collaborators from the Netherlands Cancer Institute have demonstrated that treatment of cancer cells with LB-100 disrupts the normal processing of the mRNA that encodes proteins, thereby generating neo-antigens that are presented to the host immune system. This new mechanism adds to several previous discoveries showing that LB-100 sensitizes cancer cells to immune checkpoint blockade. \n  * LIXTE will present at two upcoming investor conferences: the 2004 Summit Summer 2024 Virtual Conference, August 20, 2024, and the H.C. Wainwright 26th Annual Global Investor Conference, September 9-11, 2024. Both conferences will be virtual presentations. \n\n\n\n**About LIXTE Biotechnology Holdings, Inc.**\n\n[LIXTE Biotechnology Holdings, Inc](https://www.globenewswire.com/Tracker?data=Zqe9twZeYhXQfdglRnCNPtZ4FLKZNOoSgV9MJ1TLYacBq8ke_yLZh38LjKd-FK9RqMO0KEp9tLMQQ2_r5oIyVPPQmjVCBme0b9N9Sc3s9-SXom7LWrDzac3HAtwtyvNDYR4cWjvC0OBuU4R06UjIVLq7zZHhm_xHArguOtyJK8mH54WOs9t7SvQ1YS9jLyI6-QpLDoLJ5Nhu_6VrU3Xm-eKpd3ebsh5nd_prxjOVrTiRjyNLBgyZfbRX-5Jeue7oryDRkqkNfpHqdhEp7FkJqY1Ewij8K-38BB1glkV1jJ8= \"Opens in a new window\"). is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see [www.lixte.com](https://www.globenewswire.com/Tracker?data=dlzecCwQOf1WwOdxGQXkS3ge3c30VxiEzHthqVhKIHA6XAQMTg1_ptYUiuiDUGqnJrHOIzbIwf253PvmdOsnMEogqexNALTRoPSJo4xf5yVEfmrJl2kLZ-iLZF4VfOKwzEk31IYATqf5_Tb4aRVtNZ9OcNZniK0qnmB-FTr8FhD3-Kk4Unl_DT0EhVEeRUCDEPmhmWhn06uZN63v8aOz5L_7ASxa48q4oxDFxeN6gCk= \"Opens in a new window\")), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.\n\nLIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for colorectal, ovarian and sarcoma cancers. Additional information about LIXTE can be found at [www.lixte.com](https://www.globenewswire.com/Tracker?data=dlzecCwQOf1WwOdxGQXkS3pEU-niNErLdwjSrYoDYgbxKK76c9RbSTuQCCwuRbo8Z2zX_w48XRPRMr_48hIhmadSyI7_3T47H_rrA8CdhaS44t3TxyQ-o0-UpkShJiai2Zs61Wy3vOASlK56wGG5pR_P7R2l4krxX43Tnt98z_o7npGzVhU2o07KJAYrv32L48g8MmnjU8qFSF00l1MSr5tj63cJLQ9-6PAPf7xIKHs= \"Opens in a new window\").\n\n**Forward-Looking Statement Disclaimer**\n\nThis announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company’s ability to obtain and maintain compliance with Nasdaq’s continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as \"intend,\" anticipate,\" \"believe,\" \"estimate,\" \"potential(ly),\" \"continue,\" \"forecast,\" \"predict,\" \"plan,\" \"may,\" \"will,\" \"could,\" \"would,\" \"should,\" \"expect\" or the negative of such terms or other comparable terminology.\n\nThe Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.\n\nReaders are urged to read the risk factors set forth in the Company’s filings with the United States Securities and Exchange Commission at [https://www.sec.gov](https://www.globenewswire.com/Tracker?data=puI55WBO8jRJ4ByobzFImhYThO-ERZPzcg0EKURh8AxubBoGrG4xVtOQxLVZAcoW7sMPRFudXC5obnn5y9Mi5g== \"Opens in a new window\"). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.\n\n**For more information about LIXTE, Contact:**[info@lixte.com](https://www.globenewswire.com/Tracker?data=lqMCSs7D4kMREkTxXLdxTMqhYwReCIjNqv0wbXJrP8OZpbB2bqTtHP-zL5RPLcd8uWcJ5qkAkuNOdhl9G9wSLA== \"Opens in a new window\") General Phone: (631) 830-7092; Investor Phone: (888) 289-5533\n\nOr\n\nPondelWilkinson Inc. Investor Relations [pwinvestor@pondel.com](https://www.globenewswire.com/Tracker?data=zYctzAwQ7dRZNjql0724wGeKJekjOrDXkkCALzMk8fn8vP-u-mwA7-Yzt_dCHLDJ9cPjMHJ_9NzsnaKs-wHVU5h2nLMQeoZzDFv32b3NFlo= \"Opens in a new window\")Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962\n\n[![Primary Logo](https://ml.globenewswire.com/media/7e828ef4-6c8f-4c94-b376-4e3749530fba/small/logo-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/7e828ef4-6c8f-4c94-b376-4e3749530fba)\n\nSource: Lixte Biotechnology Holdings, Inc. \n\nReleased August 19, 2024\n\n  * [emailEmail Alerts](/news-events/email-alerts)\n  * [location_cityCompany Profile](/company-information)\n  * [contact_pageContacts](/company-information/contacts)\n  * [rss_feedRSS News Feed](https://ir.lixte.com/news-events/press-releases/rss \"Opens in a new window\")\n  * [account_treeSitemap](/sitemap)\n\n\n"
        },
        {
          "title": "LIXTE Biotechnology Holdings to Present at Two Investor Conferences",
          "url": "https://ir.lixte.com/news-events/press-releases/detail/113/lixte-biotechnology-holdings-to-present-at-two-investor-conferences",
          "content": "[Skip to main content](#mainContent) [Skip to section navigation](#sectionNav) [Skip to footer](#Footer)\n\n[ ![LIXTE-logo-web-horz-black-190](https://d1io3yog0oux5.cloudfront.net/_dc5892ca2b7f04aeb93d8225863bdadd/lixte/files/theme/site-files/20231127/lixte.com/wp-content/uploads/2023/10/LIXTE-logo-web-horz-black-190.png#763) ](https://lixte.com)\n\n  * [Our Approach](https://lixte.com)\n  * [Science](https://lixte.com/science/)\n  * [Programs](https://lixte.com/programs/)\n  * [Team](https://lixte.com/team/)\n  * [Investor Information](https://ir.lixte.com)\n\n\n\n[ ](#)\n\n✕\n\n  * [Our Approach](https://lixte.com)\n  * [Science](https://lixte.com/science/)\n  * [Programs](https://lixte.com/programs/)\n  * [Team](https://lixte.com/team/)\n  * [Investor Information](https://ir.lixte.com)\n\n\n\nPress Releases\n\n# LIXTE Biotechnology Holdings to Present at Two Investor Conferences\n\nAugust 15, 2024 8:30 am EDT  [ Download as PDF ](https://d1io3yog0oux5.cloudfront.net/_dc5892ca2b7f04aeb93d8225863bdadd/lixte/news/2024-08-15_LIXTE_Biotechnology_Holdings_to_Present_at_Two_113.pdf \"PDF: LIXTE Biotechnology Holdings to Present at Two Investor Conferences\")\n\n**_-Company to Present August 20 at Investor Summit Summer 2024 Virtual Conference;_****_and September 9-11 at H.C. Wainwright 26_**** _th_**** _Annual Global Investment Conference-_**\n\n**PASADENA, CALIF., Aug. 15, 2024 (GLOBE NEWSWIRE) --**[LIXTE Biotechnology Holdings, Inc](https://www.globenewswire.com/Tracker?data=ICrOuUYzLH2djbom5HvNV0KYXbyf5iHegNX9S2QVdk5x_w1i05dl61m4VBo7U_8Aq2UFdbExLjWegglkZQEA6YfQBb3SHi2-eM7R9fUKSNw= \"Opens in a new window\"). (“LIXTE” or the “Company”) ([Nasdaq: LIXT](https://www.globenewswire.com/Tracker?data=ZQ1lm_BBaV7tkew9czDjDrzMsqIyolkllLWfgTv9WyIAKyJ7k_D9Jg6TdbybCDurVJNkVEl2zkRRfk7lOBW8Tz1nVUlggd9D1D1GYns3ew5LD4dza30dNt1zBVtdSBV_ \"Opens in a new window\") and LIXTW), a clinical stage pharmaceutical company, today announced it will be presenting at two investor conferences:\n\n  * The Investor Summit Summer 2024 Virtual Conference Tuesday, August 20, 2024, at 2 p.m. EDT/11 a.m. PDT. To access the presentation, visit LIXTE’s investor relations website at <https://ir.lixte.com/news-events/ir-calendar>. \n  * The H.C. Wainwright 26th Annual Global Investor Conference, on demand starting at 7 a.m. EDT/4 a.m. PDT, September 9-11, 2024. To access the virtual presentation, register for the conference at [www.hcwevents.com/annualconference](http://www.hcwevents.com/annualconference \"Opens in a new window\"). \n\n\n\nBas van der Baan, CEO of LIXTE, will present an overview of the Company’s clinical trials with LB-100, its proprietary compound focused on enhancing chemotherapy and immunotherapy treatments as cancer therapies. Proof-of-concept clinical trials are currently in progress for colorectal, ovarian and sarcoma cancers, including trials funded by GSK and Roche.\n\n**About LIXTE Biotechnology Holdings**\n\n[LIXTE Biotechnology Holdings, Inc](https://www.globenewswire.com/Tracker?data=ICrOuUYzLH2djbom5HvNV0KYXbyf5iHegNX9S2QVdk50YFcDPeW02kxPlV4cAO64rSy-_bQtqmSuOYe1D2Jr7NXBpkiYkiOUesCOgVwmwzn1I87caP09eJM6U5gwKaz51KO39cyU9CLMpnFcrlfmUlSufM2FtPbscj7GHGr38vEd4_4cbb9ocbI-CIWpBfSg4nKh2eCV8pHbq1F27vpiCkbCebB-3XAdJ-TvQZTS1S7k8eWlx7cMyyzqGBdJPRnaIpSTLzr_9mwbDnWdwVaAgg== \"Opens in a new window\"). is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see [www.lixte.com](https://www.globenewswire.com/Tracker?data=HAHPHoxUIUxwKrMOIdkjzI3ETokTl5zkxrJEE6TfLPH40Nfg1pOI74Cf-ZKXkgSZOAB6dmdtJbLc3r9o_DE-m76VsE3Xo8mZ-gyChPn5KkfMoMqJIIkAJ5ZAf401zivjRLkqsJsS4k1WCWiGxQVXo0FsXZLPTb9XxAvMrQG91aosMa6TSYbbkXSBaOGRBxptGF86KoETU8xcUofvWSKRYCL6CWQFmssnMe2QYiitH9o= \"Opens in a new window\")), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.\n\nLIXTE’s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for colorectal, ovarian and sarcoma cancers. Additional information about LIXTE can be found at [www.lixte.com](https://www.globenewswire.com/Tracker?data=HAHPHoxUIUxwKrMOIdkjzNYSvTEvyF2uWxO4dyYD5_dbl7kJg4czRaf0eJGVGg6KA9L69atE29tBO1fAlueA9MAVGb3tFyELo9QhdAFFCx_kp6HGQNOikgTSKSR0NNLkyC2FvVqWdHhDfdBNKxPz_6nKx5brfPVgCTCGR7LQNf32WqlNSOa0kW5PC2IOXFkphGxOUsJeBEtEn_zy-Ct9qh6WEIKQGMlY5J6SZBgQtww= \"Opens in a new window\").\n\n**For more information about LIXTE, Contact:**[info@lixte.com](https://www.globenewswire.com/Tracker?data=rYFgNqvLhy0s4vcbyLuOISJxT780zUdxdMhlKshCgaclP5dUvxb7jWyK5uoivQOteAhV_dc_va9pCwl1X8F9ZA== \"Opens in a new window\")General Phone: (631) 830-7092Investor Phone: (888) 289-5533or[PondelWilkinson Inc.](https://www.globenewswire.com/Tracker?data=Ph2lo8FG_o349EnF1rF3s7LbX39uNK5Sq-mQwi30k_cR_Y2Pkv06XvIPgmR-ZpyB3J_Nsx_BXE_jSPDLawp8ZrjW_8P6ctx4HVSYOBLQcKA= \"Opens in a new window\") Investor Relations[pwinvestor@pondel.com](https://www.globenewswire.com/Tracker?data=52EyhHIgQcTG_wJyTN9MBrB0FKuupxAXFFcxQjpe9sMVehaCHlf_Tj3H-39bFcFdSNO2lMu0khsp8ATPUv-F7r9ok8KvQ-Z6alVNL3ySYxg= \"Opens in a new window\")Roger Pondel: (310) 279-5965Laurie Berman: (310) 279-5962\n\n# # #\n\n[![Primary Logo](https://ml.globenewswire.com/media/7e828ef4-6c8f-4c94-b376-4e3749530fba/small/logo-jpg.jpg)](https://www.globenewswire.com/NewsRoom/AttachmentNg/7e828ef4-6c8f-4c94-b376-4e3749530fba)\n\nSource: Lixte Biotechnology Holdings, Inc. \n\nReleased August 15, 2024\n\n  * [emailEmail Alerts](/news-events/email-alerts)\n  * [location_cityCompany Profile](/company-information)\n  * [contact_pageContacts](/company-information/contacts)\n  * [rss_feedRSS News Feed](https://ir.lixte.com/news-events/press-releases/rss \"Opens in a new window\")\n  * [account_treeSitemap](/sitemap)\n\n\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "10-Q",
          "url": "https://ir.lixte.com/sec-filings/all-sec-filings/content/0001493152-24-044810/0001493152-24-044810.pdf",
          "content": "UNITED STATES\nSECURITIES AND EXCHANGE COMMISSION\nWashington, D.C. 20549\nFORM 10-Q\n☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\nFor the quarterly period ended September 30, 2024\n☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934\nCommission file number: 001-39717\nLIXTE BIOTECHNOLOGY HOLDINGS, INC.\n(Exact name of registrant as specified in its charter)\nDelaware 20-2903526\n(State or other jurisdiction of (I.R.S. Employer\nincorporation or organization) Identification Number)\n680 East Colorado Boulevard, Suite 180\nPasadena, California 91101\n(Address of principal executive offices, including Zip Code)\n(631) 830-7092\n(Registrant’s telephone number, including area code)\nSecurities registered pursuant to Section 12(b) of the Act:\nTitle of each class Trading Symbol(s) Name of each exchange on which registered\nCommon Stock, par value $0.0001 per share LIXT The Nasdaq Stock Market LLC\nWarrants to Purchase Common Stock, par value $0.0001 per share LIXTW The Nasdaq Stock Market LLC\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12\nmonths (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.\nYes ☒ No ☐\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T\n(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).\nYes ☒ No ☐\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth\ncompany. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.\nLarge accelerated filer ☐ Accelerated filer ☐\nNon-accelerated filer ☒ Smaller reporting company ☒\nEmerging growth company ☐\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial\naccounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).\nYes ☐ No ☒\nAs of November 1, 2024, the Company had 2,249,290 shares of common stock issued and outstanding.\nLIXTE BIOTECHNOLOGY HOLDINGS, INC.\nAND SUBSIDIARY\nTABLE OF CONTENTS\nPage\nNumber\nPART I - FINANCIAL INFORMATION 3\nItem 1. Condensed Consolidated Financial Statements 3\nCondensed Consolidated Balance Sheets – September 30, 2024 (Unaudited) and December 31, 2023 3\nCondensed Consolidated Statements of Operations (Unaudited) – Three Months and Nine Months Ended September 30, 2024 and 2023 4\nCondensed Consolidated Statements of Stockholders’ Equity (Unaudited) – Three Months and Nine Months Ended September 30, 2024 and 2023 5\nCondensed Consolidated Statements of Cash Flows (Unaudited) – Nine Months Ended September 30, 2024 and 2023 7\nNotes to Condensed Consolidated Financial Statements (Unaudited) – Three Months and Nine Months Ended September 30, 2024 and 2023 8\nItem 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 36\nItem 3. Quantitative and Qualitative Disclosures About Market Risk 56\nItem 4. Controls and Procedures 56\nPART II - OTHER INFORMATION 57\nItem 1. Legal Proceedings 57\nItem 1A. Risk Factors 57\nItem 2. Unregistered Sales of Equity Securities and Use of Proceeds 57\nItem 3. Defaults Upon Senior Securities 58\nItem 4. Mine Safety Disclosures 58\nItem 5. Other Information 58\nItem 6. Exhibits 58\nSIGNATURES 59\n2\nPART I - FINANCIAL INFORMATION\nITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\nLIXTE BIOTECHNOLOGY HOLDINGS, INC.\nAND SUBSIDIARY\nCONDENSED CONSOLIDATED BALANCE SHEETS\nSeptember 30, December 31,\n2024 2023\n(Unaudited)\nASSETS\nCurrent assets:\nCash $ 1,637,627 $ 4,203,488\nAdvances on research and development contract services — 78,016\nPrepaid insurance 17,081 17,116\nOther prepaid expenses 34,256 10,000\nTotal current assets 1,688,964 4,308,620\nDeferred offering costs 6,928 —\nTotal assets $ 1,695,892 $ 4,308,620\nLIABILITIES AND STOCKHOLDERS’ EQUITY\nCurrent liabilities:\nAccounts payable and accrued expenses, including $0 and $36,250 to related parties at September 30,\n2024 and December 31, 2023, respectively $ 72,859 $ 156,758\nResearch and development contract liabilities, including $0 and $120,768 to related parties at September\n30, 2024 and December 31, 2023, respectively 256,097 157,100\nTotal current liabilities 328,956 313,858\nCommitments and contingencies\nStockholders’ equity:\nPreferred Stock, $0.0001 par value; authorized – 10,000,000 shares; issued and outstanding – 350,000\nshares of Series A Convertible Preferred Stock, $10.00 per share stated value, liquidation preference\nbased on assumed conversion into common shares – 72,917 shares at September 30, 2024 and December\n31, 2023 3,500,000 3,500,000\nCommon stock, $0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 2,249,290\nshares at September 30, 2024 and December 31, 2023 225 225\nAdditional paid-in capital 49,316,710 48,976,265\nAccumulated deficit (51,449,999) (48,481,728)\nTotal stockholders’ equity 1,366,936 3,994,762\nTotal liabilities and stockholders’ equity $ 1,695,892 $ 4,308,620\nSee accompanying notes to condensed consolidated financial statements.\n3\nLIXTE BIOTECHNOLOGY HOLDINGS, INC.\nAND SUBSIDIARY\nCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS\n(Unaudited)\nThree Months Ended Nine Months Ended\nSeptember 30, September 30,\n2024 2023 2024 2023\nRevenues $ — $ — $ — $ —\nCosts and expenses:\nGeneral and administrative costs:\nCompensation to related parties, including stock-based\ncompensation expense of $106,827 and $112,106 for the\nthree months ended September 30, 2024 and 2023,\nrespectively, and $340,445 and $669,146 for the nine\nmonths ended September 30, 2024 and 2023, respectively 283,053 356,001 907,069 1,398,042\nPatent and licensing legal and filing fees and costs 45,416 178,012 192,239 835,362\nOther costs and expenses 293,158 357,681 1,168,582 1,081,893\nResearch and development costs, including $76,278 and\n$51,568 for the three months ended September 30, 2024 and\n2023, respectively, and $210,362 and $156,950 for the nine\nmonths ended September 30, 2024 and 2023, respectively, to a\nrelated party 361,630 132,487 691,402 749,029\nTotal costs and expenses 983,257 1,024,181 2,959,292 4,064,326\nLoss from operations (983,257) (1,024,181) (2,959,292) (4,064,326)\nInterest income 1,437 5,809 6,529 13,538\nInterest expense (1,049) (279) (12,389) (6,088)\nForeign currency gain (loss) (3,161) (109) (3,119) 2,102\nNet loss $ (986,030) $ (1,018,760) $ (2,968,271) $ (4,054,774)\nNet loss per common share – basic and diluted $ (0.44) $ (0.49) $ (1.32) $ (2.25)\nWeighted average common shares outstanding – basic and\ndiluted 2,249,290 2,074,938 2,249,290 1,803,466\nSee accompanying notes to condensed consolidated financial statements.\n4\nLIXTE BIOTECHNOLOGY HOLDINGS, INC.\nAND SUBSIDIARY\nCONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY\n(Unaudited)\nThree Months and Nine Months Ended September 30, 2024 and 2023\nConvertible\nSeries A Additional Total\nPreferred Stock Common Stock Paid-in Accumulated Stockholders’\nPar\nShares Amount Shares Value Capital Deficit Equity\nThree months ended September 30, 2024:\nBalance, June 30, 2024 350,000 $3,500,000 2,249,290 $ 225 $49,209,883 $ (50,463,969) $ 2,246,139\nStock-based compensation expense — — — — 106,827 — 106,827\nNet loss — — — — — (986,030) (986,030)\nBalance, September 30, 2024 350,000 $3,500,000 2,249,290 $ 225 $49,316,710 $ (51,449,999) $ 1,366,936\nNine months ended September 30, 2024:\nBalance, December 31, 2023 350,000 $3,500,000 2,249,290 $ 225 $48,976,265 $ (48,481,728) $ 3,994,762\nStock-based compensation expense — — — — 340,445 — 340,445\nNet loss — — — — — (2,968,271) (2,968,271)\nBalance, September 30, 2024 350,000 $3,500,000 2,249,290 $ 225 $49,316,710 $ (51,449,999) $ 1,366,936\n(continued)\n5\nLIXTE BIOTECHNOLOGY HOLDINGS, INC.\nAND SUBSIDIARY\nCONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY\n(Unaudited)\n(Continued)\nThree Months and Nine Months Ended September 30, 2024 and 2023\nConvertible\nSeries A Additional Total\nPreferred Stock Common Stock Paid-in Accumulated Stockholders’\nPar\nShares Amount Shares Value Capital Deficit Equity\nThree months ended September 30, 2023:\nBalance, June 30, 2023 350,000 $3,500,000 1,665,956 $ 166 $45,623,081 $ (46,430,713) $ 2,692,534\nProceeds from sale of securities in registered direct\noffering, net of offering costs — — 180,000 18 3,137,021 — 3,137,039\nExercise of pre-funded common stock warrants — — 403,334 41 — — 41\nStock-based compensation expense — — — — 112,106 — 112,106\nNet loss — — — — — (1,018,760) (1,018,760)\nBalance, September 30, 2023 350,000 $3,500,000 2,249,290 $ 225 $48,872,208 $ (47,449,473) $ 4,922,960\nNine months ended September 30, 2023:\nBalance, December 31, 2022 350,000 $3,500,000 1,664,706 $ 166 $45,059,760 $ (43,394,699) $ 5,165,227\nProceeds from sale of securities in registered direct\noffering, net of offering costs — — 180,000 18 3,137,021 — 3,137,039\nExercise of pre-funded common stock warrants — — 403,334 41 — — 41\nExercise of common stock options — — 1,250 — 6,281 — 6,281\nStock-based compensation expense — — — — 669,146 — 669,146\nNet loss — — — — — (4,054,774) (4,054,774)\nBalance, September 30, 2023 350,000 $3,500,000 2,249,290 $ 225 $48,872,208 $ (47,449,473) $ 4,922,960\nSee accompanying notes to condensed consolidated financial statements.\n6\nLIXTE BIOTECHNOLOGY HOLDINGS, INC.\nAND SUBSIDIARY\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(Unaudited)\nNine Months Ended September 30,\n2024 2023\nCash flows from operating activities:\nNet loss $ (2,968,271) $ (4,054,774)\nAdjustments to reconcile net loss to net cash used in operating activities:\nStock-based compensation expense included in -\nGeneral and administrative costs 340,445 669,146\nResearch and development costs — —\nChanges in operating assets and liabilities:\n(Increase) decrease in -\nAdvances on research and development contract services 78,016 69,002\nPrepaid insurance 35 25,994\nOther prepaid expenses (24,256) (17,460)\nIncrease (decrease) in -\nAccounts payable and accrued expenses (90,827) (8,593)\nResearch and development contract liabilities 98,997 (74,457)\nNet cash used in operating activities (2,565,861) (3,391,142)\nCash flows from financing activities:\nProceeds from sale of securities in registered direct offering, net of\noffering costs — 3,137,039\nExercise of pre-funded common stock warrants — 41\nExercise of common stock options — 6,281\nNet cash provided by financing activities — 3,143,361\nCash:\nNet decrease (2,565,861) (247,781)\nBalance at beginning of period 4,203,488 5,353,392\nBalance at end of period $ 1,637,627 $ 5,105,611\nNon-cash investing and financing activities:\nDeferred offering costs accrued $ 6,928 $ —\nSupplemental disclosures of cash flow information:\nCash paid for -\nInterest $ 12,389 $ 6,088\nIncome taxes $ — $ —\nSee accompanying notes to condensed consolidated financial statements.\n7\nLIXTE BIOTECHNOLOGY HOLDINGS, INC.\nAND SUBSIDIARY\nNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\nThree Months and Nine Months Ended September 30, 2024 and 2023\n1. Organization and Basis of Presentation\nThe condensed consolidated financial statements of Lixte Biotechnology Holdings, Inc., a Delaware corporation), including its wholly-owned Delaware subsidiary,\nLixte Biotechnology, Inc. (collectively, the “Company”), at September 30, 2024, and for the three months and nine months ended September 30, 2024 and 2023, are unaudited.\nIn the opinion of management of the Company, all adjustments, including normal recurring accruals, have been made that are necessary to present fairly the financial position\nof the Company as of September 30, 2024, and the results of its operations for the three months and nine months ended September 30, 2024 and 2023, and its cash flows for the\nnine months ended September 30, 2024 and 2023. Operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal\nyear. The condensed consolidated balance sheet at December 31, 2023 has been derived from the Company’s audited consolidated financial statements at such date.\nThe condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange\nCommission (“SEC”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted\naccounting principles have been omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the\nfinancial statements and other information included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC.\nBusiness\nThe Company is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and commercializing\ncancer therapies. The Company’s corporate office is located in Pasadena, California.\nThe Company’s product pipeline is primarily focused on inhibitors of Protein Phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune\ncheckpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have significant therapeutic potential for a broad range of\ncancers. The Company is focusing on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-\ncancer activity at doses that produce little or no toxicity.\nThe Company’s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company has not yet commenced any\nrevenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation for a substantial portion of employee and consultant\ncompensation, and is dependent on periodic infusions of equity capital to fund its operating requirements.\nNasdaq Compliance\nThe Company’s common stock and the warrants are traded on the Nasdaq Capital Market (“Nasdaq”) under the symbols “LIXT” and “LIXTW”, respectively. On June\n2, 2023, the Company effected a 1-for-10 reverse split of its outstanding shares of common stock in order to remain in compliance with the $1.00 minimum closing bid price\nrequirement of Nasdaq. However, there can be no assurances that the Company will be able to remain in compliance with the $1.00 minimum closing bid price requirement of\nNasdaq over time. In addition, Nasdaq has other continued listing requirements, one of which is maintaining a minimum net stockholders’ equity of $2,500,000.\nOn August 19, 2024, the Company received a deficiency letter from the Listing Qualifications Department of Nasdaq indicating that it was not in compliance with\nNasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Rule”), which requires the Company to maintain a minimum stockholders’ equity of $2,500,000. This notice of non-\ncompliance has no immediate impact on the continued listing or trading of the Company’s securities on Nasdaq, which will continue to be listed and traded on Nasdaq, subject\nto the Company’s compliance with the other Nasdaq continued listing requirements.\n8\nOn October 3, 2024, the Company submitted a letter to Nasdaq with its plan to regain compliance with the Stockholders’ Equity Rule, which outlined the Company’s\nproposed initiatives to regain compliance by raising equity capital through various registered equity offerings.\nOn October 21, 2024, Nasdaq provided the Company notice that it had granted an extension through February 18, 2025 for the Company to regain compliance with the\nStockholders’ Equity Rule. The Company must complete its capital raising initiatives and evidence compliance with the Stockholders’ Equity Rule through filing a Current\nReport on Form 8-K with the SEC providing certain required information by February 18, 2025.\nIf the Company fails to evidence compliance with the Stockholders’ Equity Rule upon filing its periodic report for the quarter ending March 31, 2025 with the SEC,\nthe Company may be subject to delisting. If Nasdaq determines to delist the Company’s common stock, the Company will have the right to appeal to a Nasdaq hearings panel.\nThe hearing request would stay any suspension or delisting action pending the conclusion of the hearing process.\nThe Company intends to take reasonable measures available to regain compliance under Nasdaq’s listing rules and to remain listed on Nasdaq. However, there can be\nno assurances that the Company will ultimately regain compliance with the Stockholders’ Equity Rule, or be able to maintain compliance with all other applicable requirements\nfor continued listing on Nasdaq. If the Company does not regain compliance with Nasdaq’s listing rules within the time period permitted by Nasdaq, then the Company’s\nsecurities will be delisted from Nasdaq.\nGoing Concern\nFor the nine months ended September 30, 2024, the Company recorded a net loss of $2,968,271 and used cash in operations of $2,565,861. At September 30, 2024, the\nCompany had cash of $1,637,627 available to fund its operations. Because the Company is currently engaged in various early-stage clinical trials, it is expected that it will take\na significant amount of time and resources to develop any product or intellectual property capable of generating sustainable revenues. Accordingly, the Company’s business is\nunlikely to generate any sustainable operating revenues in the next several years and may never do so. Even if the Company is able to generate revenues through licensing its\ntechnology, product sales or other commercial activities, there can be no assurance that the Company will be able to achieve and maintain positive earnings and operating cash\nflows. At September 30, 2024, the Company’s remaining financial contractual commitments pursuant to clinical trial agreements and clinical trial monitoring agreements not\nyet incurred aggregated approximately $3,918,000 (see Note 8), which are currently scheduled to be incurred through approximately December 31, 2027.\nThe Company’s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of\nassets and satisfaction of liabilities in the normal course of business. The consolidated financial statements also do not reflect any adjustments relating to the recoverability of\nassets and liabilities that might be necessary if the Company is unable to continue as a going concern. The Company has no recurring source of revenues and has experienced\nnegative operating cash flows since inception. The Company has financed its working capital requirements through the recurring sale of its equity securities.\nBased on the foregoing, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the\ndate that the consolidated financial statements are being issued. In addition, our independent registered public accounting firm has included an explanatory paragraph in their\nreport with respect to this uncertainty that accompanies our audited consolidated financial statements as of and for the year ended December 31, 2023. The Company’s\nconsolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.\nThe Company’s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research and development activities and\nto ultimately achieve sustainable operating revenues and profitability. The amount and timing of future cash requirements depends on the pace, design, and results of the\nCompany’s clinical trial program, which, in turn, depends on the availability of operating capital to fund such activities.\n9\nBased on current operating plans, the Company estimates that its existing cash resources at September 30, 2024 will provide sufficient working capital to fund the\ncurrent clinical trial program with respect to the development of the Company’s lead anti-cancer clinical compound, LB-100, through the first quarter of 2025. As existing cash\nresources will not be sufficient to complete the clinical development of, and obtain regulatory approval for, the Company’s product candidate, the Company will need to raise\nadditional capital in one or more tranches to fund its operations during the next few months in order to be able to effectively manage its current business plan during 2025 and\nthereafter, as well as to maintain its listing on Nasdaq. Furthermore, the Company’s operating plans and capital requirements may change as a result of many factors that are\ncurrently unknown and/or outside of the control of the Company. The Company is considering various strategies and alternatives to obtain the required additional capital.\nAs market conditions present uncertainty as to the Company’s ability to secure additional funds, there can be no assurance that the Company will be able to secure\nadditional financing on acceptable terms, as and when necessary, to continue to conduct operations.\nIf cash resources are insufficient to satisfy the Company’s ongoing cash requirements, the Company would be required to scale back or discontinue its clinical trial\nprogram, or obtain funds, if available, through strategic alliances or joint ventures that could require the Company to relinquish rights to and/or control of LB-100, or to\ndiscontinue operations entirely.\n2. Summary of Significant Accounting Policies\nPrinciples of Consolidation\nThe accompanying condensed consolidated financial statements of the Company have been prepared in accordance with United States generally accepted accounting\nprinciples (“GAAP”) and include the financial statements of Lixte Biotechnology Holdings, Inc. and its wholly-owned subsidiary, Lixte Biotechnology, Inc. Intercompany\nbalances and transactions have been eliminated in consolidation.\nSegment Information\nThe Company operates and reports in one segment, which consists of the development of a drug class called Protein Phosphatase 2A inhibitors. The Company’s\noperating segment is reported in a manner consistent with the internal reporting provided to the Company’s Chief Operating Decision Maker, which is the Company’s President\nand Chief Executive Officer.\nUse of Estimates\nThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets\nand liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Some of those judgments can be subjective and complex,\nand therefore, actual results could differ materially from those estimates under different assumptions or conditions. Management bases its estimates on historical experience and\non various assumptions that are believed to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis\nfor making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and\nassumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience, and reasonable assumptions.\nAfter such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those\nrelated to assumptions used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for services.\nCash\nCash is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC (“Morgan\nStanley”). Morgan Stanley is a FINRA-regulated broker-dealer. The Company’s policy is to maintain its cash balances with financial institutions in the United States with high\ncredit ratings and in accounts insured by the Federal Deposit Insurance Corporation (the “FDIC”) and/or by the Securities Investor Protection Corporation (the “SIPC”). The\nCompany periodically has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $250,000 and $500,000, respectively. Morgan Stanley\nWealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not experienced any losses to date resulting from\nthis policy.\n10\nResearch and Development\nResearch and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation, design, development,\nconduct and management of clinical trials with respect to the Company’s clinical compound and product candidate. Research and development costs also include the costs to\nmanufacture compounds used in research and clinical trials, which are charged to operations as incurred. The Company’s inventory of LB-100 for clinical use has been\nmanufactured separately in the United States and in the European Union in accordance with the laws and regulations of such jurisdictions.\nResearch and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of milestones, the\ncompletion of contracted work, the termination of an agreement, or other information indicates that a different expensing schedule is more appropriate. However, payments for\nresearch and development costs that are contractually defined as non-refundable are charged to operations as incurred.\nObligations incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research and\ndevelopment costs in the Company’s consolidated statement of operations based on the achievement of such milestones, as specified in the respective agreement. Obligations\nincurred with respect to mandatory scheduled payments under agreements without milestone provisions are accounted for when due, are recognized ratably over the appropriate\nperiod, as specified in the respective agreement, and are recorded as liabilities in the Company’s consolidated balance sheet, with a corresponding charge to research and\ndevelopment costs in the Company’s consolidated statement of operations.\nPayments made pursuant to contracts are initially recorded as advances on research and development contract services in the Company’s consolidated balance sheet\nand are then charged to research and development costs in the Company’s consolidated statement of operations as those contract services are performed. Expenses incurred\nunder contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Company’s consolidated balance sheet, with a corresponding\ncharge to research and development costs in the Company’s consolidated statement of operations. The Company reviews the status of its various clinical trial and research and\ndevelopment contracts on a quarterly basis.\nPrepaid Insurance\nPrepaid insurance represents the premiums paid for directors and officers insurance coverage and for general liability insurance coverage in excess of the amortization\nof the total policy premium charged to operations at each balance sheet date. Such amount is determined by amortizing the total policy premium charged on a straight-line basis\nover the respective policy period. As the policy premiums incurred are generally amortizable over the ensuing twelve-month period, they are recorded as a current asset in the\nCompany’s consolidated balance sheet at each reporting date and appropriately amortized to the Company’s consolidated statement of operations for each reporting period.\nDeferred Offering Costs\nDeferred offering costs consist of costs incurred with respect to pending equity financing transactions, including legal fees. Such costs are deferred and charged to\nadditional paid-in capital upon the successful completion of such financings, or are charged to operations if and when such financings are abandoned or terminated.\nPatent and Licensing Legal and Filing Fees and Costs\nDue to the significant uncertainty associated with the successful development of commercially viable products based on the Company’s research efforts and related\npatent applications, all patent and licensing legal and filing fees and costs related to the development and protection of the Company’s intellectual property are charged to\noperations as incurred. Patent and licensing legal and filing fees and costs were $45,416 and $178,012 for the three months ended September 30, 2024 and 2023, respectively,\nand $192,239 and $835,362 for the nine months ended September 30, 2024 and 2023, respectively. Patent and licensing legal and filing fees and costs are included in general\nand administrative costs in the Company’s consolidated statement of operations.\n11\nConcentration of Risk\nThe Company periodically contracts with vendors and consultants to provide services related to the Company’s operations. Charges incurred for these services can be\nfor a specific period (typically one year) or for a specific project or task. Costs and expenses incurred that represented 10% or more of general and administrative costs or\nresearch and development costs for the three months ended September 30, 2024 and 2023 are described below.\nGeneral and administrative costs for the three months ended September 30, 2024 and 2023 include charges from legal firms and other vendors for general licensing\nand patent prosecution costs relating to the Company’s intellectual properties representing 7.3% and 20.0% of total general and administrative costs, respectively. General and\nadministrative costs for the three months ended September 30, 2024 and 2023 also included charges for the cost of directors and officer’s insurance of 18.4% and 11.9%,\nrespectively, corporate legal fees of 9.8% and 10.6%, respectively, and for the fair value of stock options granted to directors and corporate officers representing 17.2% and\n12.6%, respectively, of total general and administrative costs.\nResearch and development costs for the three months ended September 30, 2024 include charges from three vendors and consultants representing 57.2%, 21.1% and\n15.1%, respectively, of total research and development costs. Research and development costs for the three months ended September 30, 2023 include charges from four\nvendors and consultants representing 38.9%, 24.9%, 15.9% and 14.9%, respectively, of total research and development costs.\nCosts and expenses incurred that represented 10% or more of general and administrative costs or research and development costs for the nine months ended September\n30, 2024 and 2023 are described below.\nGeneral and administrative costs for the nine months ended September 30, 2024 and 2023 include charges from legal firms and other vendors for general licensing and\npatent prosecution costs relating to the Company’s intellectual properties representing 8.5% and 25.2% of total general and administrative costs, respectively. General and\nadministrative costs for the nine months ended September 30, 2024 and 2023 also included charges for the cost of directors and officer’s insurance of 16.0% and 9.3%,\nrespectively, corporate legal fees of 11.5% and 7.5%, respectively, and for the fair value of stock options granted to directors and corporate officers representing 15.0% and\n20.2%, respectively, of total general and administrative costs.\nResearch and development costs for the nine months ended September 30, 2024 include charges from three vendors and consultants representing 41.2%, 30.4% and\n12.6%, respectively, of total research and development costs. Research and development costs for the nine months ended September 30, 2023 include charges from three\nvendors and consultants representing 35.9%, 21.0%, and 12.4%, respectively, of total research and development costs.\nIncome Taxes\nThe Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company\nrecognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities.\nThe Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. Due to the uncertainty of the\nCompany’s ability to realize the benefit of the deferred tax assets, the net deferred tax assets are fully offset by a valuation allowance at September 30, 2024 and December 31,\n2023. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the\ndeferred tax assets would be credited to operations in the period such determination was made. Should the Company determine that it would not be able to realize all or part of\nits deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.\nThe Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized,\nall previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The\nCompany had no unrecognized tax benefits as of September 30, 2024 or December 31, 2023 and does not anticipate any material amount of unrecognized tax benefits through\nDecember 31, 2024.\n12\nThe Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation, and\ndisclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-\nlikely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of\nthe position are recognized. The Company had not recorded any liability for uncertain tax positions as of September 30, 2024 or December 31, 2023. Subsequent to September\n30, 2024, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense.\nStock-Based Compensation\nThe Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members, contractors and\nconsultants for services rendered. Options vest and expire according to terms established at the issuance date of each grant. Stock grants, which are generally time vested, are\nmeasured at the grant date fair value and charged to operations ratably over the vesting period.\nThe Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors, and consultants by\nmeasuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense on the\nstraight-line basis in the Company’s financial statements over the vesting period of the awards. Recognition of compensation expense for non-employees is in the same period\nand manner as if the Company had paid cash for the services.\nThe fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several\nvariables, the most significant of which are the expected life of the stock option, the exercise price of the stock option as compared to the fair market value of the common stock\non the grant date, and the estimated volatility of the common stock. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as\nthe mid-point between the vesting period and the contractual term (the “simplified method”). The estimated volatility is based on the historical volatility of the Company’s\ncommon stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock option being granted. The risk-free interest rate is based on the\nU.S. Treasury yield curve in effect at the time of grant. The fair market value of the common stock is determined by reference to the quoted market price of the Company’s\ncommon stock on the grant date. The expected dividend yield is based on the Company’s expectation of dividend payouts and is assumed to be zero.\nThe Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development costs, as appropriate,\nin the Company’s consolidated statements of operations. The Company issues new shares of common stock to satisfy stock option exercises.\nWarrants\nThe Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable\nauthoritative guidance in Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC\n815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and\nwhether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock\nand whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity\nclassification. The Company has determined that the warrants issued in the July 20, 2023 equity financing (see Note 4) meet the requirements for equity classification. This\nassessment, which requires the use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the warrants are\noutstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in\ncapital at the time of issuance. For issued or modified warrants that do not meet all of the criteria for equity classification, the warrants are required to be liability classified and\nrecorded at their initial fair value on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value of the warrants\nthat are liability classified are recognized as a non-cash gain or loss in the statement of operations.\n13\nEarnings (Loss) Per Share\nThe Company’s computation of earnings (loss) per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common\nstockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis\nof potential common shares (e.g., preferred shares, warrants and stock options) as if they had been converted at the beginning of the respective periods presented, or issuance\ndate, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of\ndiluted EPS.\nLoss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the respective periods. Basic and\ndiluted loss per common share was the same for all periods presented because all preferred shares, warrants and stock options outstanding were anti-dilutive.\nAt September 30, 2024 and 2023, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common\nstock, from its calculation of earnings per share, as their effect would have been anti-dilutive.\nSeptember 30,\n2024 2023\nSeries A Convertible Preferred Stock 72,917 72,917\nCommon stock warrants 808,365 808,365\nCommon stock options, including options issued in the form of warrants 623,232 674,896\nTotal 1,504,514 1,556,178\nForeign Currency Translation\nThe consolidated financial statements are presented in the United States dollar, which is the functional and reporting currency of the Company.\nThe Company periodically incurs a cost or expense in a foreign jurisdiction denominated in a local currency. The Company purchases the required foreign currency to\npay such cost or expense on an as-needed basis. Such cost or expense is converted into United States dollars for financial statement purposes based on the foreign currency\nconversion rate in effect on the transaction date. The Company purchases the requisite foreign currency to pay such cost or expense on an as-needed basis. Any gain or loss\nresulting from the purchase of the foreign currency is included as foreign currency gain (loss) in the consolidated statement of operations.\nDuring the three months ended September 30, 2024 and 2023, the Company incurred various costs and expenses denominated in Euros, which were converted into\nUnited States dollars at the average rate of 1.0991 and 1.0885, respectively. During the nine months ended September 30, 2024 and 2023, the Company incurred various costs\nand expenses denominated in Euros, which were converted into United States dollars at the average rate of 1.0991 and 1.0839, respectively. As of September 30, 2024 and\nDecember 31, 2023, the Company did not hold any currencies other than the United States dollar in its bank accounts, and was not a party to any foreign currency forward or\nexchange contracts.\nFair Value of Financial Instruments\nThe authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into\nthree levels and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and\nout of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.\nLevel 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement\ndate. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives.\nLevel 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration\nwith observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange-based derivatives, mutual funds, and fair-\nvalue hedges.\n14\nLevel 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions.\nFinancial assets and liabilities utilizing Level 3 inputs include infrequently traded non-exchange-based derivatives and commingled investment funds and are measured using\npresent value pricing models.\nThe Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is\nsignificant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting\nperiod end.\nThe carrying value of financial instruments, which consists of accounts payable and accrued expenses is considered to be representative of their respective fair values\ndue to the short-term nature of those instruments.\nRecent Accounting Pronouncements\nIn July 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-03, Presentation of Financial Statements (Topic\n205), Income Statement — Reporting Comprehensive Income (Topic 220), Distinguishing Liabilities from Equity (Topic 480), Equity (Topic 505), and Compensation — Stock\nCompensation (Topic 718) Presentation of Financial Statements (“ASU 2023-03”). ASU 2023-03 amends the FASB Accounting Standards Codification to include Amendments\nto SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No. 120, SEC Staff Announcement at the March 24, 2022 EITF Meeting, and SEC Staff Accounting Bulletin\nTopic 6.B, Accounting Series Release 280 — General Revision of Regulation S-X: Income or Loss Applicable to Common Stock. As ASU 2023-03 did not provide any new\nguidance, there was no transition or effective date associated with its adoption. Accordingly, the Company adopted ASU 2023-03 immediately upon its issuance in July 2023.\nThe adoption of ASU 2023-03 did not have any impact on the Company’s consolidated financial statements, including their presentation and related disclosures.\nManagement does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the\nCompany’s financial statements, including their presentation and related disclosures.\n3. Research and Development Costs\nA summary of research and development costs for the three months and nine months ended September 30, 2024 and 2023, including costs associated with clinical\ntrials involving the Company’s lead clinical compound LB-100, are summarized below based on the respective geographical regions where such costs have been incurred.\nThree Months Ended Nine Months Ended\nSeptember 30, September 30,\n2024 2023 2024 2023\nUnited States $ 278,808 $ 68,315 $ 427,736 $ 291,846\nSpain 6,544 9,496 51,022 283,035\nChina — 3,108 2,282 17,198\nNetherlands 76,278 51,568 210,362 156,950\nTotal $ 361,630 $ 132,487 $ 691,402 $ 749,029\n4. Stockholders’ Equity\nPreferred Stock\nThe Company is authorized to issue a total of 10,000,000 shares of preferred stock, par value $0.0001 per share. On March 17, 2015, the Company filed a Certificate\nof Designations, Preferences, Rights and Limitations of its Series A Convertible Preferred Stock with the Delaware Secretary of State to amend the Company’s certificate of\nincorporation. The Company has designated a total of 350,000 shares as Series A Convertible Preferred Stock, which are non-voting and are not subject to increase without the\nwritten consent of a majority of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Preferences, Rights and Limitations. The holders of each\ntranche of 175,000 shares of the Series A Convertible Preferred Stock are entitled to receive a per share dividend equal to 1% of the annual net revenue of the Company divided\nby 175,000, until converted or redeemed. As of September 30, 2024 and December 31, 2023, the Company had 9,650,000 shares of undesignated preferred stock, which may be\nissued with such rights and powers as the Board of Directors may designate.\n15\nEach share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into 0.20833 shares of common stock (subject to customary anti-\ndilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion rate in the event of a merger or sale transaction resulting\nin gross proceeds to the Company of at least $21,875,000. The Series A Convertible Preferred Stock has a liquidation preference based on its assumed conversion into shares of\ncommon stock. The Series A Convertible Preferred Stock does not have any cash liquidation preference rights or any registration rights. The 350,000 outstanding shares of\nSeries A Convertible Preferred Stock were convertible into a total of 72,917 shares of common stock at September 30, 2024 and December 31, 2023.\nBased on the attributes of the Series A Convertible Preferred Stock as previously described, the Company has accounted for the Series A Convertible Preferred Stock\nas a permanent component of stockholders’ equity.\nCommon Stock\nThe Company is authorized to issue a total of 100,000,000 shares of common stock, par value $0.0001 per share. As of September 30, 2024 and December 31, 2023,\nthe Company had 2,249,290 shares of common stock issued and outstanding.\nOn June 2, 2023, the Company effected a 1-for-10 reverse split of its outstanding shares of common stock.\nThe authorized number of shares of common stock and the par value per share were not affected by the reverse stock split. No fractional shares were issued in\nconnection with the reverse stock split, with all fractional shares being rounded up to the next whole share.\nAll share and per share amounts and information presented herein have been retroactively adjusted to reflect the reverse stock split for all periods presented.\nEffective March 10, 2023, the Company issued 1,250 shares of common stock upon the exercise of a stock option in the form of a warrant held by a consultant to the\nCompany for 1,250 shares exercisable at $5.025 per share for total cash proceeds of $6,281.\nEffective July 20, 2023, the Company sold 180,000 shares of common stock at a price of $6.00 per share and pre-funded warrants to purchase 403,334 shares of\ncommon stock at a price of $5.9999 per pre-funded warrant to an institutional investor in a registered direct offering. The pre-funded warrants had an exercise price of $0.0001\nper share, were immediately exercisable upon issuance, and were valid and exercisable until all pre-funded warrants were exercised in full.\nDuring the period from July 24, 2023 through August 7, 2023, the 403,334 pre-funded warrants, exercisable at $0.0001 per common share, were exercised for total\ncash proceeds of $41, resulting in the issuance of 403,334 shares of common stock. The pre-funded warrants were determined to be common stock equivalents.\nIn a concurrent private placement to the institutional investor, the Company also sold warrants to purchase 583,334 shares of common stock. Each common warrant\nhad an initial exercise price of $6.00 per share, was immediately exercisable upon issuance, and expires five years thereafter on July 20, 2028. The common warrants and the\nshares of common stock issuable upon exercise of the common warrants were not registered under the Securities Act of 1933, as amended (the “Securities Act”) and were\noffered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. The shares of common stock issuable upon\nexercise of the warrants were registered for resale on a registration statement on Form S-3 declared effective by the SEC on May 2, 2024.\nThe registered direct offering and the concurrent private placement generated gross proceeds of $3,499,964. The total cash costs of the registered direct offering and\nthe private placement were $362,925, resulting in net proceeds of $3,137,039. Pursuant to the placement agent agreement, the Company granted the placement agent warrants\nto purchase 35,000 shares of common stock at an exercise price of $6.60 per share and expiring on July 20, 2028.\n16\nThe exercise prices of the warrants issued to the institutional investor (exercisable at $6.00 per share) and to the placement agent (exercisable at $6.60 per share) are\nsubject to customary adjustments for stock splits, stock dividends, stock combinations, reclassifications, reorganizations, or similar events affecting the Company’s common\nstock. In addition, the warrants issued to the institutional investor contain a “fundamental transaction” provision which provides that if any defined fundamental transactions are\nwithin the Company’s control and are consummated, the holder of the unexercised common stock warrants would be entitled to receive, at its option, in exchange for\nextinguishment of such warrants, cash consideration equal to a Black-Scholes valuation amount, as defined in the warrant agreement. The fundamental transaction provision\nincludes (i) a sale, lease, assignment, transfer, conveyance or other disposition of all or substantially all of the assets of the Company in one or a series of related transactions, or\n(ii) a change in control of the Company by which it, directly or indirectly, in one or more related transactions, consummates a stock or share purchase agreement or other\nbusiness combination with another person or group, whereby such other person or group acquires more than 50% of the voting power of the common equity of the Company.\nIf such fundamental transaction is not within the Company’s control, including not being approved by the Company’s Board of Directors, the warrant holder would\nonly be entitled to receive the same type or form of consideration (and in the same proportion) equal to the Black-Scholes valuation amount of the remaining unexercised\nportion of the warrant on the date of consummation of such fundamental transaction as the holders of the Company’s common stock receive. Accordingly, these warrants are\nclassified as a component of permanent stockholders’ equity. The Company will account for any cash payment for a warrant redemption as a distribution from stockholders’\nequity, as and when a fundamental transaction is consummated and such cash payment is required to be made.\nCommon Stock Warrants\nA summary of common stock warrant activity, including warrants to purchase common stock that were issued in conjunction with the Company’s public offering,\nduring the nine months ended September 30, 2024 is presented below.\nWeighted Average\nRemaining\nWeighted Average Contractual\nNumber of Shares Exercise Price Life (in Years)\nWarrants outstanding at December 31, 2023 808,365 $ 16.407\nIssued — —\nExercised — —\nExpired — —\nWarrants outstanding at September 30, 2024 808,365 $ 16.407 3.24\nWarrants exercisable at December 31, 2023 808,365 $ 16.407\nWarrants exercisable at September 30, 2024 808,365 $ 16.407 3.24\nAt September 30, 2024, the outstanding warrants are exercisable at the following prices per common share:\nWarrants\nExercise Prices Outstanding (Shares)\n$ 6.000 583,334\n$ 6.600 35,000\n$ 20.000 29,000\n$ 37.000 11,331\n$ 57.000 149,700\n808,365\n17\nThe warrants exercisable at $57.00 per share at September 30, 2024 consist of 1,497,000 publicly-traded warrants, described herein on a pre-split 1-for-10 basis, that\nwere issued as part of the Company’s November 2020 public offering of units, and are exercisable for a period of five years thereafter. As a result of the 1-for-10 reverse split of\nthe Company’s common stock effective June 2, 2023, each such publicly-traded warrant currently now represents the right to purchase 1/10th of a share of common stock at the\noriginal exercise price of $5.70 per share. Accordingly, the exercise of 10 warrants, each exercisable at $5.70, are required to acquire one share of post-split common stock,\nwhich is equivalent to a purchase price of $57.00 per share.\nBased on the closing fair market value of $1.87 per share on September 30, 2024, there was no intrinsic value attributed to exercisable but unexercised common stock\nwarrants at September 30, 2024.\nInformation with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 6.\n5. Related Party Transactions\nRelated party transactions include transactions with the Company’s officers, directors and affiliates.\nEmployment Agreements with Officers\nDuring July and August 2020, the Company entered into one-year employment agreements with each of its executive officers at that time, consisting of Dr. John S.\nKovach, Eric J. Forman, Dr. James S. Miser, and Robert N. Weingarten, payable monthly, as described below. These employment agreements were automatically renewable for\nadditional one-year periods unless terminated by either party upon 60 days written notice prior to the end of the applicable one-year period, or by death, or by termination for\ncause. Except as noted below, these employment agreements were automatically renewed for additional one-year periods in July and August 2021, 2022, 2023 and 2024.\nThe Company entered into an employment agreement with Dr. Kovach dated July 15, 2020, effective October 1, 2020, to provide for Dr. Kovach to continue to act as\nthe Company’s President, Chief Executive Officer and Chief Scientific Officer, with an annual salary of $250,000. The employment agreement with Dr. Kovach terminated\nupon his death on October 5, 2023. During the three months and nine months ended September 30, 2023, the Company paid $62,500 and $187,500, respectively, to Dr. Kovach\nunder this employment agreement, which costs are included in general and administrative costs in the Company’s consolidated statement of operations for such periods.\nThe Company entered into an employment agreement with Dr. James S. Miser, M.D., effective August 1, 2020, to act as the Company’s Chief Medical Officer, with an\nannual salary of $150,000. Effective May 1, 2021, Dr. Miser’s annual salary was increased to $175,000. Dr. Miser was required to devote at least 50% of his business time to\nthe Company’s activities. During the three months ended September 30, 2024 and 2023, the Company paid $14,583 and $43,750, respectively, to Dr. Miser under this\nemployment agreement, which costs are included in general and administrative costs in the Company’s consolidated statements of operations for such periods. During the nine\nmonths ended September 30, 2024 and 2023, the Company paid $102,083 and $131,250, respectively, to Dr. Miser under this employment agreement, which costs are included\nin general and administrative costs in the Company’s consolidated statement of operations for such periods. On May 29, 2024, the Company elected not to renew its\nemployment agreement with Dr. Miser, as a result of which such employment agreement expired on July 31, 2024.\nThe Company entered into an employment agreement with Eric J. Forman effective July 15, 2020, as amended on August 12, 2020, to act as the Company’s Chief\nAdministrative Officer, with an annual salary of $120,000. Mr. Forman is the son-in-law of Gil Schwartzberg (deceased), a former member of the Company’s Board of\nDirectors who died on October 30, 2022 and was a significant stockholder of and consultant to the Company, and is the son of Dr. Stephen Forman, a member of the\nCompany’s Board of Directors. Julie Forman, the wife of Mr. Forman and the daughter of Gil Schwartzberg, is Vice President of Morgan Stanley Wealth Management, at which\nfirm the Company’s cash is on deposit and with which the Company maintains a continuing banking relationship. Effective May 1, 2021, Mr. Forman’s annual salary was\nincreased to $175,000. Additionally, effective November 6, 2022, Mr. Forman was promoted to Vice President and Chief Operating Officer with an annual salary of $200,000.\nEffective October 1, 2022, Mr. Forman has been provided a monthly office rent allowance, pursuant to which for the three months ended September 30, 2024 and 2023, the\nCompany paid $3,218 and $7,323 respectively, on Mr. Forman’s behalf. For the nine months ended September 30, 2024 and 2023, Mr. Forman has been provided a monthly\noffice rent allowance, pursuant to which the Company paid $13,099 and $11,436 respectively, on Mr. Forman’s behalf. During the three months ended September 30, 2024 and\n2023, the Company paid $50,000 and $50,000, respectively, to Mr. Forman under this employment agreement, which costs are included in general and administrative costs in\nthe Company’s consolidated statements of operations for such periods. During the nine months ended September 30, 2024 and 2023, the Company paid $150,000 and $150,000,\nrespectively, to Mr. Forman under this employment agreement, which costs are included in general and administrative costs in the Company’s consolidated statement of\noperations for such periods.\n18\nThe Company entered into an employment agreement with Robert N. Weingarten effective August 12, 2020 to act as the Company’s Vice President and Chief\nFinancial Officer, with an annual salary of $120,000. Effective May 1, 2021, Mr. Weingarten’s annual salary was increased to $175,000. During the three months ended\nSeptember 30, 2024 and 2023, the Company paid $43,750 and $43,750, respectively, to Mr. Weingarten under this employment agreement, which costs are included in general\nand administrative costs in the Company’s consolidated statements of operations for such periods. During the nine months ended September 30, 2024 and 2023, the Company\npaid $131,250 and $131,250, respectively, to Mr. Weingarten under this employment agreement, which costs are included in general and administrative costs in the Company’s\nconsolidated statement of operations for such periods.\nThe Company entered into an employment agreement with Bastiaan van der Baan effective September 26, 2023 to act as the Company’s President and Chief Executive\nOfficer and as Vice Chairman of the Board of Directors, with an annual salary of $150,000. Effective October 6, 2023, Mr. van der Baan was appointed as Chairman of the\nBoard of Directors upon the death of Dr. Kovach on October 5, 2023. Mr. van der Baan’s annual salary may be increased from time to time at the sole discretion of the Board of\nDirectors. In addition, Mr. van der Baan is eligible to receive an annual bonus as determined at the sole discretion of the Board of Directors. The term of the employment\nagreement is for three years and is automatically renewable for additional one-year periods unless terminated by either party, subject to early termination provisions as\ndescribed in the employment agreement. During the three months ended September 30, 2024 and 2023, the Company paid $39,175 and $1,667, respectively, to Mr. van der\nBaan under this employment agreement, which costs are included in general and administrative costs in the Company’s consolidated statement of operations for such periods.\nDuring the nine months ended September 30, 2024 and 2023, the Company paid $115,754 and $1,667, respectively, to Mr. van der Baan under this employment agreement,\nwhich costs are included in general and administrative costs in the Company’s consolidated statement of operations for such periods.\nOn May 31, 2024, the Company entered into a consulting agreement with Dr. Jan H.M. Schellens, M.D., Ph.D., Pursuant to the agreement, effective July 1, 2024, the\nCompany engaged Dr. Schellens as a consultant, and, effective August 1, 2024, as the Company’s Chief Medical Officer. The term of the agreement are in effect from July 1,\n2024 until the earliest of (i) termination by either party upon sixty days’ notice, (ii) Dr. Schellens’ death or disability, or (iii) termination by the Company for breach as provided\nin the agreement. Under the agreement, Dr. Schellens provides his services for two days per week with the specific days in each week based on arrangements agreed to from\ntime to time between Dr. Schellens and the Company’s Chief Executive Officer. The Company pays Dr. Schellens an annual compensation of 104,000 Euros (approximately\n$116,000 as of September 30, 2024), payable on a monthly basis. During the three months and nine months ended September 30, 2024, the Company paid $28,718 and\n$28,718, respectively, to Dr. Schellens under this consulting agreement, which costs are included in general and administrative costs in the Company’s consolidated statement\nof operations for such periods.\nAppointment of Dr. René Bernards to the Board of Directors\nEffective as of June 15, 2022, Dr. René Bernards was appointed to the Company’s Board of Directors as an independent director. Dr. Bernards is a leader in the field of\nmolecular carcinogenesis and is employed by the Netherlands Cancer Institute in Amsterdam. Upon his appointment, it was agreed that Dr. Bernards would receive annual\ncompensation for his services on the Board only in the form of cash, in lieu of the annual June 30 grant of stock options as provided to the Company’s other non-officer\ndirectors. During the three months ended September 30, 2024 and 2023, the Company recorded charges to general and administrative costs in the consolidated statement of\noperations of $0 and $10,000, respectively, with respect to his annual cash board compensation. During the nine months ended September 30, 2024 and 2023, the Company\nrecorded charges to general and administrative costs in the consolidated statement of operations of $10,000 and $30,000, respectively, with respect to his annual cash board\ncompensation.\nIn conjunction with the Company’s efforts to preserve cash, effective with the quarter ended June 30, 2024, Dr. Bernards agreed to receive equity-based compensation\nfor his services on the Board, for the quarters ended June 30, 2024, September 30, 2024 and December 31, 2024. In order to reconcile his Board compensation with that of the\nother non-officer directors, Dr. Bernards has agreed to receive the same Board compensation, both in form and amount, as the other non-officer directors.\n19\nPreviously, on October 8, 2021, the Company had entered into a Development Collaboration Agreement (subsequently amended and extended) with the Netherlands\nCancer Institute, Amsterdam, one of the world’s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center, to identify\nthe most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular\nmechanisms underlying the identified combinations (see Note 8).\nCompensatory Arrangements for Members of the Board of Directors\nEffective April 9, 2021, the Board of Directors approved a comprehensive cash and equity compensation program for the non-officer directors for their services on the\nBoard of Directors (the “Board Plan”), which was subsequently amended effective May 25, 2022 and July 9, 2024. Officers who also serve on the Board of Directors are not\ncompensated separately for their service on the Board of Directors.\nCash compensation for directors, payable quarterly, is as follows:\nBase director compensation - $20,000 per year (except for Dr. Bernards, who was paid an additional annual cash fee of $40,000, in lieu of the annual June 30\ngrant of stock option as described below, through March 31, 2024)\nChairman of audit committee – additional $10,000 per year\nChairman of any other committees – additional $5,000 per year\nMember of audit committee – additional $5,000 per year\nMember of any other committees – additional $2,500 per year\nIn conjunction with the Company’s efforts to preserve cash, the Board approved an amendment to the Board Plan, such that for the quarters ended June 30,\n2024, September 30, 2024 and December 31, 2024, the non-officer directors (including Dr. Bernards) will receive, in lieu of cash compensation, stock options\nexercisable for a period of five years, vesting immediately, to purchase common stock at an exercise price based on the closing market price at the end of each\nof the applicable quarters, with the amount of such stock options equal to the cash payment such director would otherwise have been entitled to receive for\nsuch quarter, divided by their quarter-end value as determined pursuant to the Black-Scholes option-pricing model. The Board may extend this amendment to\nthe Board Plan for additional quarterly periods subsequent to December 31, 2024.\nEquity compensation for directors is as follows:\nAppointment of new directors – The Company grants options to purchase 25,000 shares of common stock, exercisable for a period of five years, at the closing\nmarket price on the date of grant, vesting 50% on the grant date and the remaining 50% vesting 12.5% on the last day of each calendar quarter beginning in\nthe quarter immediately subsequent to the date of the grant until fully vested, subject to continued service. At the discretion of the Board of Directors, for a\nnominee to the Board of Directors who is restricted by their respective institution or employer from receiving equity-based compensation, in lieu of the grant\nof such stock options, the Company may elect to pay a one-time cash fee of $100,000 to such director, payable upfront.\nAnnual grant of options to directors – Effective on the last business day of the month of June, the Company grants options to purchase 10,000 shares of\ncommon stock, exercisable for a period of five years, at the closing market price on the date of grant, vesting 12.5% on the last day of each calendar quarter\nbeginning in the quarter immediately subsequent to the date of grant until fully vested, subject to continued service. If any director has served for less than 12\nfull calendar months on the grant date, the amount of such stock option grant is prorated based on the length of service of such director. At the discretion of\nthe Board of Directors, for a nominee to the Board of Directors who is restricted by their respective institution or employer from receiving equity-based\ncompensation, in lieu of the grant of such stock options, the Company may elect to pay an annual cash fee of $40,000 to such director, payable quarterly.\nTotal cash compensation paid to non-officer directors was $0 and $42,228, respectively, for the three months ended September 30, 2024 and 2023. Total cash\ncompensation paid to non-officer directors was $38,819 and $127,229, respectively, for the nine months ended September 30, 2024 and 2023.\n20\nStock-based compensation granted to members of the Company’s Board of Directors, officers and affiliates is described at Note 6.\nA summary of related party costs, including compensation under employment and consulting agreements and fees paid to non-officer directors for their services on the\nBoard of Directors, for the three months and nine months ended September 30, 2024 and 2023, is presented below.\nThree Months Ended Nine Months Ended\nSeptember 30, September 30,\n2024 2023 2024 2023\nRelated party costs:\nCash-based $ 176,226 $ 243,895 $ 566,624 $ 728,896\nStock-based 106,827 112,106 340,445 669,146\nTotal $ 283,053 $ 356,001 $ 907,069 $ 1,398,042\n6. Stock-Based Compensation\nThe Company periodically issues common stock and stock options as incentive compensation to directors and as compensation for the services of employees,\ncontractors, and consultants of the Company.\nOn July 14, 2020, the Board of Directors of the Company adopted the 2020 Stock Incentive Plan (the “2020 Plan”), which was subsequently approved by the\nstockholders of the Company. The 2020 Plan provides for the granting of equity-based awards, consisting of stock options, restricted stock, restricted stock units, stock\nappreciation rights, and other stock-based awards to employees, officers, directors and consultants of the Company and its affiliates, initially for a total of 233,333 shares of the\nCompany’s common stock, under terms and conditions as determined by the Company’s Board of Directors. On October 7, 2022, the stockholders of the Company approved an\namendment to the 2020 Plan to increase the number of common shares issuable thereunder by 180,000 shares, to a total of 413,333 shares. On November 27, 2023, the\nstockholders of the Company approved an amendment to the 2020 Plan to increase the number of common shares issuable thereunder by 336,667 shares, to a total of 750,000\nshares.\nAs of September 30, 2024, unexpired stock options for 623,232 shares were issued and outstanding under the 2020 Plan and 126,768 shares were available for\nissuance under the 2020 Plan.\nThe fair value of a stock option award is calculated on the grant date using the Black-Scholes option-pricing model. The risk-free interest rate is based on the U.S.\nTreasury yield curve in effect as of the grant date. The expected dividend yield assumption is based on the Company’s expectation of dividend payouts and is assumed to be\nzero. The estimated volatility is based on the historical volatility of the Company’s common stock, calculated utilizing a look-back period approximately equal to the\ncontractual life of the stock option being granted. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as the mid-point\nbetween the vesting period and the contractual term (the “simplified method”). The fair market value of the common stock is determined by reference to the quoted market\nprice of the common stock on the grant date.\nFor stock options requiring an assessment of value during the nine months ended September 30, 2024, the fair value of each stock option award was estimated using\nthe Black-Scholes option-pricing model with the following assumptions:\nRisk-free interest rate 3.550% to 4.290%\nExpected dividend yield 0%\nExpected volatility 125.59% to 126.45%\nExpected life 2.5 to 3.5 years\n21\nFor stock options requiring an assessment of value during the nine months ended September 30, 2023, the fair value of each stock option award was estimated using\nthe Black-Scholes option-pricing model with the following assumptions:\nRisk-free interest rate 4.565% to 4.843%\nExpected dividend yield 0%\nExpected volatility 138.05%\nExpected life 4.0 years\nOn July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement with Eric J. Forman, Mr. Forman was granted stock options to\npurchase 5,833 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options are exercisable for a period of five years at an exercise\nprice of $71.40 per share, which was equal to the closing market price of the Company’s common stock on the grant date. The options vested 25% on August 12, 2020, 2021\nand 2022, respectively, with the final 25% vesting on August 12, 2023. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,\nwas determined to be $400,855 ($68.718 per share), of which $100,214 was attributable to the portion of the stock options fully vested on August 12, 2020 and was therefore\ncharged to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from August 12, 2020 through\nAugust 12, 2023. The Company recorded a charge to general and administrative costs in the consolidated statement of operations for the three months and nine months ended\nSeptember 30, 2023 of $11,806 and $61,501, respectively, with respect to these stock options.\nOn August 1, 2020, in connection with an employment agreement with Dr. James S. Miser, M.D., Dr. Miser was granted stock options to purchase 8,333 shares of the\nCompany’s common stock. The options can be exercised on a cashless basis. The options are exercisable for a period of five years at an exercise price of $71.40 per share,\nwhich was equal to the closing market price of the Company’s common stock on the effective date of the employment agreement. The options vested 25% on August 1, 2020,\n2021 and 2022, respectively, with the final 25% vesting on August 1, 2023. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing\nmodel, was determined to be $572,650 ($68.718 per share), of which $143,163 was attributable to the portion of the stock options fully vested on August 1, 2020 and was\ntherefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from August 1, 2020\nthrough August 1, 2023. The Company recorded a charge to general and administrative costs in the consolidated statement of operations for the three months and nine months\nended September 30, 2023 of $12,551 and $83,544, respectively, with respect to these stock options.\nOn August 12, 2020, in connection with the employment agreement with Robert N. Weingarten, Mr. Weingarten was granted stock options to purchase 5,833 shares of\nthe Company’s common stock. The options can be exercised on a cashless basis. The options are exercisable for a period of five years at an exercise price of $71.40 per share,\nwhich was equal to the closing market price of the Company’s common stock on the grant date. The options vested 25% on August 12, 2020, 2021 and 2022, respectively, with\nthe final 25% vesting on August 12, 2023. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be\n$400,855 ($68.718 per share), of which $100,214 was attributable to the portion of the stock options fully vested on August 12, 2020 and was therefore charged to operations\non that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from August 12, 2020 through August 12, 2023. The\nCompany recorded a charge to general and administrative costs in the consolidated statement of operations for the three months and nine months ended September 30, 2023 of\n$11,806 and $61,501, respectively, with respect to these stock options.\nOn May 11, 2021, the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board of Directors, and in\naccordance with the Company’s cash and equity compensation package for members of the Board of Directors, Ms. Brown was granted stock options to purchase 25,000 shares\nof the Company’s common stock, exercisable for a period of five years at an exercise price of $28.00 per share (the closing market price on the grant date), vesting 50% on the\ngrant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested. The fair value of these stock options, as calculated\npursuant to the Black-Scholes option-pricing model, was determined to be $658,363 ($26.335 per share), of which $329,188 was attributable to the portion of the stock options\nfully vested on May 11, 2021 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to\noperations ratably from May 11, 2021 through June 30, 2023. The Company recorded a charge to general and administrative costs in the consolidated statement of operations\nfor the three months and nine months ended September 30, 2023 of $0 and $76,388, respectively, with respect to these stock options.\n22\nOn June 30, 2021, the Board of Directors, in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, granted to\neach of the five non-officer directors of the Company stock options to purchase 10,000 shares (a total of 50,000 shares) of the Company’s common stock, exercisable for a\nperiod of five years at an exercise price of $30.30 per share (the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end\nuntil fully vested. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $1,421,095 ($28.423 per share),\nwhich was charged to operations ratably from July 1, 2021 through June 30, 2023. The Company recorded a charge to general and administrative costs in the consolidated\nstatement of operations for the three months and nine months ended September 30, 2023 of $0 and $211,413, respectively, with respect to these stock options.\nOn June 17, 2022, the Board of Directors appointed Bas van der Baan to the Board of Directors. In connection with his appointment to the Board of Directors, and in\naccordance with the Company’s cash and equity compensation package for members of the Board of Directors, Mr. Baan was granted stock options to purchase 25,000 shares\nof the Company’s common stock, exercisable for a period of five years at an exercise price of $7.40 per share (the closing market price on the grant date), vesting 50% on the\ngrant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested, subject to continued service. The fair value of these stock\noptions, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $158,525 ($6.341 per share), of which $79,263 was attributable to the portion\nof the stock options fully vested on June 17, 2022 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options\nwas charged to operations ratably from June 17, 2022 through June 30, 2024. During the three months ended September 30, 2024 and 2023, the Company recorded charges to\ngeneral and administrative costs in the consolidated statement of operations of $0 and $9,801, respectively, with respect to these stock options. During the nine months ended\nSeptember 30, 2024 and 2023, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $19,390 and $29,084,\nrespectively, with respect to these stock options.\nOn June 30, 2022, the Board of Directors, in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, granted to\neach of the five non-officer directors of the Company stock options to purchase 10,000 shares (a total of 50,000 shares) of the Company’s common stock, exercisable for a\nperiod of five years at an exercise price of $7.40 per share (the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end\nuntil fully vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be\n$316,700 ($6.334 per share), which was charged to operations ratably from July 1, 2022 through June 30, 2024. During the three months ended September 30, 2024 and 2023,\nthe Company recorded charges to general and administrative costs in the consolidated statement of operations of $0 and $23,916, respectively, with respect to these stock\noptions. During the nine months ended September 30, 2024 and 2023, the Company recorded charges to general and administrative costs in the consolidated statement of\noperations of $47,310 and $70,964, respectively, with respect to these stock options.\nOn November 6, 2022, the Board of Directors granted to each of the four officers of the Company stock options to purchase 20,000 shares (a total of 80,000 shares) of\nthe Company’s common stock, exercisable for a period of five years at an exercise price of $20.00 per share, vesting 25% on issuance and 25% on each anniversary date\nthereafter until fully vested, subject to continued service. The total fair value of the 80,000 stock options, as calculated pursuant to the Black-Scholes option-pricing model, was\ndetermined to be $262,560 ($3.282 per share), which is being charged to operations ratably from November 6, 2022 through November 6, 2025. During the three months ended\nSeptember 30, 2024 and 2023, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $9,641 and $16,528,\nrespectively, with respect to these stock options. During the nine months ended September 30, 2024 and 2023, the Company recorded charges to general and administrative\ncosts in the consolidated statement of operations of $34,301 and $49,053, respectively, with respect to these stock options.\nOn June 30, 2023, the Board of Directors, in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, granted to\neach of the four non-officer directors of the Company stock options to purchase 10,000 shares (a total of 40,000 shares) of the Company’s common stock, exercisable for a\nperiod of five years at an exercise price of $5.88 per share (the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end\nuntil fully vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be\n$192,593 ($4.8131 per share), which is being charged to operations ratably from July 1, 2023 through June 30, 2025. During the three months ended September 30, 2024 and\n2023, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $24,232 and $24,232, respectively, with respect to these\nstock options. During the nine months ended September 30, 2024 and 2023, the Company recorded charges to general and administrative costs in the consolidated statement of\noperations of $72,300 and $24,232, respectively, with respect to these stock options.\n23\nOn September 26, 2023, in connection with the employment agreement entered into with Bas van der Baan, Mr. van der Baan was granted stock options to purchase\n250,000 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options are exercisable for a period of five years at an exercise price of\n$1.95 per share, which was equal to the closing market price of the Company’s common stock on the grant date. The options vest in equal increments quarterly over a three-\nyear period commencing on the last day of each calendar quarter commencing October 1, 2023, subject to continued service. The fair value of these stock options, as calculated\npursuant to the Black-Scholes option-pricing model, was determined to be $403,066 ($1.612 per share), which is being charged to operations ratably from September 26, 2023\nthrough September 30, 2026. During the three months ended September 30, 2024 and 2023, the Company recorded charges to general and administrative costs in the\nconsolidated statement of operations of $33,712 and $1,466, respectively, with respect to these stock options. During the nine months ended September 30, 2024 and 2023, the\nCompany recorded charges to general and administrative costs in the consolidated statement of operations of $100,402 and $1,466, respectively, with respect to these stock\noptions.\nOn June 30, 2024, the Board of Directors, in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, granted to\neach of the four non-officer directors of the Company stock options to purchase 10,000 shares (a total of 40,000 shares) of the Company’s common stock, exercisable for a\nperiod of five years at an exercise price of $2.37 per share (the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end\nuntil fully vested, subject to continued service. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be\n$73,976 ($1.8494 per share), which is being charged to operations ratably from July 1, 2024 through June 30, 2026. During the three months and nine months ended September\n30, 2024, the Company record a charge general and administrative costs in the consolidated statement of operations of $9,324 and $9,324, respectively, with respect to these\nstock options.\nOn June 30, 2024, the Board of Directors, in conjunction with the Company’s efforts to preserve cash, granted to the four non-officer directors of the Company a total\nof 16,598 stock options to purchase shares of the Company’s common stock, exercisable for a period of five years at an exercise price of $2.37 per share (the closing market\nprice on the grant date) The stock options were granted in lieu of cash compensation, are exercisable for a period of five years and were immediately vested. The number of\nstock options granted to each of the four non-officer directors of the Company was determined to be equal to the cash payment such director would otherwise have been entitled\nto receive for such quarter, divided by their quarter-end value as determined pursuant to the Black-Scholes option-pricing model and was determined to be $27,500 ($1.6570\nper share), which was charged to operations on June 30, 2024, the date on which they became fully vested.\nOn July 1, 2024, in connection with the consulting agreement with Dr. Jan H.M. Schellens, M.D., Ph.D., Dr. Schellens was granted stock options to purchase 15,000\nshares of the Company’s common stock. The options can be exercised on a cashless basis. The options are exercisable for a period of five years at an exercise e price of $2.39\nper share, which was equal to the closing market price of the Company’s common stock on the grant date. The options vest quarterly over a three-year period commencing on\nthe last day of each calendar quarter commencing September 30, 2024. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model,\nwas determined to be $29,074 ($1.9382 per share), which is being charged to operations ratably from July 1, 2024 through June 30, 2027. During the three months and nine\nmonths ended September 30, 2024, the Company record a charge general and administrative costs in the consolidated statement of operations of $2,418 and $2,418,\nrespectively, with respect to these stock options.\nOn September 30, 2024, the Board of Directors, in conjunction with the Company’s efforts to preserve cash, granted to the four non-officer directors of the Company a\ntotal of 21,217 stock options to purchase shares of the Company’s common stock, exercisable for a period of five years at an exercise price of $1.87 per share (the closing\nmarket price on the grant date) The stock options were granted in lieu of cash compensation, are exercisable for a period of five years and were immediately vested. The\nnumber of stock options granted to each of the four non-officer directors of the Company was determined to be equal to the cash payment such director would otherwise have\nbeen entitled to receive for such quarter, divided by their quarter-end value as determined pursuant to the Black-Scholes option-pricing model and was determined to be\n$27,500 ($1.2961 per share), which was charged to operations on September 30, 2024, the date on which they became fully vested.\n24\nDr. Philip Palmedo, a director of the Company since 2006, did not stand for re-election to the Company’s Board of Directors at the Company’s annual meeting of\nstockholders held on October 7, 2022. Gil Schwartzberg, a former director of the Company, died on October 30, 2022. Dr. John S. Kovach, the Chairman of the Board of\nDirectors and the Company’s President and Chief Executive Officer, and Chief Scientific Officer, died on October 5, 2023, and the employment agreement of the Company’s\nChief Medical Officer, Dr. James S. Miser expired on July 31, 2024. Accordingly, the unvested stock options for each such person ceased vesting effective as of the respective\ndates that their services to the Company terminated. Furthermore, the expiration date of all vested stock options owned by each such person contractually expired one year from\nthe respective dates that their services to the Company terminated.\nA summary of stock-based compensation costs for the three months and nine months ended September 30, 2024 and 2023 is as follows:\nThree Months Ended Nine Months Ended\nSeptember 30, September 30,\n2024 2023 2024 2023\nRelated parties $ 106,827 $ 112,106 $ 340,445 $ 669,146\nNon-related parties — — — —\nTotal stock-based compensation costs $ 106,827 $ 112,106 $ 340,445 $ 669,146\nA summary of stock option activity, including options issued in the form of warrants, during the nine months ended September 30, 2024 is as follows:\nWeighted Average\nWeighted Average Remaining\nNumber of Exercise Contractual Life\nShares Price (in Years)\nStock options outstanding at December 31, 2023 552,083 $ 15.330\nGranted 92,815 2.259\nExercised — —\nExpired (21,666) 42.461\nStock options outstanding at September 30, 2024 623,232 $ 12.441 3.36\nStock options exercisable at December 31, 2023 252,292 $ 28.387\nStock options exercisable at September 30, 2024 372,815 $ 18.305 2.87\nTotal deferred compensation expense for the outstanding value of unvested stock options was approximately $467,000 at September 30, 2024, which will be\nrecognized subsequent to September 30, 2024 over a weighted-average period of approximately 21 months.\nAt September 30, 2024, the outstanding common stock options, including options issued in the form of warrants, are exercisable at the following prices per common\nshare:\nOptions Options\nExercise Prices Outstanding (Shares) Exercisable (Shares)\n$ 1.870 21,217 21,217\n$ 1.950 250,000 83,333\n$ 2.370 56,598 21,598\n$ 2.390 15,000 1,250\n$ 5.025 8,750 8,750\n$ 5.880 40,000 25,000\n$ 7.400 55,000 55,000\n$ 20.000 55,000 35,000\n$ 20.600 20,000 20,000\n$ 28.000 25,000 25,000\n$ 30.300 30,000 30,000\n$ 32.100 10,000 10,000\n$ 60.000 8,333 8,333\n$ 71.400 20,000 20,000\n$ 120.000 8,334 8,334\n623,232 372,815\n25\nBased on the closing fair market value of $1.87 per share on September 30, 2024, there was no intrinsic value attributed to exercisable but unexercised common stock\noptions at September 30, 2024.\nOutstanding stock options to acquire 250,417 shares of the Company’s common stock had not vested at September 30, 2024.\nUpon the exercise of such stock options, the Company expects to satisfy the related stock obligations through the issuance of authorized but unissued shares of\ncommon stock.\n7. Income Taxes\nDuring the three months and nine months ended September 30, 2024 and 2023, the Company did not record any provision for income taxes, as the Company incurred\nlosses during such periods. Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial\nreporting purposes and the amounts used for income tax purposes. The Company has recorded a full valuation allowance against its deferred tax assets for all periods presented\nas the Company currently believes it is more likely than not that the deferred tax assets will not be realized.\n8. Commitments and Contingencies\nLegal Claims\nThe Company may be subject to legal claims and actions from time to time as part of its business activities. As of September 30, 2024 and December 31, 2023, the\nCompany was not subject to any threatened or pending lawsuits, legal claims or legal proceedings.\nPrincipal Commitments\nClinical Trial Agreements\nAt September 30, 2024, the Company’s remaining financial contractual commitments pursuant to clinical trial agreements and clinical trial monitoring agreements not\nyet incurred, as described below, aggregated $3,918,000, including clinical trial agreements of $3,616,000 and clinical trial monitoring agreements of $302,000, which, based\non current estimates, are currently scheduled to be incurred through approximately December 31, 2027. The Company’s ability to conduct and fund these contractual\ncommitments is subject to the timely availability of sufficient capital to fund such expenditures, as well as any changes in the allocation or reallocation of such funds to the\nCompany’s current or future clinical trial programs. The Company expects that the full amount of these expenditures will be incurred only if such clinical trial programs are\nconducted as originally designed and their respective enrollments and duration are not modified or reduced. Clinical trial programs, such as the types that the Company is\nengaged in, can be highly variable and can frequently involve a series of changes and modifications over time as clinical data is obtained and analyzed, and is frequently\nmodified, suspended or terminated, in part based on receipt or lack of receipt of an indication of clinical benefit or activity, before the clinical trial endpoint is reached.\nAccordingly, such contractual commitments as discussed herein should be considered as estimates only based on current clinical assumptions and conditions and are typically\nsubject to significant modifications and revisions over time.\n26\nThe following is a summary of the Company’s ongoing contractual clinical trials described below as of September 30, 2024:\nExpected\nNumber Date of Remaining\nDescription of Preliminary Financial\nof Clinical Start Projected Patients Study Clinical Efficacy Contractual\nTrial Institution Date End Date in Trial Objective Update Signal NCT No. Commitment\nLB-100\ncombined\nwith\natezolizumab\nin\nmicrosatellite First\nstable Netherlands patient\nmetastatic Cancer Determine entered\ncolon cancer Institute August December RP2D with August\n(Phase 1b) (NKI) 2024 2026 37 atezolizumab 2024 June 2026 NCT06012734 (1)\nLB-100\ncombined\nwith\ndoxorubicin\nin advanced Recruitment\nsoft tissue completed Determine Fourteen\nsarcoma June September MTD and patients\n(Phase 1b) GEIS 2023 2024 9 to 18 RP2D entered March 2025 NCT05809830 $ 284,000\nDoxorubicin Clinical\nwith or trial not\nwithout LB- yet begun\n100 in (subject to\nadvanced completion\nsoft tissue of Phase\nsarcoma Determine 1b GEIS\n(Randomized efficacy: clinical December\nPhase 2) GEIS TBD TBD 150 PFS trial) 2026 NCT05809830 $ 3,332,000\nLB-100\ncombined Determine\nwith the OS of\ndostarlimab patients with\nin ovarian recurrent\nclear cell ovarian clear Seven\ncarcinoma MD January December cell patients December\n(Phase 1b/2) Anderson 2024 2027 21 carcinoma entered 2026 NCT06065462 (1)\nTotal $ 3,616,000\n(1) The Company has no financial contractual commitment associated with this clinical trial at September 30, 2024.\nNetherlands Cancer Institute. Effective June 10, 2024, the Company entered into a Clinical Trial Agreement with the Netherlands Cancer Institute (“NKI”) (see Note\n5) to conduct a Phase 1b clinical trial of the Company’s protein phosphatase inhibitor, LB-100, combined with atezolizumab, a PD-L1 inhibitor, the proprietary molecule of F.\nHoffman-La Roche Ltd. (“Roche”), for patients with microsatellite stable metastatic colon cancer. Under the agreement, the Company will provide its lead compound, LB-100,\nand under a separate agreement between NKI and Roche, Roche will provide atezolizumab and financial support for the clinical trial. The Company has no obligation to and\nwill not provide any reimbursement of clinical trial costs. Pursuant to the agreement and the protocol set forth in the agreement, the clinical trial will be conducted by NKI at\nNKI’s site in Amsterdam by principal investigator Neeltje Steeghs, MD, PhD, and NKI will be responsible for the recruitment of patients. The agreement provides for the\nprotection of the respective intellectual property rights of each of the Company, NKI and Roche.\n27\nThis Phase 1b clinical trial will evaluate safety, optimal dose and preliminary efficacy of LB-100 combined with atezolizumab for the treatment of patients with\nmetastatic microsatellite stable colorectal cancer. Immunotherapy using monoclonal antibodies like atezolizumab can enhance the body’s immune response against cancer and\nhinder tumor growth and spread. LB-100 has been found to improve the effectiveness of anticancer drugs in killing cancer cells by inhibiting a protein called PP2A on cell\nsurfaces. Blocking PP2A increases stress signals in tumor cells expressing the PP2A protein. Accordingly, combining atezolizumab with LB-100 may enhance treatment\nefficacy for metastatic colorectal cancer, as cancer cells with heightened stress signals are more vulnerable to immunotherapy.\nThis study comprises a dose escalation phase and a dose expansion phase. The objective of the dose escalation phase is to determine the recommended Phase 2 dose\n(RP2D) of LB-100 when combined with the standard dosage of atezolizumab. The dose expansion phase will further investigate the preliminary efficacy, safety, tolerability,\nand pharmacokinetics/dynamics of the LB-100 and atezolizumab combination. The clinical trial opened in August 2024 with the enrollment of the first patient. Patient accrual\nis expected to take up to 24 months, with a maximum of 37 patients with advanced colorectal cancer to be enrolled in this study.\nThe principal investigator of the colorectal study testing LB-100 in combination with atezolizumab is currently investigating two Serious Adverse Events (“SAEs”)\nobserved in the clinical trial. Evaluation is underway to determine next steps (see “Serious Adverse Events” below for additional information).\nThe Company has no financial contractual commitment associated with this clinical trial.\nCity of Hope. Effective January 18, 2021, the Company executed a Clinical Research Support Agreement (the “Agreement”) with the City of Hope National Medical\nCenter, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively, “City of Hope”), to carry out a Phase 1b clinical trial of LB-100,\nthe Company’s first-in-class protein phosphatase inhibitor, combined with an FDA-approved standard regimen for treatment of untreated extensive-stage disease small cell lung\ncancer (“ED-SCLC”). LB-100 was given in combination with carboplatin, etoposide and atezolizumab, an FDA-approved standard of care regimen, to previously untreated\nED-SCLC patients. The LB-100 dose was to be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended Phase 2 dose (“RP2D”). Patient entry\nwas to be expanded so that a total of 12 patients would be evaluable at the RP2D to confirm the safety of the LB-100 combination and to look for potential therapeutic activity\nas assessed by objective response rate, duration of overall response, progression-free survival, and overall survival.\nThe clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. Because patient accrual was slower than\nexpected, effective March 6, 2023, the Company and City of Hope added the Sarah Cannon Research Institute (“SCRI”), Nashville, Tennessee, to the ongoing Phase 1b clinical\ntrial. The Company and City of Hope continued efforts to increase patient accrual by adding additional sites and by modifying the protocol to increase the number of patients\neligible for the clinical trial. The impact of these efforts to increase patient accrual and to decrease time to completion was evaluated in subsequent quarters.\nAfter evaluating patient accrual through June 30, 2024, the Company and City of Hope agreed to close the clinical trial. Pursuant to the terms of the Agreement, the\nCompany provided notice to City of Hope of the Company’s intent to terminate the Agreement effective as of July 8, 2024. Upon closure, the Company incurred a prorated\ncharge of $207,004 for the cost of patients enrolled to date. The Company is exploring alternative sites, including international locations, for the conduct of a small cell lung\ncancer clinical trial.\nDuring the three months ended September 30, 2024 and 2023, the Company incurred costs of $207,004 and $0, respectively, pursuant to this Agreement. During the\nnine months ended September 30, 2024 and 2023, the Company incurred costs of $285,019 and $69,001, respectively, pursuant to this Agreement. As of September 30, 2024,\ntotal costs of $732,532 had been incurred pursuant to this Agreement.\nGEIS. Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the Spanish Sarcoma Group\n(Grupo Español de Investigación en Sarcomas or “GEIS”), Madrid, Spain, to carry out a study entitled “Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin\nalone in first line of advanced soft tissue sarcoma”. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined with\ndoxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (“ASTS”). Doxorubicin alone has been the\nmainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding cytotoxic compounds to or substituting other cytotoxic compounds\nfor doxorubicin. In animal models, LB-100 consistently enhances the anti-tumor activity of doxorubicin without apparent increases in toxicity.\n28\nGEIS has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative studies in ASTS. The\nCompany agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as well as to provide funding for the clinical trial. The goal is to\nenter approximately 150 to 170 patients in this clinical trial over a period of two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to\ndetermine the recommended Phase 2 dose of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase 2 portion\nof the study assumes a median progression-free survival (“PFS”), no evidence of disease progression or death from any cause, of 4.5 months in the doxorubicin arm and an\nalternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate a statistically significant decrease in relative risk of progression or death by adding\nLB-100. There is a planned interim analysis of the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.\nThe Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July 2020, the Spanish\nregulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol, it required that the Company manufacture new inventory\nof LB-100 under current Spanish pharmaceutical manufacturing standards. These standards were adopted subsequent to the production of the Company’s existing LB-100\ninventory.\nIn order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out the multiple tasks\nneeded to make and gain approval of a new clinical product for investigational study in Spain. These tasks included the synthesis under good manufacturing practice (GMP) of\nthe active pharmaceutical ingredient (API), with documentation of each of the steps involved by an independent auditor. The API was then transferred to a vendor that prepares\nthe clinical drug product, also under GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,\nprovide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal application documenting all steps taken to prepare\nthe clinical drug product for clinical use was submitted to the appropriate regulatory authorities for review and approval before being used in a clinical trial.\nAs of December 31, 2023, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially for subsequent\nmultiple trials within the European Union, had cost approximately $1,144,000.\nOn October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Española de Medicamentos y Productos\nSanitarios or “AEMPS”) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company’s lead clinical compound, plus doxorubicin, versus doxorubicin alone,\nthe global standard for initial treatment of ASTS. Consequently, this clinical trial commenced during the quarter ended June 30, 2023 and is expected to be completed and a\nreport prepared by December 31, 2026. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at Fundación Jiménez Díaz University\nHospital (Madrid). Up to 170 patents will be entered into the clinical trial. The recruitment for the Phase 1b portion of the protocol was extended with two patients and was\ncompleted during the quarter ended September 30, 2024. The Company expects to have data on toxicity and preliminary efficacy from this portion of the clinical trial by\nDecember 31, 2024, and a full report by June 30, 2025. Subject to clinical results and the availability of sufficient working capital resources, the Company anticipates that it\nwill then be in a position to decide whether to proceed to the related Phase 2 portion of the study.\nThe interim analysis of the Phase 2 portion of this clinical trial will be done before full accrual of patients is completed to determine whether the study has the\npossibility of showing superiority of the combination of LB-100 plus doxorubicin compared to doxorubicin alone. A positive study would have the potential to change the\nstandard therapy for this disease after four decades of failure to improve the marginal benefit of doxorubicin alone.\nThe Company’s agreement with GEIS provides for various payments based on achieving specific milestones over the term of the agreement. During the three months\nended September 30, 2024 and 2023, the Company did not incur any costs pursuant to this agreement. During the nine months ended September 30, 2024 and 2023, the\nCompany incurred costs of $0 and $268,829, respectively, pursuant to this agreement. Through September 30, 2024, the Company has incurred charges of $684,652 for work\ndone under this agreement through the fourth milestone.\n29\nThe Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $3,616,000 (consisting of $284,000 for\nthe Phase 1b portion and $3,332,000 for the Phase 2 portion) as of September 30, 2024, which is scheduled to be incurred through December 31, 2027. As the work is being\nconducted in Europe and is paid for in Euros, final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro. Such fluctuations are\nrecorded in the consolidated statements of operations as foreign currency gain or loss, as appropriate, and have not been significant.\nMD Anderson Cancer Center Clinical Trial. On September 20, 2023, the Company announced an investigator-initiated Phase 1b/2 collaborative clinical trial to\nassess whether adding LB-100 to a human programmed death receptor-1 (“PD-1”) blocking antibody of GSK plc (“GSK”), dostarlimab-gxly, may enhance the effectiveness of\nimmunotherapy in the treatment of ovarian clear cell carcinoma (“OCCC”). The study objective is to determine the overall survival (“OS”) of patients with OCCC. The clinical\ntrial is being sponsored by The University of Texas MD Anderson Cancer Center (“MD Anderson”) and is being conducted at The University of Texas - MD Anderson Cancer\nCenter. The Company is providing LB-100 and GSK is providing dostarlimab-gxly and financial support for the clinical trial. On January 29, 2024, the Company announced\nthe entry of the first patient into this clinical trial. The Company currently expects that this clinical trial will be completed by December 31, 2027.\nMoffitt. Effective August 20, 2018, the Company entered into a Clinical Trial Research Agreement with the Moffitt Cancer Center and Research Institute Hospital\nInc., Tampa, Florida (“Moffitt”), effective for a term of five years. Pursuant to the Clinical Trial Research Agreement, Moffitt agreed to conduct and manage a Phase 1b/2\nclinical trial to evaluate the toxicity and therapeutic benefit of the Company’s lead anti-cancer clinical compound LB-100 to be administered intravenously in patients with low\nor intermediate-1 risk myelodysplastic syndrome (“MDS”).\nIn November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug (“IND”) Application to conduct a\nPhase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of LB-100 in patients with low and intermediate-1 risk MDS who had failed or were intolerant of\nstandard treatment. This Phase 1b/2 clinical trial utilized LB-100 as a single agent in the treatment of patients with low and intermediate-1 risk MDS.\nThe clinical trial began at a single site in April 2019 and the first patient was entered into the clinical trial in July 2019. During the year ended December 31, 2023, the\nclinical trial was closed. Although the maximum tolerated dose (“MTD”) was not achieved, there was no dose-limiting toxicity noted.\nDuring the three months and nine months ended September 30, 2024 and 2023, the Company did not incur any costs pursuant to this agreement. As of September 30,\n2024, total costs of $147,239 had been incurred pursuant to this agreement.\nDuring September 2023, the Company decided not to pursue further studies in MDS, as other, more promising, opportunities had become available (see “Patent and\nLicense Agreements - Moffitt” below).\nNational Cancer Institute Pharmacologic Clinical Trial. In May 2019, the National Cancer Institute (“NCI”) initiated a glioblastoma (“GBM”) pharmacologic\nclinical trial. This study was being conducted and funded by the NCI under a Cooperative Research and Development Agreement, with the Company responsible for providing\nthe LB-100 clinical compound. The NCI study was designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove\none or more tumors received one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100 present and to determine\nwhether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its molecular target. As a result of the innovative design of the NCI\nstudy, it was believed that data from a few patients would be sufficient to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding\nLB-100 to the standard treatment regimen for GBMs. Blood and brain tumor tissue were analyzed from seven patients after intravenous infusion of a single dose of LB-100.\nResults of the investigation demonstrated that there was virtually no entry of LB-100 into the brain tumor tissue. Accordingly, alternative methods of drug delivery will be\nrequired to determine if LB-100 has meaningful clinical anti-cancer activity against glioblastoma multiforme and other aggressive brain tumors. The Company is considering an\nadditional clinical study to address the delivery of LB-100 to the brain.\nClinical Trial Monitoring Agreements\nMD Anderson Cancer Center Clinical Trial. On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen investigator-\ninitiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 (“PD-1”) blocking antibody of GSK plc (“GSK”),\ndostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (“OCCC”). On August 19, 2024, the Company signed a\nwork order agreement with Theradex to monitor the MD Anderson clinical trial. The study oversight is expected to be completed by January 31, 2027.\n30\nCosts under this letter of intent and related work order agreement are estimated to be approximately $95,000. During the three months and nine months ended\nSeptember 30, 2024, the Company incurred costs of $12,610 and $20,838 pursuant to this letter of intent and subsequent work order. As of September 30, 2024, total costs of\n$20,838 have been incurred pursuant to this letter of intent and subsequent work order.\nThe Company’s aggregate commitment pursuant to this letter of intent, less amounts previously paid to date, totaled approximately $78,000 as of September 30, 2024,\nwhich is expected to be incurred through December 31, 2027.\nCity of Hope. On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated clinical trial in\nsmall cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this work order agreement were estimated to be approximately\n$335,000. During the three months ended September 30, 2024 and 2023, the Company incurred costs of $1,603 and $4,500, respectively, pursuant to this work order. During\nthe nine months ended September 30, 2024 and 2023, the Company incurred costs of $10,603 and $15,740, respectively, pursuant to this work order. As of September 30, 2024,\ntotal costs of $89,284 had been incurred pursuant to this work order agreement.\nAs a result of the closure of the Agreement with City of Hope effective July 8, 2024 (see “Clinical Trial Agreements – City of Hope” above), the work order agreement\nwith Theradex to monitor this clinical trial was concurrently terminated, although nominal oversight trailing costs subsequent to July 8, 2024 are expected to be incurred\nrelating to the closure of this study.\nGEIS. On June 22, 2023, the Company finalized a work order agreement with Theradex, to monitor the GEIS investigator-initiated clinical Phase I/II randomized trial\nof LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma. The study oversight is expected to be completed by December 31, 2026.\nCosts under this work order agreement are estimated to be approximately $153,000, with such payments expected to be allocated approximately 72% to Theradex for\nservices and approximately 28% for payments for pass-through software costs. During the three months ended September 30, 2024 and 2023, the Company incurred costs of\n$13,475 and $3,750, respectively, pursuant to this work order. During the nine months ended September 30, 2024 and 2023, the Company incurred costs of $26,208 and\n$10,000, respectively, pursuant to this work order. As of September 30, 2024, total costs of $41,070 have been incurred pursuant to this work order agreement.\nThe Company’s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled approximately $118,000 as of\nSeptember 30, 2024, which is expected to be incurred through December 31, 2026.\nNetherlands Cancer Institute. On August 27, 2023, the Company finalized a work order agreement with Theradex, to monitor the NKI Phase 1b clinical trial of LB-\n100 combined with atezolizumab, a PD-L1 inhibitor, for patients with microsatellite stable metastatic colon cancer. The study oversight is expected to be completed by May 31,\n2027.\nCosts under this work order agreement are estimated to be approximately $106,380, with such payments expected to be allocated approximately 47% to Theradex for\nservices and approximately 53% for payments for pass-through software costs. During the three months and nine months ended September 30, 2024, the Company incurred\ncosts of $14,900 pursuant to this work order. As of September 30, 2024, total costs of $14,900 have been incurred pursuant to this work order agreement.\nThe Company’s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled approximately $106,380 as of\nSeptember 30, 2024, which is expected to be incurred through May 31, 2027.\n31\nPatent and License Agreements\nNational Institute of Health. Effective February 23, 2024, the Company entered into a Patent License Agreement (the “License Agreement”) with the National\nInstitute of Neurological Disorders and Stroke (“NINDS”) and the National Cancer Institute (“NCI”), each an institute or center of the National Institute of Health (“NIH”).\nPursuant to the License Agreement, the Company has licensed on an exclusive basis the NIH’s intellectual property rights claimed for a Cooperative Research and\nDevelopment Agreement (“CRADA”) subject invention co-developed with the Company, and the licensed field of use, which focuses on promoting anti-cancer activity alone,\nor in combination with standard anti-cancer drugs. The scope of this clinical research extends to checkpoint inhibitors, immunotherapy, and radiation for the treatment of\ncancer. The License Agreement is effective, and shall extend, on a licensed product, licensed process, and country basis, until the expiration of the last-to-expire valid claim of\nthe jointly owned licensed patent rights in each such country in the licensed territory, estimated at twenty years, unless sooner terminated.\nThe License Agreement contemplates that the Company will seek to work with pharmaceutical companies and clinical trial sites (including comprehensive cancer\ncenters) to initiate clinical trials within timeframes that will meet certain benchmarks. Data from the clinical trials will be the subject of various regulatory filings for marketing\napproval in applicable countries in the licensed territories. Subject to the receipt of marketing approval, the Company would be expected to commercialize the licensed products\nin markets where regulatory approval has been obtained.\nThe Company is obligated to pay the NIH a non-creditable, non-refundable license issue royalty of $50,000 and a first minimum annual royalty within sixty days from\nthe effective date of the Agreement. The first minimum annual royalty of $25,643 was prorated from the effective date of the License Agreement to the next subsequent January\n1. Thereafter, the minimum annual royalty of $30,000 is due each January 1 and may be credited against any earned royalties due for sales made in that year. The license issue\nroyalty of $50,000 and the first minimum annual royalty of $25,643, were paid in April 2024.\nThe Company is obligated to pay the NIH, on a country-by-country basis, earned royalties of 2% on net sales of each royalty-bearing product and process, subject to\nreduction by 50% under certain circumstances relating to royalties paid by the Company to third parties, but not less than 1%. The Company’s obligation to pay earned royalties\nunder the License Agreement commences on the date of the first commercial sale of a royalty-bearing product or process and expires on the date on which the last valid claim\nof the licensed product or licensed process expires in such country.\nThe Company is obligated to pay the NIH benchmark royalties, on a one-time basis, within sixty days from the first achievement of each such benchmark. The License\nAgreement defines four such benchmarks, which the Company is required to pursue based on “commercially reasonable efforts” as defined in the License Agreement, with\ndeadlines of October 1, 2024, 2027, 2029 and 2031, respectively, each with a different specified benchmark payment amount payable within thirty days of achieving such\nbenchmark. The October 1, 2024 benchmark of $100,000 was defined as the dosing of the first patient with a licensed product in a Phase 2 clinical study of such licensed\nproduct in the licensed fields of use. The Company had not commenced a Phase 2 clinical study as of September 30, 2024. The total of all such benchmark payments is\n$1,225,000.\nThe Company is obligated to provide annual reports to the NIH on its progress toward the development and commercialization of products under the licensed patents.\nThese reports, due within sixty days following the end of each calendar year, must include updates on research and development activities, regulatory submissions,\nmanufacturing efforts, sublicensing, and sales initiatives. If any deviations from the established commercial development plan or agreed-upon benchmarks occur, the Company\nis obligated to provide explanation and may amend the commercial development plan and the benchmarks, which, subject to certain conditions, the NIH shall not unreasonably\nwithhold, condition, or delay approval of any request of the Company to amend the commercial development plan and/or the benchmarks and to extend the time periods of the\nbenchmarks.\nThe Company is obligated to pay the NIH sublicensing royalties of 5% on sublicensing revenue received for granting each sublicense within sixty days of receipt of\nsuch sublicensing revenue.\nDuring the three months ended September 30, 2024, the Company incurred costs of $7,537 in connection with its obligations under the License Agreement. During the\nnine months ended September 30, 2024, the Company incurred costs of $68,106 in connection with its obligations under the License Agreement. Such costs when incurred have\nbeen included in general and administrative costs in the Company’s consolidated statement of operations. As of September 30, 2024, total costs of $68,106 have been incurred\npursuant to this agreement. The Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $1,795,000 as of\nSeptember 30, 2024, which is expected to be incurred over approximately the next twenty years.\n32\nMoffitt. Effective August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt. Pursuant to the License Agreement, Moffitt granted the\nCompany an exclusive license under certain patents owned by Moffitt (the “Licensed Patents”) relating to the treatment of MDS and a non-exclusive license under inventions,\nconcepts, processes, information, data, know-how, research results, clinical data, and the like (other than the Licensed Patents) necessary or useful for the practice of any claim\nunder the Licensed Patents or the use, development, manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under the\nLicensed Patents.\nOn October 4, 2023, the Company received a counter-signed termination letter dated September 29, 2023 with respect to the Exclusive License Agreement dated\nAugust 20, 2018 between the Company and Moffitt, effective September 30, 2023. The Company and Moffitt agreed that no termination fee was due or payable by the\nCompany, and Moffitt acknowledged that no payments are owed by the Company under the Agreement.\nDuring the three months and nine months ended September 30, 2023, the Company recorded credits to operations of $21,507 and $9,109, respectively, representing the\nreversal of obligations previously recorded with respect to the Exclusive License Agreement.\nOther Significant Agreements and Contracts\nNDA Consulting Corp. On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. for consultation and advice in the field of\noncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel D. Von Hoff, M.D., to become a member of the\nCompany’s Scientific Advisory Committee. The term of the agreement was for one year and provided for a quarterly cash fee of $4,000. The agreement has been automatically\nrenewed for additional one-year terms on its anniversary date since 2014. Consulting and advisory fees charged to operations pursuant to this agreement were $4,000 and\n$4,000 for the three months ended September 30, 2024 and 2023, respectively. Consulting and advisory fees charged to operations pursuant to this agreement were $12,000 and\n$12,000 for the nine months ended September 30, 2024 and 2023, respectively. This agreement was terminated effective July 3, 2024.\nBioPharmaWorks. Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company\nengaged BioPharmaWorks to perform certain services for the Company. Those services included, among other things, assisting the Company to commercialize its products and\nstrengthen its patent portfolio; identifying large pharmaceutical companies with a potential interest in the Company’s product pipeline; assisting in preparing technical\npresentations concerning the Company’s products; consultation in drug discovery and development; and identifying providers and overseeing tasks relating to clinical\ndevelopment of new compounds.\nBioPharmaWorks was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience. The\nCollaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated by a party not less than 60 days prior to\nthe expiration of the applicable period. In connection with the Collaboration Agreement, the Company agreed to pay BioPharmaWorks a monthly fee of $10,000, subject to the\nright of the Company to pay a negotiated hourly rate in lieu of the monthly fee. Effective March 1, 2024, the compensation payable under the Collaboration Agreement was\nconverted to an hourly rate structure.\nThe Company recorded charges to operations pursuant to this Collaboration Agreement of $8,000 and $30,000 during the three months ended September 30, 2024 and\n2023, respectively, which were included in research and development costs in the consolidated statements of operations. The Company recorded charges to operations pursuant\nto this Collaboration Agreement of $35,200 and $90,000 during the nine months ended September 30, 2024 and 2023, respectively, which were included in research and\ndevelopment costs in the consolidated statements of operations.\nNetherlands Cancer Institute. On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer Institute,\nAmsterdam (“NKI”) (see Note 5), one of the world’s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center, for a\nterm of three years. The Development Collaboration Agreement was subsequently modified by Amendment No. 1 thereto. The Development Collaboration Agreement is a\npreclinical study intended to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers, as well as\nto identify the specific molecular mechanisms underlying the identified combinations. The Company agreed to fund the preclinical study, at an approximate cost of 391,000\nEuros and provide a sufficient supply of LB-100 to conduct the preclinical study.\n33\nOn October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with NKI, which provides for additional research\nactivities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and added 500,000 Euros to the operating budget being\nfunded by the Company.\nDuring the three months ended September 30, 2024 and 2023, the Company incurred charges in the amount of $76,278 and $51,568, respectively, with respect to this\nagreement, which amounts are included in research and development costs in the Company’s consolidated statements of operations. During the nine months ended September\n30, 2024 and 2023, the Company incurred charges in the amount of $210,362 and $156,950, respectively, with respect to this agreement, which amounts are included in\nresearch and development costs in the Company’s consolidated statements of operations. As of September 30, 2024, total costs of $695,918 have been incurred pursuant to this\nagreement. The Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $279,000 as of September 30, 2024,\nwhich is expected to be incurred through October 8, 2026. As the work is being conducted in Europe and is paid for in Euros, final costs are subject to foreign currency\nfluctuations between the United States Dollar and the Euro.\nMRI Global. As amended, the Company has contracted with MRI Global for stability analysis, storage and distribution of LB-100 for clinical trials in the United\nStates. During the three months ended September 30, 2024 and 2023, the Company incurred costs of $9,062 and $21,045, respectively, pursuant to this contract. During the\nnine months ended September 30, 2024 and 2023, the Company incurred costs of $18,932 and $30,628, respectively, pursuant to this contract. As of September 30, 2024, total\ncosts of $334,147 have been incurred pursuant to this contract.\nThe Company’s aggregate commitment pursuant to this contract, less amounts previously paid to date, totaled approximately $124,000 as of September 30, 2024.\nSpecific Risks Associated with the Company’s Business Activities\nSerious Adverse Events\nThe Company’s lead drug candidate, LB-100, is currently undergoing various clinical trials, and there is a risk that one or more of these trials could be placed on hold\nby regulatory authorities due to serious adverse events (SAEs) related to our drug candidate or to another company’s drug used in combination in one of our clinical trials. It is\npossible that the SAEs could be attributable to our drug candidate and could include, but not be limited to, unexpected severe side effects, treatment-related deaths, or long-term\nhealth complications. A dose given could result in non-tolerable adverse events defined as dose-limiting toxicity (DLT). When two DLTs occur at the same dose-level that dose-\nlevel is considered too high and unsafe. Further treatment is only allowed at lower dose-levels that have previously been found safe.\nIf an SAE or a pattern of SAEs is observed during the course of a clinical trial involving our drug candidate, the U.S. Food and Drug Administration (FDA), European\nMedicines Agency (EMA), or other regulatory authorities may issue a clinical hold, requiring us to pause or discontinue further enrollment and dosing in our clinical trial. It is\nalso possible that the clinical trial could be terminated. Any of these actions could delay or halt the development of our drug candidate, increase development costs, and\nnegatively impact our ability to ultimately achieve regulatory approval. Additionally, if an SAE is confirmed to be drug-related, we may be required to conduct additional\nstudies, modify the study design, or abandon further development of the drug candidate altogether, which could materially impact our business, financial condition, and\nprospects.\nThe occurrence of an SAE and any resulting clinical hold could also harm our reputation with patients, physicians, health institutions, and investors, diminish our\nability to attract clinical trial participants, and damage our ability to interest investors and obtain financing in the future. There can be no assurance that we will not experience\nsuch SAEs in the future or that any related clinical hold will be lifted in a timely manner, or at all.\nThe principal investigator of the colorectal study testing LB-100 in combination with atezolizumab (Roche PD-L1 inhibitor) is currently investigating two SAEs\nobserved in the clinical trial that was launched in August 2024. Evaluation is underway to determine next steps.\n34\nOther Business Risks\nCovid-19 Virus. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout the world as\nbusinesses and governments implemented broad actions to mitigate this public health crisis. Although the Covid-19 outbreak has subsided, the extent to which the coronavirus\nor any other pandemics may reappear and impact the Company’s clinical trial programs and capital raising efforts in the future is uncertain and cannot be predicted.\nInflation and Interest Rate Risk. The Company does not believe that inflation or increasing interest rates has had a material effect on its operations to date, other\nthan its impact on the general economy. However, there is a risk that the Company’s operating costs could become subject to inflationary and interest rate pressures in the\nfuture, which would have the effect of increasing the Company’s operating costs (including, specifically, clinical trial costs), and which would put additional stress on the\nCompany’s working capital resources.\nSupply Chain Issues. The Company does not currently expect that supply chain issues will have a significant impact on its business activities, including its ongoing\nclinical trials.\nPotential Recession. There are some indications that the United States economy may be at risk of entering a recessionary period. Although unclear at this time, an\neconomic recession would likely impact the general business environment and the capital markets, which could, in turn, affect the Company.\nGeopolitical Risk. The geopolitical landscape poses inherent risks that could significantly impact the operations and financial performance of the Company. In the\nevent of a military conflict, supply chain disruptions, geopolitical uncertainties, and economic repercussions may adversely affect the Company’s ability to conduct research,\ndevelop, test and manufacture products, and distribute them globally. This could lead to delays in product development, interruptions in the supply of critical materials, and\ndelays in clinical trials, thereby impeding the Company’s clinical development and commercialization plans. Furthermore, the impact of a conflict on global financial markets\nmay result in increased volatility and uncertainty in the capital markets, thereby affecting the valuation of the Company’s publicly-traded shares. Investor confidence, market\nsentiment, and access to capital may all be negatively influenced. Such geopolitical risks are outside the control of the Company, and the actual effects on the Company’s\nbusiness, financial condition and results of operations may differ from current estimates.\nCybersecurity Risks. The Company has established policies and processes for assessing, identifying and managing material risk from cybersecurity threats, and has\nintegrated these processes into its overall risk management systems and processes. The Company routinely assesses material risks from cybersecurity threats, including any\npotential unauthorized occurrence on or conducted through its information and email systems that may result in adverse effects on the confidentiality, integrity, or availability of\nthe Company’s information and email systems or any information residing therein. The Company conducts periodic risk assessments to identify cybersecurity threats, as well as\nassessments in the event of a material change in the Company’s business practices that may affect information systems that are vulnerable to such cybersecurity threats. These\nrisk assessments include identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the\nsufficiency of existing policies, procedures, systems and safeguards in place to manage such risks. The Company has not encountered any cybersecurity challenges that have\nmaterially impaired its operations or financial condition. Additional information regarding risks from cybersecurity threats is provided in the Company’s Annual Report on\nForm 10-K for the fiscal year ended December 31, 2023.\nThe Company is continuing to monitor these matters and will adjust its current business and financing plans as more information and guidance become available.\n9. Subsequent Events\nThe Company performed an evaluation of subsequent events through the date of filing of these consolidated financial statements with the SEC. There were no material\nsubsequent events which affected, or could affect, the amounts or disclosures in the consolidated financial statements.\n35\nITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS\nForward-Looking Statements\nThis Quarterly Report on Form 10-Q of Lixte Biotechnology Holdings, Inc. (the “Company”) contains certain forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These might include statements regarding the Company’s financial position,\nbusiness strategy and other plans and objectives for future operations, and assumptions and predictions about future clinical trials and their timing and costs, product demand,\nsupply, manufacturing costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as “intend”,\n“anticipate”, “believe”, “estimate”, “potential(ly)”, “continue”, “forecast”, “predict”, “plan”, “may”, “will”, “could”, “would”, “should”, “expect” or the negative of such terms\nor other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on\ninformation available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the\nCompany will take any action that the Company may presently be planning. These forward-looking statements are inherently subject to known and unknown risks and\nuncertainties. Actual results or experience may differ materially from those expected, anticipated or implied in the forward-looking statements. Factors that could cause or\ncontribute to such differences include, but are not limited to, regulatory policies or changes thereto, available cash, research and development results, competition from other\nsimilar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes\nthereto included in Item 1 of this Quarterly Report on Form 10-Q and the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including the\nsection entitled “Item 1A. Risk Factors”. The Company does not intend to update or revise any forward-looking statements to reflect new information, future events or\notherwise.\nOverview\nThe Company is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and commercializing\ncancer therapies. The Company’s corporate office is located in Pasadena, California.\nThe Company’s product pipeline is primarily focused on inhibitors of Protein Phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune\ncheckpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have significant therapeutic potential for a broad range of\ncancers. The Company is focusing on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-\ncancer activity at doses that produce little or no toxicity.\nThe Company’s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company has not yet commenced any\nrevenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation for a substantial portion of employee and consultant\ncompensation, and is dependent on periodic infusions of equity capital to fund its operating requirements.\nRecent Developments\nOn September 4, 2024, the Company announced it had received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent\napplication number 16/467,721, titled, “Oxabicycloheptanes for Modulation of Immune Response,” for combining the Company’s lead compound, LB-100, with various\ninnovative cancer immunotherapies.\nGoing Concern\nFor the nine months ended September 30, 2024, the Company recorded a net loss of $2,968,271 and used cash in operations of $2,565,861. At September 30, 2024, the\nCompany had cash of $1,637,627 available to fund its operations. Because the Company is currently engaged in various early-stage clinical trials, it is expected that it will take\na significant amount of time and resources to develop any product or intellectual property capable of generating sustainable revenues. Accordingly, the Company’s business is\nunlikely to generate any sustainable operating revenues in the next several years and may never do so. Even if the Company is able to generate revenues through licensing its\ntechnology, product sales or other commercial activities, there can be no assurance that the Company will be able to achieve and maintain positive earnings and operating cash\nflows. At September 30, 2024, the Company’s remaining financial contractual commitments pursuant to clinical trial agreements and clinical trial monitoring agreements not\nyet incurred aggregated approximately $3,918,000, which are currently scheduled to be incurred through approximately December 31, 2027.\n36\nThe Company’s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of\nassets and satisfaction of liabilities in the normal course of business. The consolidated financial statements also do not reflect any adjustments relating to the recoverability of\nassets and liabilities that might be necessary if the Company is unable to continue as a going concern. The Company has no recurring source of revenues and has experienced\nnegative operating cash flows since inception. The Company has financed its working capital requirements through the recurring sale of its equity securities.\nBased on the foregoing, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the\ndate that the consolidated financial statements are being issued. In addition, our independent registered public accounting firm has included an explanatory paragraph in their\nreport with respect to this uncertainty that accompanies our audited consolidated financial statements as of and for the year ended December 31, 2023. The Company’s\nconsolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.\nThe Company’s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research and development activities and\nto ultimately achieve sustainable operating revenues and profitability. The amount and timing of future cash requirements depends on the pace, design, and results of the\nCompany’s clinical trial program, which, in turn, depends on the availability of operating capital to fund such activities.\nBased on current operating plans, the Company estimates that its existing cash resources at September 30, 2024 will provide sufficient working capital to fund the\ncurrent clinical trial program with respect to the development of the Company’s lead anti-cancer clinical compound, LB-100, through the first quarter of 2025. As existing cash\nresources will not be sufficient to complete the clinical development of, and obtain regulatory approval for, the Company’s product candidate, the Company will need to raise\nadditional capital in one or more tranches to fund its operations during the next few months in order to be able to effectively manage its current business plan during 2025 and\nthereafter, as well as to maintain its listing on Nasdaq. Furthermore, the Company’s operating plans and capital requirements may change as a result of many factors that are\ncurrently unknown and/or outside of the control of the Company. The Company is considering various strategies and alternatives to obtain the required additional capital.\nAs market conditions present uncertainty as to the Company’s ability to secure additional funds, there can be no assurance that the Company will be able to secure\nadditional financing on acceptable terms, as and when necessary, to continue to conduct operations.\nIf cash resources are insufficient to satisfy the Company’s ongoing cash requirements, the Company would be required to scale back or discontinue its clinical trial\nprogram, or obtain funds, if available, through strategic alliances or joint ventures that could require the Company to relinquish rights to and/or control of LB-100, or to\ndiscontinue operations entirely.\nNasdaq Compliance\nThe Company’s common stock and the warrants are traded on the Nasdaq Capital Market (“Nasdaq”) under the symbols “LIXT” and “LIXTW”, respectively. On June\n2, 2023, the Company effected a 1-for-10 reverse split of its outstanding shares of common stock in order to remain in compliance with the $1.00 minimum closing bid price\nrequirement of Nasdaq. However, there can be no assurances that the Company will be able to remain in compliance with the $1.00 minimum closing bid price requirement of\nNasdaq over time. In addition, Nasdaq has other continued listing requirements, one of which is maintaining a minimum net stockholders’ equity of $2,500,000.\nOn August 19, 2024, the Company received a deficiency letter from the Listing Qualifications Department of Nasdaq indicating that it was not in compliance with\nNasdaq Listing Rule 5550(b)(1) (the “Stockholders’ Equity Rule”), which requires the Company to maintain a minimum stockholders’ equity of $2,500,000. This notice of non-\ncompliance has no immediate impact on the continued listing or trading of the Company’s securities on Nasdaq, which will continue to be listed and traded on Nasdaq, subject\nto the Company’s compliance with the other Nasdaq continued listing requirements.\n37\nOn October 3, 2024, the Company submitted a letter to Nasdaq with its plan to regain compliance with the Stockholders’ Equity Rule, which outlined the Company’s\nproposed initiatives to regain compliance by raising equity capital through various registered equity offerings.\nOn October 21, 2024, Nasdaq provided the Company notice that it had granted an extension through February 18, 2025 for the Company to regain compliance with the\nStockholders’ Equity Rule. The Company must complete its capital raising initiatives and evidence compliance with the Stockholders’ Equity Rule through filing a Current\nReport on Form 8-K with the SEC providing certain required information by February 18, 2025.\nIf the Company fails to evidence compliance with the Stockholders’ Equity Rule upon filing its periodic report for the quarter ending March 31, 2025 with the SEC,\nthe Company may be subject to delisting. If Nasdaq determines to delist the Company’s common stock, the Company will have the right to appeal to a Nasdaq hearings panel.\nThe hearing request would stay any suspension or delisting action pending the conclusion of the hearing process.\nThe Company intends to take reasonable measures available to regain compliance under Nasdaq’s listing rules and to remain listed on Nasdaq. However, there can be\nno assurances that the Company will ultimately regain compliance with the Stockholders’ Equity Rule, or be able to maintain compliance with all other applicable requirements\nfor continued listing on Nasdaq. If the Company does not regain compliance with Nasdaq’s listing rules within the time period permitted by Nasdaq, then the Company’s\nsecurities will be delisted from Nasdaq.\nRecent Accounting Pronouncements\nInformation with respect to recent accounting pronouncements is provided at Note 2 to the condensed consolidated financial statements for the three months and nine\nmonths ended September 30, 2024 and 2023 included elsewhere in this document.\nConcentration of Risk\nInformation with respect to concentration of risk is provided at Note 2 to the condensed consolidated financial statements for the three months and nine months ended\nSeptember 30, 2024 and 2023 included elsewhere in this document.\nCritical Accounting Policies and Estimates\nThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets\nand liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Some of those judgments can be subjective and complex,\nand therefore, actual results could differ materially from those estimates under different assumptions or conditions. Management bases its estimates on historical experience and\non various assumptions that are believed to be reasonable in relation to the financial statements taken, as a whole, under the circumstances, the results of which form the basis\nfor making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and\nassumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience, and reasonable assumptions.\nAfter such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those\nrelated to assumptions used in the calculation of accruals for clinical trial costs and other potential liabilities, and valuing equity instruments issued for services.\nThe following critical accounting policies affect the more significant judgements and estimates used in the preparation of the Company’s consolidated financial\nstatements.\nCash\nCash is held in a cash bank deposit program maintained by Morgan Stanley Wealth Management, a division of Morgan Stanley Smith Barney LLC (“Morgan\nStanley”). Morgan Stanley is a FINRA-regulated broker-dealer. The Company’s policy is to maintain its cash balances with financial institutions in the United States with high\ncredit ratings and in accounts insured by the Federal Deposit Insurance Corporation (the “FDIC”) and/or by the Securities Investor Protection Corporation (the “SIPC”). The\nCompany periodically has cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $250,000 and $500,000, respectively. Morgan Stanley\nWealth Management also maintains supplemental insurance coverage for the cash balances of its customers. The Company has not experienced any losses to date resulting from\nthis policy.\n38\nSegment Information\nThe Company operates and reports in one segment, which consisted of the development of a drug class called Protein Phosphatase 2A inhibitors. The Company’s\noperating segment is reported in a manner consistent with the internal reporting provided to the Company’s Chief Operating Decision Maker, which is the Company’s President\nand Chief Executive Officer.\nResearch and Development\nResearch and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the negotiation, design, development,\nconduct and management of clinical trials with respect to the Company’s clinical compound and product candidate. Research and development costs also include the costs to\nmanufacture compounds used in research and clinical trials, which are charged to operations as incurred. The Company’s inventory of LB-100 for clinical use has been\nmanufactured separately in the United States and in the European Union in accordance with the laws and regulations of such jurisdictions.\nResearch and development costs are generally charged to operations ratably over the life of the underlying contracts, unless the achievement of milestones, the\ncompletion of contracted work, the termination of an agreement, or other information indicates that a different expensing schedule is more appropriate. However, payments for\nresearch and development costs that are contractually defined as non-refundable are charged to operations as incurred.\nObligations incurred with respect to mandatory scheduled payments under agreements with milestone provisions are recognized as charges to research and\ndevelopment costs in the Company’s consolidated statement of operations based on the achievement of such milestones, as specified in the respective agreement. Obligations\nincurred with respect to mandatory scheduled payments under agreements without milestone provisions are accounted for when due, are recognized ratably over the appropriate\nperiod, as specified in the respective agreement, and are recorded as liabilities in the Company’s consolidated balance sheet, with a corresponding charge to research and\ndevelopment costs in the Company’s consolidated statement of operations.\nPayments made pursuant to contracts are initially recorded as advances on research and development contract services in the Company’s consolidated balance sheet\nand are then charged to research and development costs in the Company’s consolidated statement of operations as those contract services are performed. Expenses incurred\nunder contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Company’s consolidated balance sheet, with a corresponding\ncharge to research and development costs in the Company’s consolidated statement of operations. The Company reviews the status of its various clinical trial and research and\ndevelopment contracts on a quarterly basis.\nPatent and Licensing Legal and Filing Fees and Costs\nDue to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts\nand related patent applications, all patent and licensing legal and filing fees and costs are charged to operations as incurred. Patent and licensing legal and filing fees and costs\nare included in general and administrative costs in the Company’s consolidated statements of operations.\nDuring the three months ended September 30, 2024 and 2023, patent and licensing legal and filing fees and costs related to the development and protection of its\nintellectual property were $45,416 and $178,012, respectively, a decrease of $132,596, or 74.5%, in 2024 as compared to 2023.\nDuring the nine months ended September 30, 2024 and 2023, patent and licensing legal and filing fees and costs related to the development and protection of its\nintellectual property were $192,239 and $835,362, respectively, a decrease of $643,123, or 77.0%, in 2024 as compared to 2023.\nIn September 2023, the Company appointed a new President and Chief Executive Officer, who, with the assistance of the Company’s management, Board of Directors\nand patent legal counsel, conducted a comprehensive analysis of the Company’s extensive patent portfolio in order to implement a program to balance patent prosecution costs\nwith intellectual property protection benefits. As a result, the Company identified certain patent filings that it does not intend to continue to support in 2024 and thereafter. In\naddition, effective July 1, 2024, the Company changed its intellectual property law firm. The Company expects that patent and licensing legal and filing fees and costs will\ncontinue to be a significant continuing cost in 2024 and thereafter as the Company continues to develop and expand its patent portfolio related to the clinical development of\nLB-100.\n39\nA descriptive summary of the patent portfolio for the Company’s most important clinical programs involving the development of LB-100, as well as a detailed listing\nof each domestic and international patent that has been issued, is presented at “ITEM 1. BUSINESS – Intellectual Property” in the Company’s Annual Report on Form 10-K for\nthe fiscal year ended December 31, 2023.\nStock-Based Compensation\nThe Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members, contractors and\nconsultants for services rendered. Options vest and expire according to terms established at the issuance date of each grant. Stock grants, which are generally time vested, are\nmeasured at the grant date fair value and charged to operations ratably over the vesting period.\nThe Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members, contractors, and consultants by\nmeasuring the cost of services received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense on the\nstraight-line basis in the Company’s financial statements over the vesting period of the awards. Recognition of compensation expense for non-employees is in the same period\nand manner as if the Company had paid cash for the services.\nThe fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several\nvariables, the most significant of which are the expected life of the stock option, the exercise price of the stock option as compared to the fair market value of the common stock\non the grant date, and the estimated volatility of the common stock. Unless sufficient historical exercise data is available, the expected life of the stock option is calculated as\nthe mid-point between the vesting period and the contractual term (the “simplified method”). The estimated volatility is based on the historical volatility of the Company’s\ncommon stock, calculated utilizing a look-back period approximately equal to the contractual life of the stock option being granted. The risk-free interest rate is based on the\nU.S. Treasury yield curve in effect at the time of grant. The fair market value of the common stock is determined by reference to the quoted market price of the Company’s\ncommon stock on the grant date. The expected dividend yield is based on the Company’s expectation of dividend payouts and is assumed to be zero.\nThe Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development costs, as appropriate,\nin the Company’s consolidated statements of operations. The Company issues new shares of common stock to satisfy stock option exercises.\nWarrants\nThe Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable\nauthoritative guidance in Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC\n815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and\nwhether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock\nand whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity\nclassification. The Company has determined that the warrants issued in the July 20, 2023 equity financing meet the requirements for equity classification. This assessment,\nwhich requires the use of professional judgment, is conducted when the warrants are issued and at the end each subsequent quarterly period while the warrants are outstanding.\nFor issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the\ntime of issuance. For issued or modified warrants that do not meet all of the criteria for equity classification, the warrants are required to be liability classified and recorded at\ntheir initial fair value on the date of issuance and remeasured at fair value at each balance sheet date thereafter. Changes in the estimated fair value of the warrants that are\nliability classified are recognized as a non-cash gain or loss in the statement of operations.\n40\nSummary of Business Activities and Plans\nCompany Overview\nThe Company is focusing its development activities on its lead compound LB-100. The Company believes that the mechanism by which LB-100 affects cancer cell\ngrowth is different from cancer agents currently approved for clinical use. LB-100 is currently being tested in clinical trials in Ovarian Clear Cell Carcinoma, Metastatic Micro\nSatellite Stable (MSS) Colon Cancer and Advanced Soft Tissue Sarcoma. LB-100 has shown anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma,\nand medulloblastoma, all cancers of neural tissue. LB-100 enhances the effectiveness of commonly used anti-cancer drugs in melanoma, breast cancer and sarcoma animal\nmodels. The enhancement of anti-cancer activity of these anti-cancer drugs occurs at doses of LB-100 that do not significantly increase toxicity in animals. It is therefore hoped\nthat, when combined with standard anti-cancer regimens against many tumor types, LB-100 will improve therapeutic benefit.\nAs a compound moves through the FDA-approval process, it becomes an increasingly valuable property, but at a cost of additional investment at each stage. As the\npotential effectiveness of LB-100 has been documented at the clinical trial level, the Company has allocated resources to expand the breadth and depth of its patent portfolio.\nThe Company’s approach has been to operate with a minimum of overhead, moving compounds forward as efficiently and inexpensively as possible, and to raise funds to\nsupport each of these stages as certain milestones are reached. The Company’s longer-term objective is to secure one or more strategic partnerships or licensing agreements\nwith pharmaceutical companies with major programs in cancer.\nIntellectual Property\nThe Company’s intellectual property includes proprietary know-how, proprietary methodologies and extensive clinical validation data and publications. To provide\nlegal protection of the Company’s intellectual property, the Company relies on a combination of patents, licenses, trade secrets, trademarks, confidentiality and non-disclosure\nclauses and agreements, and other forms of intellectual property protection to define and protect our rights to the Company’s product candidates.\nThe Company’s product candidates are expected to be covered by its patents. These patents now cover sole rights to the composition and synthesis of the Company’s\nLB-100 series of drugs, which is the Company’s lead clinical compound in development. The Company has filed patent applications covering the treatment of cancer with LB-\n100. The Company has also filed joint patent applications with the NIH and the Netherlands Cancer Institute for the treatment of cancer using LB-100 in combination with\nother drugs such as an immune checkpoint inhibitor and a WEE1 inhibitor.\nPatent applications for the LB-100 series (oxabicycloheptanes and oxabicycloheptenes) have been filed in the United States and internationally under the Patent\nCooperation Treaty. Patents for composition of matter and for several uses of the LB-100 series have been issued in the United States, Mexico, Australia, Japan, China, Hong\nKong, Canada, and by the European Patent Office\nThe Company strives to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the development of its\nbusiness, including seeking, maintaining, and defending its patent rights, which are owned solely by the Company’s wholly-owned Delaware subsidiary, Lixte Biotechnology,\nInc., except in several instances jointly with one of the Company’s many collaborators. The Company also relies on trade secrets relating to its proprietary pipeline of product\ncandidates and on know-how and continuing technological innovation to develop and strengthen its pipeline. The Company intend to rely on regulatory protection afforded by\nregulatory agencies through data exclusivity, market exclusivity, and patent term extensions, where available.\nThe Company’s success will depend in large part on its ability to obtain and maintain patent and other proprietary protection for commercially important technology,\ninventions and know-how related to its business; defend and enforce its patents; preserve the confidentiality of its trade secrets; and operate without infringing valid and\nenforceable patents or proprietary rights of third parties. The Company’s ability to stop third parties from making, using, selling, offering to sell, or importing its technology\nmay depend on the extent to which the Company has rights under valid and enforceable licenses, patents, or trade secrets that cover these activities. In some cases, enforcement\nof these rights may depend on cooperation of the joint owners of the Company’s jointly owned patents and patent applications.\n41\nWith respect to both the Company’s solely and jointly owned intellectual property, the Company cannot be sure that patents will be granted on any of its pending\npatent applications or on any patent applications filed solely or jointly by the Company in the future; the Company cannot be sure that any of its existing patents or any patents\nthat may be granted to the Company in the future will be commercially useful in protecting the Company’s intended commercial products or therapeutic methods; and the\nCompany cannot be sure that an agency or court would determine that its solely or jointly owned patents are valid and enforceable.\nSpecific Risks Associated with the Company’s Business Activities\nSerious Adverse Events\nThe Company’s lead drug candidate, LB-100, is currently undergoing various clinical trials, and there is a risk that one or more of these trials could be placed on hold\nby regulatory authorities due to serious adverse events (SAEs) related to our drug candidate or to another company’s drug used in combination in one of our clinical trials. It is\npossible that the SAEs could be attributable to our drug candidate and could include, but not be limited to, unexpected severe side effects, treatment-related deaths, or long-term\nhealth complications. A dose given could result in non-tolerable adverse events defined as dose-limiting toxicity (DLT). When two DLTs occur at the same dose-level that dose-\nlevel is considered too high and unsafe. Further treatment is only allowed at lower dose-levels that have previously been found safe.\nIf an SAE or a pattern of SAEs is observed during the course of a clinical trial involving our drug candidate, the U.S. Food and Drug Administration (FDA), European\nMedicines Agency (EMA), or other regulatory authorities may issue a clinical hold, requiring us to pause or discontinue further enrollment and dosing in our clinical trial. It is\nalso possible that the clinical trial could be terminated. Any of these actions could delay or halt the development of our drug candidate, increase development costs, and\nnegatively impact our ability to ultimately achieve regulatory approval. Additionally, if an SAE is confirmed to be drug-related, we may be required to conduct additional\nstudies, modify the study design, or abandon further development of the drug candidate altogether, which could materially impact our business, financial condition, and\nprospects.\nThe occurrence of an SAE and any resulting clinical hold could also harm our reputation with patients, physicians, health institutions, and investors, diminish our\nability to attract clinical trial participants, and damage our ability to interest investors and obtain financing in the future. There can be no assurance that we will not experience\nsuch SAEs in the future or that any related clinical hold will be lifted in a timely manner, or at all.\nThe principal investigator of the colorectal study testing LB-100 in combination with atezolizumab (Roche PD-L1 inhibitor) is currently investigating two SAEs\nobserved in the clinical trial that was launched in August 2024. Evaluation is underway to determine next steps.\nOther Business Risks\nCovid-19 Virus. The global outbreak of the novel coronavirus (Covid-19) in early 2020 led to disruptions in general economic activities throughout the world as\nbusinesses and governments implemented broad actions to mitigate this public health crisis. Although Covid-19 outbreak has subsided, the extent to which the coronavirus or\nany other pandemics may reappear and impact the Company’s clinical trial programs and capital raising efforts in the future is uncertain and cannot be predicted.\nInflation and Interest Rate Risk. The Company does not believe that inflation or increasing interest rates has had a material effect on its operations to date, other\nthan its impact on the general economy. However, there is a risk that the Company’s operating costs could become subject to inflationary and interest rate pressures in the\nfuture, which would have the effect of increasing the Company’s operating costs (including, specifically, clinical trial costs), and which would put additional stress on the\nCompany’s working capital resources.\nSupply Chain Issues. The Company does not currently expect that supply chain issues will have a significant impact on its business activities, including its ongoing\nclinical trials.\nPotential Recession. There are some indications that the United States economy may be at risk of entering a recessionary period. Although unclear at this time, an\neconomic recession would likely impact the general business environment and the capital markets, which could, in turn, affect the Company.\n42\nGeopolitical Risk. The geopolitical landscape poses inherent risks that could significantly impact the operations and financial performance of the Company. In the\nevent of a military conflict, supply chain disruptions, geopolitical uncertainties, and economic repercussions may adversely affect the Company’s ability to conduct research,\ndevelop, test and manufacture products, and distribute them globally. This could lead to delays in product development, interruptions in the supply of critical materials, and\ndelays in clinical trials, thereby impeding the Company’s clinical development and commercialization plans. Furthermore, the impact of a conflict on global financial markets\nmay result in increased volatility and uncertainty in the capital markets, thereby affecting the valuation of the Company’s publicly-traded shares. Investor confidence, market\nsentiment, and access to capital may all be negatively influenced. Such geopolitical risks are outside the control of the Company, and the actual effects on the Company’s\nbusiness, financial condition and results of operations may differ from current estimates.\nCybersecurity Risks. The Company has established policies and processes for assessing, identifying and managing material risk from cybersecurity threats, and has\nintegrated these processes into its overall risk management systems and processes. The Company routinely assesses material risks from cybersecurity threats, including any\npotential unauthorized occurrence on or conducted through its information and email systems that may result in adverse effects on the confidentiality, integrity, or availability of\nthe Company’s information and email systems or any information residing therein. The Company conducts periodic risk assessments to identify cybersecurity threats, as well as\nassessments in the event of a material change in the Company’s business practices that may affect information systems that are vulnerable to such cybersecurity threats. These\nrisk assessments include identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the\nsufficiency of existing policies, procedures, systems and safeguards in place to manage such risks. The Company has not encountered any cybersecurity challenges that have\nmaterially impaired its operations or financial condition. Additional information regarding risks from cybersecurity threats is provided in the Company’s Annual Report on\nForm 10-K for the fiscal year ended December 31, 2023.\nThe Company is continuing to monitor these matters and will adjust its current business and financing plans as more information and guidance become available.\nResults of Operations\nAt September 30, 2024, the Company had not yet commenced any revenue-generating operations, does not have any positive cash flows from operations, and is\ndependent on its ability to raise equity capital to fund its operating requirements.\nThe Company’s condensed consolidated statements of operations as discussed herein are presented below.\nThree Months Ended Nine Months Ended\nSeptember 30, September 30,\n2024 2023 2024 2023\nRevenues $ — $ — $ — $ —\nCosts and expenses:\nGeneral and administrative costs:\nCompensation to related parties 283,053 356,001 907,069 1,398,042\nPatent and licensing legal and filing fees and costs 45,416 178,012 192,239 835,362\nOther costs and expenses 293,158 357,681 1,168,582 1,081,893\nResearch and development costs 361,630 132,487 691,402 749,029\nTotal costs and expenses 983,257 1,024,181 2,959,292 4,064,326\nLoss from operations (983,257) (1,024,181) (2,959,292) (4,064,326)\nInterest income 1,437 5,809 6,529 13,538\nInterest expense (1,049) (279) (12,389) (6,088)\nForeign currency gain (loss) (3,161) (109) (3,119) 2,102\nNet loss $ (986,030) $ (1,018,760) $ (2,968,271) $ (4,054,774)\nNet loss per common share – basic and diluted $ (0.44) $ (0.49) $ (1.32) $ (2.25)\nWeighted average common shares outstanding – basic and\ndiluted 2,249,290 2,074,938 2,249,290 1,803,466\n43\nThree Months Ended September 30, 2024 and 2023\nRevenues. The Company did not have any revenues for the three months ended September 30, 2024 and 2023.\nGeneral and Administrative Costs. For the three months ended September 30, 2024, general and administrative costs were $621,627, which consisted of the fair value\nof vested stock options issued to directors and officers of $106,827 (including quarterly director and board committee fees of $27,500), patent and licensing legal and filing fees\nand costs of $45,416, other consulting and professional fees of $146,610, insurance expense of $116,440, officer salaries and related costs of $161,728, cash-based director and\nboard committee fees of $0, licensing and royalties of $7,537, shareholder reporting costs of $2,941, listing fees of $12,375, filing fees of $2,864, taxes and licenses of $56,\ninvestor relations of $13,397, rent of $3,218, and other operating costs of $2,218.\nFor the three months ended September 30, 2023, general and administrative costs were $891,694, which consisted of the fair value of vested stock options issued to\ndirectors and officers of $112,106 (including quarterly director and board committee fees of $0), patent and licensing legal and filing fees and costs of $178,012, other\nconsulting and professional fees of $199,884, insurance expense of $107,910, officer salaries and related costs of $216,880, cash-based director and board committee fees of\n$42,228, shareholder reporting costs of $3,887, listing fees of $15,500, filing fees of $4,439, taxes and licenses of $3,946, investor relations of $14,172, rent of $7,323, and\nother operating costs of $6,914, offset by a credit to licensing and royalties of $21,507 relating to the termination of the Moffitt agreement.\nGeneral and administrative costs decreased by $270,067, or 30.3%, in 2024 as compared to 2023, primarily as a result of a decrease in the fair value of vested stock\noptions issued to directors and officers of $5,279, a decrease in patent and licensing legal and filing fees and costs of $132,596, a decrease in officer salaries and related costs of\n$55,152, a decrease in cash-based director and board committee fees of $42,228, and a decrease in other consulting and professional fees of $53,274, offset by an increase in\nlicensing and royalties of $29,044.\nResearch and Development Costs. For the three months ended September 30, 2024, research and development costs were $361,630, which consisted of clinical and\nrelated oversight costs of $250,342, regulatory service costs of $11,405, and preclinical research focused on development of additional novel anti-cancer compounds to add to\nthe Company’s clinical pipeline of $99,883.\nIncluded in clinical and related oversight costs for the three months ended September 30, 2024 is $207,004 for the cost of patients enrolled in the City of Hope clinical\ntrial prior to its termination on July 8, 2024.\nFor the three months ended September 30, 2023, research and development costs were $132,487, which consisted of clinical and related oversight costs of $8,816,\nregulatory service costs of $10,919, and pre-clinical research focused on development of additional novel anti-cancer compounds to add to the Company’s clinical pipeline of\n$124,752, offset by a credit of $12,000 relating to the termination of the Moffitt agreement.\nEffective June 10, 2024, the Company entered into a Clinical Trial Agreement with the Netherlands Cancer Institute (“NKI”) to conduct a Phase 1b/2 clinical trial of\nthe Company’s protein phosphatase inhibitor, LB-100, combined with atezolizumab, a PD-L1 inhibitor, the proprietary molecule of F. Hoffman-La Roche Ltd. (“Roche”), for\npatients with metastatic colon cancer. NKI employs Dr. René Bernards, a director of the Company since June 15, 2022. The Company has no financial contractual commitment\nassociated with this clinical trial.\nIncluded in preclinical research costs for the three months ended September 30, 2024 and 2023 were $76,278 and $51,568, respectively, of costs paid to the\nNetherlands Cancer Institute, On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer Institute, Amsterdam, one\nof the world’s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center, to identify the most promising drugs to be\ncombined with LB-100, and potential LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the\nidentified combinations.\n44\nOn October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with the Netherlands Cancer Institute, which provides\nfor additional research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and added 500,000 Euros to the\noperating budget being funded by the Company (see “Principal Commitments – Other Significant Agreements and Contracts – Netherlands Cancer Institute” below).\nResearch and development costs increased by $229,143, or 173.0%, in 2024 as compared to 2023, primarily as a result of a charge of $207,004 for the cost of patients\nenrolled in the City of Hope clinical trial prior to its termination on July 8, 2024.\nInterest Income. For the three months ended September 30, 2024, the Company had interest income of $1,437, as compared to interest income of $5,809 for the three\nmonths ended September 30, 2023, related to the investment of the Company’s cash resources.\nInterest Expense. For the three months ended September 30, 2024, the Company had interest expense of $1,049, as compared to interest expense of $279 for the three\nmonths ended September 30, 2023, related to the financing of the premium for the Company’s directors and officers liability insurance policy.\nForeign Currency Loss. For the three months ended September 30, 2024, the Company had a foreign currency loss of $3,161, as compared to a foreign currency loss of\n$109 for the three months ended September 30, 2023, from foreign currency transactions.\nNet Loss. For the three months ended September 30, 2024, the Company incurred a net loss of $986,030, as compared to a net loss of $1,018,760 for the three months\nended September 30, 2023.\nNine Months Ended September 30, 2024 and 2023\nRevenues. The Company did not have any revenues for the nine months ended September 30, 2024 and 2023.\nGeneral and Administrative Costs. For the nine months ended September 30, 2024, general and administrative costs were $2,267,890, which consisted of the fair value\nof vested stock options issued to directors and officers of $340,445 (including quarterly director and board committee fees of $55,000), patent and licensing legal and filing fees\nand costs of $192,239, other consulting and professional fees of $510,582, insurance expense of $370,167, officer salaries and related costs of $549,317, cash-based director\nand board committee fees of $38,819, licensing and royalties of $68,106, shareholder reporting costs of $15,690, listing fees of $37,125, filing fees of $21,917, taxes and\nlicenses of $30,869, investor relations of $48,191, rent of $13,099, conference fees of $14,475 and other operating costs of $16,849.\nFor the nine months ended September 30, 2023, general and administrative costs were $3,315,297, which consisted of the fair value of vested stock options issued to\ndirectors and officers of $669,146, patent and licensing legal and filing fees and costs of $835,362, other consulting and professional fees of $529,830, insurance expense of\n$316,214, officer salaries and related costs of $649,483, cash-based director and board committee fees of $127,229, shareholder reporting costs of $64,783, listing fees of\n$46,500, filing fees of $14,634, taxes and licenses of $11,483, investor relations of $36,516, rent of $11,436, conference fees of $0 and other operating costs of $11,790, offset\nby a credit to licensing fees of $9,109 relating to the termination of the Moffitt agreement.\nGeneral and administrative costs decreased by $1,047,407, or 31.6%, in 2024 as compared to 2023, primarily as a result of a decrease in the fair value of vested stock\noptions issued to directors and officers of $328,701, a decrease in patent and licensing legal and filing fees and costs of $643,123, a decrease in shareholder reporting costs of\n$49,093, a decrease in officer salaries and related costs of $100,166, and a decrease in cash-based director and board committee fees of $88,410, offset by increases in licensing\nand royalties of $77,215, taxes and licenses of $19,386, and in insurance expense of $53,953.\nResearch and Development Costs. For the nine months ended September 30, 2024, research and development costs were $691,402, which consisted of clinical and\nrelated oversight costs of $358,318, regulatory service costs of $14,021, and preclinical research focused on development of additional novel anti-cancer compounds to add to\nthe Company’s clinical pipeline of $319,063.\n45\nIncluded in clinical and related oversight costs for the nine months ended September 30, 2024 is $207,004 for the cost of patients enrolled in the City of Hope clinical\ntrial prior to its termination on July 8, 2024.\nFor the nine months ended September 30, 2023, research and development costs were $749,029, which consisted of clinical and related oversight costs of $390,708,\nregulatory service costs of $18,738, and preclinical research focused on development of additional novel anti-cancer compounds to add to the Company’s clinical pipeline of\n$339,583.\nEffective June 10, 2024, the Company entered into a Clinical Trial Agreement with the Netherlands Cancer Institute (“NKI”) to conduct a Phase 1b/2 clinical trial of\nthe Company’s protein phosphatase inhibitor, LB-100, combined with atezolizumab, a PD-L1 inhibitor, the proprietary molecule of F. Hoffman-La Roche Ltd. (“Roche”), for\npatients with metastatic colon cancer. NKI employs Dr. René Bernards, a director of the Company since June 15, 2022. The Company has no financial contractual commitment\nassociated with this clinical trial.\nIncluded in preclinical research costs for the nine months ended September 30, 2024 and 2023 were $210,362 and $156,950, respectively, of costs paid to the\nNetherlands Cancer Institute, On October 8, 2021, the Company entered into a Development Collaboration Agreement with the Netherlands Cancer Institute, Amsterdam, one\nof the world’s leading comprehensive cancer centers, and Oncode Institute, Utrecht, a major independent cancer research center, to identify the most promising drugs to be\ncombined with LB-100, and potential LB-100 analogues, to be used to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the\nidentified combinations.\nOn October 3, 2023, the Company entered into Amendment No. 2 to the Development Collaboration Agreement with the Netherlands Cancer Institute, which provides\nfor additional research activities, extends the termination date of the Development Collaboration Agreement by two years to October 8, 2026, and added 500,000 Euros to the\noperating budget being funded by the Company (see “Principal Commitments – Other Significant Agreements and Contracts – Netherlands Cancer Institute” below).\nResearch and development costs decreased by $57,627, or 7.7%, in 2024 as compared to 2023, primarily as a result of a decrease in clinical and related oversight costs\nof $32,390.\nInterest Income. For the nine months ended September 30, 2024, the Company had interest income of $6,529, as compared to interest income of $13,538 for the nine\nmonths ended September 30, 2023, related to the investment of the Company’s cash resources.\nInterest Expense. For the nine months ended September 30, 2024, the Company had interest expense of $12,389, as compared to interest expense of $6,088 for the\nnine months ended September 30, 2023, related to the financing of the premium for the Company’s directors and officers liability insurance policy.\nForeign Currency Gain (Loss). For the nine months ended September 30, 2024, the Company had a foreign currency loss of $3,119, as compared to a foreign currency\ngain of $2,102 for the nine months ended September 30, 2023, from foreign currency transactions.\nNet Loss. For the nine months ended September 30, 2024, the Company incurred a net loss of $2,968,271, as compared to a net loss of $4,054,774 for the nine months\nended September 30, 2023.\nLiquidity and Capital Resources – September 30, 2024\nThe Company’s consolidated statements of cash flows as discussed herein are as follows:\nNine Months Ended September 30,\n2024 2023\nNet cash used in operating activities $ (2,565,861) $ (3,391,142)\nNet cash provided by (used in) investing activities — —\nNet cash provided by financing activities — 3,143,361\nNet decrease in cash $ (2,565,861) $ (247,781)\n46\nAt September 30, 2024, the Company had working capital of $1,360,008, as compared to working capital of $3,994,762 at December 31, 2023, reflecting a decrease in\nworking capital of $2,634,754 for the nine months ended September 30, 2024. The decrease in working capital during the nine months ended September 30, 2024 was primarily\nthe result of the funding of the Company’s ongoing research and development activities and other ongoing operating expenses, including maintaining and developing the\nCompany’s patent portfolio. At September 30, 2024, the Company had cash of $1,637,627 available to fund its operations.\nThe Company’s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research and development activities and\nto ultimately achieve sustainable operating revenues and profitability. The amount and timing of future cash requirements depends on the pace, design, and results of the\nCompany’s clinical trial program, which, in turn, depends on the availability of operating capital to fund such activities.\nBased on current operating plans, the Company estimates that its existing cash resources at September 30, 2024 will provide sufficient working capital to fund the\ncurrent clinical trial program with respect to the development of the Company’s lead anti-cancer clinical compound, LB-100, through the first quarter of 2025. As existing cash\nresources will not be sufficient to complete the clinical development of, and obtain regulatory approval for, the Company’s product candidate, the Company will need to raise\nadditional capital in one or more tranches to fund its operations during the next few months in order to be able to effectively manage its current business plan during 2025 and\nthereafter, as well as to maintain its listing on Nasdaq. Furthermore, the Company’s operating plans and capital requirements may change as a result of many factors that are\ncurrently unknown and/or outside of the control of the Company. The Company is considering various strategies and alternatives to obtain the required additional capital.\nAt September 30, 2024, the Company’s remaining financial contractual commitments pursuant to clinical trial agreements and clinical trial monitoring agreements not\nyet incurred aggregated $3,918,000, which are currently scheduled to be incurred through approximately December 31, 2027.\nAt September 30, 2024, the Company did not have any transactions, obligations or relationships that could be considered off-balance sheet arrangements.\nOperating Activities. For the nine months ended September 30, 2024, operating activities utilized cash of $2,565,861, as compared to utilizing cash of $3,391,142 for\nthe nine months ended September 30, 2023, to fund the Company’s ongoing research and development activities and to fund its other ongoing operating expenses, including\nmaintaining and developing its patent portfolio.\nInvesting Activities. For the nine months ended September 30, 2024 and 2023, the Company had no investing activities.\nFinancing Activities. For the nine months ended September 30, 2024, the Company had no financing activities. For the nine months ended September 30, 2023,\nfinancing activities consisted primarily of the gross proceeds from the sale of securities in the Company’s registered direct offering of $3,499,964, reduced by offering costs of\n$362,925, and $6,281 from the exercise of common stock options.\nPrincipal Commitments\nClinical Trial Agreements\nAt September 30, 2024, the Company’s remaining financial contractual commitments pursuant to clinical trial agreements and clinical trial monitoring agreements not\nyet incurred, as described below, aggregated $3,918,000, including clinical trial agreements of $3,616,000 and clinical trial monitoring agreements of $302,000, which, based\non current estimates, are currently scheduled to be incurred through approximately December 31, 2027. The Company’s ability to conduct and fund these contractual\ncommitments is subject to the timely availability of sufficient capital to fund such expenditures, as well as any changes in the allocation or reallocation of such funds to the\nCompany’s current or future clinical trial programs. The Company expects that the full amount of these expenditures will be incurred only if such clinical trial programs are\nconducted as originally designed and their respective enrollments and duration are not modified or reduced. Clinical trial programs, such as the types that the Company is\nengaged in, can be highly variable and can frequently involve a series of changes and modifications over time as clinical data is obtained and analyzed, and is frequently\nmodified, suspended or terminated, in part based on receipt or lack of receipt of an indication of clinical benefit or activity, before the clinical trial endpoint is reached.\nAccordingly, such contractual commitments as discussed herein should be considered as estimates only based on current clinical assumptions and conditions and are typically\nsubject to significant modifications and revisions over time.\n47\nThe following is a summary of the Company’s ongoing contractual clinical trials described below as of September 30, 2024:\nExpected\nDate of Remaining\nNumber of Preliminary Financial\nDescription of Projected Patients Study Clinical Efficacy Contractual\nClinical Trial Institution Start Date End Date in Trial Objective Update Signal NCT No. Commitment\nLB-100\ncombined with\natezolizumab\nin\nmicrosatellite\nstable\nmetastatic Netherlands Determine First patient\ncolon cancer Cancer December RP2D with entered\n(Phase 1b) Institute (NKI) August 2024 2026 37 atezolizumab August 2024 June 2026 NCT06012734 (1)\nLB-100\ncombined with\ndoxorubicin in Recruitment\nadvanced soft completed Determine Fourteen\ntissue sarcoma September MTD and patients\n(Phase 1b) GEIS June 2023 2024 9 to 18 RP2D entered March 2025 NCT05809830 $ 284,000\nDoxorubicin Clinical trial\nwith or without not yet begun\nLB-100 in (subject to\nadvanced soft completion\ntissue sarcoma of Phase 1b\n(Randomized Determine GEIS clinical December\nPhase 2) GEIS TBD TBD 150 efficacy: PFS trial) 2026 NCT05809830 $ 3,332,000\nDetermine\nLB-100 the OS of\ncombined with patients with\ndostarlimab in recurrent\novarian clear ovarian clear Seven\ncell carcinoma December cell patients December\n(Phase 1b/2) MD Anderson January 2024 2027 21 carcinoma entered 2026 NCT06065462 (1)\nTotal $ 3,616,000\n(1) The Company has no financial contractual commitment associated with this clinical trial at September 30, 2024.\n48\nNetherlands Cancer Institute. Effective June 10, 2024, the Company entered into a Clinical Trial Agreement with the Netherlands Cancer Institute (“NKI”) to\nconduct a Phase 1b clinical trial of the Company’s protein phosphatase inhibitor, LB-100, combined with atezolizumab, a PD-L1 inhibitor, the proprietary molecule of F.\nHoffman-La Roche Ltd. (“Roche”), for patients with microsatellite stable metastatic colon cancer. Under the agreement, the Company will provide its lead compound, LB-100,\nand under a separate agreement between NKI and Roche, Roche will provide atezolizumab and financial support for the clinical trial. The Company has no obligation to and\nwill not provide any reimbursement of clinical trial costs. Pursuant to the agreement and the protocol set forth in the agreement, the clinical trial will be conducted by NKI at\nNKI’s site in Amsterdam by principal investigator Neeltje Steeghs, MD, PhD, and NKI will be responsible for the recruitment of patients. The agreement provides for the\nprotection of the respective intellectual property rights of each of the Company, NKI and Roche.\nThis Phase 1b clinical trial will evaluate safety, optimal dose and preliminary efficacy of LB-100 combined with atezolizumab for the treatment of patients with\nmetastatic microsatellite stable colorectal cancer. Immunotherapy using monoclonal antibodies like atezolizumab can enhance the body’s immune response against cancer and\nhinder tumor growth and spread. LB-100 has been found to improve the effectiveness of anticancer drugs in killing cancer cells by inhibiting a protein called PP2A on cell\nsurfaces. Blocking PP2A increases stress signals in tumor cells expressing the PP2A protein. Accordingly, combining atezolizumab with LB-100 may enhance treatment\nefficacy for metastatic colorectal cancer, as cancer cells with heightened stress signals are more vulnerable to immunotherapy.\nThis study comprises a dose escalation phase and a dose expansion phase. The objective of the dose escalation phase is to determine the recommended Phase 2 dose\n(RP2D) of LB-100 when combined with the standard dosage of atezolizumab. The dose expansion phase will further investigate the preliminary efficacy, safety, tolerability,\nand pharmacokinetics/dynamics of the LB-100 and atezolizumab combination. The clinical trial opened in August 2024 with the enrollment of the first patient. Patient accrual\nis expected to take up to 24 months, with a maximum of 37 patients with advanced colorectal cancer to be enrolled in this study.\nThe principal investigator of the colorectal study testing LB-100 in combination with atezolizumab is currently investigating two Serious Adverse Events (“SAEs”)\nobserved in the clinical trial. Evaluation is underway to determine next steps (see “Serious Adverse Events” below for additional information).\nThe Company has no financial contractual commitment associated with this clinical trial.\nCity of Hope. Effective January 18, 2021, the Company executed a Clinical Research Support Agreement (the “Agreement”) with the City of Hope National Medical\nCenter, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively, “City of Hope”), to carry out a Phase 1b clinical trial of LB-100,\nthe Company’s first-in-class protein phosphatase inhibitor, combined with an FDA-approved standard regimen for treatment of untreated extensive-stage disease small cell lung\ncancer (“ED-SCLC”). LB-100 was given in combination with carboplatin, etoposide and atezolizumab, an FDA-approved standard of care regimen, to previously untreated\nED-SCLC patients. The LB-100 dose was to be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended Phase 2 dose (“RP2D”). Patient entry\nwas to be expanded so that a total of 12 patients would be evaluable at the RP2D to confirm the safety of the LB-100 combination and to look for potential therapeutic activity\nas assessed by objective response rate, duration of overall response, progression-free survival, and overall survival.\nThe clinical trial was initiated on March 9, 2021, with patient accrual expected to take approximately two years to complete. Because patient accrual was slower than\nexpected, effective March 6, 2023, the Company and City of Hope added the Sarah Cannon Research Institute (“SCRI”), Nashville, Tennessee, to the ongoing Phase 1b clinical\ntrial. The Company and City of Hope continued efforts to increase patient accrual by adding additional sites and by modifying the protocol to increase the number of patients\neligible for the clinical trial. The impact of these efforts to increase patient accrual and to decrease time to completion was evaluated in subsequent quarters.\nAfter evaluating patient accrual through June 30, 2024, the Company and City of Hope agreed to close the clinical trial. Pursuant to the terms of the Agreement, the\nCompany provided notice to City of Hope of the Company’s intent to terminate the Agreement effective as of July 8, 2024. Upon closure, the Company incurred a prorated\ncharge of $207,004 for the cost of patients enrolled to date. The Company is exploring alternative sites, including international locations, for the conduct of a small cell lung\ncancer clinical trial.\nDuring the three months ended September 30, 2024 and 2023, the Company incurred costs of $207,004 and $0, respectively, pursuant to this Agreement. During the\nnine months ended September 30, 2024 and 2023, the Company incurred costs of $285,019 and $69,001, respectively, pursuant to this Agreement. As of September 30, 2024,\ntotal costs of $732,532 had been incurred pursuant to this Agreement.\n49\nGEIS. Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the Spanish Sarcoma Group\n(Grupo Español de Investigación en Sarcomas or “GEIS”), Madrid, Spain, to carry out a study entitled “Randomized phase I/II trial of LB-100 plus doxorubicin vs. doxorubicin\nalone in first line of advanced soft tissue sarcoma”. The purpose of this clinical trial is to obtain information with respect to the efficacy and safety of LB-100 combined with\ndoxorubicin in soft tissue sarcomas. Doxorubicin is the global standard for initial treatment of advanced soft tissue sarcomas (“ASTS”). Doxorubicin alone has been the\nmainstay of first line treatment of ASTS for over 40 years, with little improvement in survival from adding cytotoxic compounds to or substituting other cytotoxic compounds\nfor doxorubicin. In animal models, LB-100 consistently enhances the anti-tumor activity of doxorubicin without apparent increases in toxicity.\nGEIS has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative studies in ASTS. The\nCompany agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial, as well as to provide funding for the clinical trial. The goal is to\nenter approximately 150 to 170 patients in this clinical trial over a period of two to four years. The Phase 1 portion of the study began in the quarter ended June 30, 2023 to\ndetermine the recommended Phase 2 dose of the combination of doxorubicin and LB-100. As advanced sarcoma is a very aggressive disease, the design of the Phase 2 portion\nof the study assumes a median progression-free survival (“PFS”), no evidence of disease progression or death from any cause, of 4.5 months in the doxorubicin arm and an\nalternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate a statistically significant decrease in relative risk of progression or death by adding\nLB-100. There is a planned interim analysis of the primary endpoint when approximately 50% of the 102 events required for final analysis is reached.\nThe Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020. However, during July 2020, the Spanish\nregulatory authority advised the Company that although it had approved the scientific and ethical basis of the protocol, it required that the Company manufacture new inventory\nof LB-100 under current Spanish pharmaceutical manufacturing standards. These standards were adopted subsequent to the production of the Company’s existing LB-100\ninventory.\nIn order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company engaged a number of vendors to carry out the multiple tasks\nneeded to make and gain approval of a new clinical product for investigational study in Spain. These tasks included the synthesis under good manufacturing practice (GMP) of\nthe active pharmaceutical ingredient (API), with documentation of each of the steps involved by an independent auditor. The API was then transferred to a vendor that prepares\nthe clinical drug product, also under GMP conditions documented by an independent auditor. The clinical drug product was then sent to a vendor to test for purity and sterility,\nprovide appropriate labels, store the drug, and distribute the drug to the clinical centers for use in the clinical trials. A formal application documenting all steps taken to prepare\nthe clinical drug product for clinical use was submitted to the appropriate regulatory authorities for review and approval before being used in a clinical trial.\nAs of December 31, 2023, this program to provide new inventory of the clinical drug product for the Spanish Sarcoma Group study, and potentially for subsequent\nmultiple trials within the European Union, had cost approximately $1,144,000.\nOn October 13, 2022, the Company announced that the Spanish Agency for Medicines and Health Products (Agencia Española de Medicamentos y Productos\nSanitarios or “AEMPS”) had authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company’s lead clinical compound, plus doxorubicin, versus doxorubicin alone,\nthe global standard for initial treatment of ASTS. Consequently, this clinical trial commenced during the quarter ended June 30, 2023 and is expected to be completed and a\nreport prepared by December 31, 2026. In April 2023, GEIS completed its first site initiation visit in preparation for the clinical trial at Fundación Jiménez Díaz University\nHospital (Madrid). Up to 170 patents will be entered into the clinical trial. The recruitment for the Phase 1b portion of the protocol was extended with two patients and was\ncompleted during the quarter ended September 30, 2024. The Company expects to have data on toxicity and preliminary efficacy from this portion of the clinical trial by\nDecember 31, 2024, and a full report by June 30, 2025. Subject to clinical results and the availability of sufficient working capital resources, the Company anticipates that it\nwill then be in a position to decide whether to proceed to the related Phase 2 portion of the study.\nThe interim analysis of the Phase 2 portion of this clinical trial will be done before full accrual of patients is completed to determine whether the study has the\npossibility of showing superiority of the combination of LB-100 plus doxorubicin compared to doxorubicin alone. A positive study would have the potential to change the\nstandard therapy for this disease after four decades of failure to improve the marginal benefit of doxorubicin alone.\n50\nThe Company’s agreement with GEIS provides for various payments based on achieving specific milestones over the term of the agreement. During the three months\nended September 30, 2024 and 2023, the Company did not incur any costs pursuant to this agreement. During the nine months ended September 30, 2024 and 2023, the\nCompany incurred costs of $0 and $268,829, respectively, pursuant to this agreement. Through September 30, 2024, the Company has incurred charges of $684,652 for work\ndone under this agreement through the fourth milestone.\nThe Company’s aggregate commitment pursuant to this agreement, less amounts previously paid to date, totaled approximately $3,616,000 (consisting of $284,000 for\nthe Phase 1b portion and $3,332,000 for the Phase 2 portion) as of September 30, 2024, which is scheduled to be incurred through December 31, 2027. As the work is being\nconducted in Europe and is paid for in Euros, final costs are subject to foreign currency fluctuations between the United States Dollar and the Euro. Such fluctuations are\nrecorded in the consolidated statements of operations as foreign currency gain or loss, as appropriate, and have not been significant.\nMD Anderson Cancer Center Clinical Trial. On September 20, 2023, the Company announced an investigator-initiated Phase 1b/2 collaborative clinical trial to\nassess whether adding LB-100 to a human programmed death receptor-1 (“PD-1”) blocking antibody of GSK plc (“GSK”), dostarlimab-gxly, may enhance the effectiveness of\nimmunotherapy in the treatment of ovarian clear cell carcinoma (“OCCC”). The study objective is to determine the overall survival (“OS”) of patients with OCCC. The clinical\ntrial is being sponsored by The University of Texas MD Anderson Cancer Center (“MD Anderson”) and is being conducted at The University of Texas - MD Anderson Cancer\nCenter. The Company is providing LB-100 and GSK is providing dostarlimab-gxly and financial support for the clinical trial. On January 29, 2024, the Company announced\nthe entry of the first patient into this clinical trial. The Company currently expects that this clinical trial will be completed by December 31, 2027.\nMoffitt. Effective August 20, 2018, the Company entered into a Clinical Trial Research Agreement with the Moffitt Cancer Center and Research Institute Hospital\nInc., Tampa, Florida (“Moffitt”), effective for a term of five years. Pursuant to the Clinical Trial Research Agreement, Moffitt agreed to conduct and manage a Phase 1b/2\nclinical trial to evaluate the toxicity and therapeutic benefit of the Company’s lead anti-cancer clinical compound LB-100 to be administered intravenously in patients with low\nor intermediate-1 risk myelodysplastic syndrome (“MDS”).\nIn November 2018, the Company received approval from the U.S. Food and Drug Administration for its Investigational New Drug (“IND”) Application to conduct a\nPhase 1b/2 clinical trial to evaluate the toxicity and therapeutic benefit of LB-100 in patients with low and intermediate-1 risk MDS who had failed or were intolerant of\nstandard treatment. This Phase 1b/2 clinical trial utilized LB-100 as a single agent in the treatment of patients with low and intermediate-1 risk MDS.\nThe clinical trial began at a single site in April 2019 and the first patient was entered into the clinical trial in July 2019. During the year ended December 31, 2023, the\nclinical trial was closed. Although the maximum tolerated dose (“MTD”) was not achieved, there was no dose-limiting toxicity noted.\nDuring the three months and nine months ended September 30, 2024 and 2023, the Company did not incur any costs pursuant to this agreement. As of September 30,\n2024, total costs of $147,239 had been incurred pursuant to this agreement.\nDuring September 2023, the Company decided not to pursue further studies in MDS, as other, more promising, opportunities had become available (see “Patent and\nLicense Agreements - Moffitt” below).\nNational Cancer Institute Pharmacologic Clinical Trial. In May 2019, the National Cancer Institute (“NCI”) initiated a glioblastoma (“GBM”) pharmacologic\nclinical trial. This study was being conducted and funded by the NCI under a Cooperative Research and Development Agreement, with the Company responsible for providing\nthe LB-100 clinical compound. The NCI study was designed to determine the extent to which LB-100 enters recurrent malignant gliomas. Patients having surgery to remove\none or more tumors received one dose of LB-100 prior to surgery and had blood and tumor tissue analyzed to determine the amount of LB-100 present and to determine\nwhether the cells in the tumors showed the biochemical changes expected to be present if LB-100 reached its molecular target. As a result of the innovative design of the NCI\nstudy, it was believed that data from a few patients would be sufficient to provide a sound rationale for conducting a larger clinical trial to determine the effectiveness of adding\nLB-100 to the standard treatment regimen for GBMs. Blood and brain tumor tissue were analyzed from seven patients after intravenous infusion of a single dose of LB-100.\nResults of the investigation demonstrated that there was virtually no entry of LB-100 into the brain tumor tissue. Accordingly, alternative methods of drug delivery will be\nrequired to determine if LB-100 has meaningful clinical anti-cancer activity against glioblastoma multiforme and other aggressive brain tumors. The Company is considering an\nadditional clinical study to address the delivery of LB-100 to the brain.\n51\nClinical Trial Monitoring Agreements\nMD Anderson Cancer Center Clinical Trial. On May 15, 2024, the Company signed a letter of intent with Theradex to monitor the MD Andersen investigator-\ninitiated Phase 1b/2 collaborative clinical trial to assess whether adding LB-100 to a human programmed death receptor-1 (“PD-1”) blocking antibody of GSK plc (“GSK”),\ndostarlimab-gxly, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (“OCCC”). On August 19, 2024, the Company signed a\nwork order agreement with Theradex to monitor the MD Anderson clinical trial. The study oversight is expected to be completed by January 31, 2027.\nCosts under this letter of intent and related work order agreement are estimated to be approximately $95,000. During the three months and nine months ended\nSeptember 30, 2024, the Company incurred costs of $12,610 and $20,838 pursuant to this letter of intent and subsequent work order. As of September 30, 2024, total costs of\n$20,838 have been incurred pursuant to this letter of intent and subsequent work order.\nThe Company’s aggregate commitment pursuant to this letter of intent, less amounts previously paid to date, totaled approximately $78,000 as of September 30, 2024,\nwhich is expected to be incurred through December 31, 2027.\nCity of Hope. On February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated clinical trial in\nsmall cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party. Costs under this work order agreement were estimated to be approximately\n$335,000. During the three months ended September 30, 2024 and 2023, the Company incurred costs of $1,603 and $4,500, respectively, pursuant to this work order. During\nthe nine months ended September 30, 2024 and 2023, the Company incurred costs of $10,603 and $15,740, respectively, pursuant to this work order. As of September 30, 2024,\ntotal costs of $89,284 had been incurred pursuant to this work order agreement.\nAs a result of the closure of the Agreement with City of Hope effective July 8, 2024 (see “Clinical Trial Agreements – City of Hope” above), the work order agreement\nwith Theradex to monitor this clinical trial was concurrently terminated, although nominal oversight trailing costs subsequent to July 8, 2024 are expected to be incurred\nrelating to the closure of this study.\nGEIS. On June 22, 2023, the Company finalized a work order agreement with Theradex, to monitor the GEIS investigator-initiated clinical Phase I/II randomized trial\nof LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcoma. The study oversight is expected to be completed by December 31, 2026.\nCosts under this work order agreement are estimated to be approximately $153,000, with such payments expected to be allocated approximately 72% to Theradex for\nservices and approximately 28% for payments for pass-through software costs. During the three months ended September 30, 2024 and 2023, the Company incurred costs of\n$13,475 and $3,750, respectively, pursuant to this work order. During the nine months ended September 30, 2024 and 2023, the Company incurred costs of $26,208 and\n$10,000, respectively, pursuant to this work order. As of September 30, 2024, total costs of $41,070 have been incurred pursuant to this work order agreement.\nThe Company’s aggregate commitment pursuant to this clinical trial monitoring agreement, less amounts previously paid to date, totaled approximately $118,000 as of\nSeptember 30, 2024, which is expected to be incurred through December 31, 2026.\nNetherlands Cancer Institute. On August 27, 2023, the Company finalized a work order agreement with Theradex, to monitor the NKI Phase 1b clinical trial of LB-\n100 combined with atezolizumab, a PD-L1 inhibitor, for patients with microsatellite stable metastatic colon cancer. The study oversight is expected to be completed by May 31,\n2027.\nCosts under this work order agreement are estimated to be approximately $106,380, with such payments expected to be allocated approximately 47% to Theradex for\nservices and approximately 53% for payments for pass-through software costs. During the three months and nine months ended September 30, 2024, the Company incurred\ncosts of $14,900 pursuant to this work order. As of September 30, 2024, total costs of $14,900 have been incurred pursuant to this work order agreement.\n52\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)J (cid:0)U(cid:0)H (cid:0)J (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)L(cid:0)W(cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)Q (cid:0)L(cid:0)W(cid:0)R (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)O(cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)Y (cid:0)L(cid:0)R (cid:0)X (cid:0)V (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)L(cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)W(cid:0)D (cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)U(cid:0)R (cid:0)[ (cid:0)L(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:25) (cid:0)(cid:15)(cid:0)(cid:22) (cid:0)(cid:27) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I\n(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)U(cid:0)R (cid:0)X (cid:0)J (cid:0)K (cid:0)(cid:3)(cid:0)0 (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:26) (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)3 (cid:0)D (cid:0)W(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U (cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V\n(cid:0)(cid:3)\n(cid:0)1 (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0), (cid:0)Q (cid:0)V (cid:0)W(cid:0)L(cid:0)W(cid:0)X (cid:0)W(cid:0)H (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)+ (cid:0)H (cid:0)D (cid:0)O(cid:0)W(cid:0)K (cid:0)(cid:17)(cid:0)(cid:3) (cid:0)( (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3) (cid:0)) (cid:0)H (cid:0)E (cid:0)U(cid:0)X (cid:0)D (cid:0)U(cid:0)\\ (cid:0)(cid:3) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)H (cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)D (cid:0)(cid:3) (cid:0)3 (cid:0)D (cid:0)W(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)‡ (cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)· (cid:0)(cid:12)(cid:0)(cid:3) (cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)1 (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)D (cid:0)O\n(cid:0),(cid:0)Q (cid:0)V (cid:0)W(cid:0)L(cid:0)W(cid:0)X (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)1 (cid:0)H (cid:0)X (cid:0)U(cid:0)R (cid:0)O(cid:0)R (cid:0)J (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)’ (cid:0)L(cid:0)V (cid:0)R (cid:0)U(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)U(cid:0)R (cid:0)N (cid:0)H (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)‡ (cid:0)1 (cid:0),(cid:0)1 (cid:0)’ (cid:0)6 (cid:0)· (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)1 (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)& (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)V (cid:0)W(cid:0)L(cid:0)W(cid:0)X (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)‡ (cid:0)1 (cid:0)& (cid:0),(cid:0)· (cid:0)(cid:12)(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)H (cid:0)D (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)V (cid:0)W(cid:0)L(cid:0)W(cid:0)X (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)1 (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)V (cid:0)W(cid:0)L(cid:0)W(cid:0)X (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)+ (cid:0)H (cid:0)D (cid:0)O(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)‡ (cid:0)1 (cid:0),(cid:0)+ (cid:0)· (cid:0)(cid:12)(cid:0)(cid:17)\n(cid:0)3 (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3) (cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)K (cid:0)D (cid:0)V (cid:0)(cid:3) (cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)(cid:3) (cid:0)H (cid:0)[ (cid:0)F (cid:0)O(cid:0)X (cid:0)V (cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3) (cid:0)E (cid:0)D (cid:0)V (cid:0)L(cid:0)V (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)1 (cid:0),(cid:0)+ (cid:0)¶(cid:0)V (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)O(cid:0)O(cid:0)H (cid:0)F (cid:0)W(cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)S (cid:0)U(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)W(cid:0)\\ (cid:0)(cid:3) (cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V (cid:0)(cid:3) (cid:0)F (cid:0)O(cid:0)D (cid:0)L(cid:0)P (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)D (cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3) (cid:0)5 (cid:0)H (cid:0)V (cid:0)H (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G\n(cid:0)’ (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)(cid:11)(cid:0)‡ (cid:0)& (cid:0)5 (cid:0)$ (cid:0)’ (cid:0)$ (cid:0)· (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)M(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)Y (cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)(cid:16)(cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)H (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)X (cid:0)V (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)F (cid:0)X (cid:0)V (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)P (cid:0)R (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)W(cid:0)L(cid:0)(cid:16)(cid:0)F (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)R (cid:0)Q (cid:0)H (cid:0)(cid:15)\n(cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)P (cid:0)E (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3) (cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)G (cid:0)D (cid:0)U(cid:0)G (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)W(cid:0)L(cid:0)(cid:16)(cid:0)F (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)G (cid:0)U(cid:0)X (cid:0)J (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)V (cid:0)F (cid:0)R (cid:0)S (cid:0)H (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3) (cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)H (cid:0)[ (cid:0)W(cid:0)H (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:3) (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)F (cid:0)K (cid:0)H (cid:0)F (cid:0)N (cid:0)S (cid:0)R (cid:0)L(cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)K (cid:0)L(cid:0)E (cid:0)L(cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)L(cid:0)P (cid:0)P (cid:0)X (cid:0)Q (cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)D (cid:0)S (cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)U(cid:0)D (cid:0)G (cid:0)L(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)W(cid:0)U(cid:0)H (cid:0)D (cid:0)W(cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)R (cid:0)I\n(cid:0)F (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)W(cid:0)H (cid:0)Q (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)G (cid:0)X (cid:0)F (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)E (cid:0)D (cid:0)V (cid:0)L(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)W(cid:0)L(cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)S (cid:0)L(cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)D (cid:0)V (cid:0)W(cid:0)(cid:16)(cid:0)W(cid:0)R (cid:0)(cid:16)(cid:0)H (cid:0)[ (cid:0)S (cid:0)L(cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)Y (cid:0)D (cid:0)O(cid:0)L(cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)D (cid:0)L(cid:0)P (cid:0)(cid:3)(cid:0)R (cid:0)I\n(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)M(cid:0)R (cid:0)L(cid:0)Q (cid:0)W(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)Z (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)W(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)H (cid:0)D (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)U(cid:0)L(cid:0)W(cid:0)R (cid:0)U(cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)H (cid:0)V (cid:0)W(cid:0)L(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)Z (cid:0)H (cid:0)Q (cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)\\ (cid:0)H (cid:0)D (cid:0)U(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)O(cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)R (cid:0)R (cid:0)Q (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)H (cid:0)P (cid:0)S (cid:0)O(cid:0)D (cid:0)W(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)H (cid:0)N (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)Z (cid:0)R (cid:0)U(cid:0)N (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)S (cid:0)K (cid:0)D (cid:0)U(cid:0)P (cid:0)D (cid:0)F (cid:0)H (cid:0)X (cid:0)W(cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)L(cid:0)W(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)S (cid:0)U(cid:0)H (cid:0)K (cid:0)H (cid:0)Q (cid:0)V (cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)U\n(cid:0)F (cid:0)H (cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)L(cid:0)W(cid:0)L(cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)L(cid:0)P (cid:0)H (cid:0)I(cid:0)U(cid:0)D (cid:0)P (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)P (cid:0)H (cid:0)H (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)Q (cid:0)F (cid:0)K (cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)’ (cid:0)D (cid:0)W(cid:0)D (cid:0)(cid:3)(cid:0)I(cid:0)U(cid:0)R (cid:0)P (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)M(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)Y (cid:0)D (cid:0)U(cid:0)L(cid:0)R (cid:0)X (cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)X (cid:0)O(cid:0)D (cid:0)W(cid:0)R (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)O(cid:0)L(cid:0)Q (cid:0)J (cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)H (cid:0)W(cid:0)L(cid:0)Q (cid:0)J\n(cid:0)D (cid:0)S (cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)O(cid:0)L(cid:0)F (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)U(cid:0)L(cid:0)W(cid:0)R (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)6 (cid:0)X (cid:0)E (cid:0)M(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)H (cid:0)L(cid:0)S (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)H (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)D (cid:0)O(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)Z (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)H (cid:0)U(cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)L(cid:0)] (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)G (cid:0)X (cid:0)F (cid:0)W(cid:0)V\n(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)H (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)X (cid:0)O(cid:0)D (cid:0)W(cid:0)R (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)E (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)E (cid:0)O(cid:0)L(cid:0)J (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)1 (cid:0),(cid:0)+ (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)Q (cid:0)(cid:16)(cid:0)F (cid:0)U(cid:0)H (cid:0)G (cid:0)L(cid:0)W(cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)Q (cid:0)(cid:16)(cid:0)U(cid:0)H (cid:0)I(cid:0)X (cid:0)Q (cid:0)G (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)R (cid:0)\\ (cid:0)D (cid:0)O(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:24) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)U(cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)L(cid:0)Q (cid:0)L(cid:0)P (cid:0)X (cid:0)P (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)Q (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)R (cid:0)\\ (cid:0)D (cid:0)O(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)L(cid:0)[ (cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)\\ (cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)U(cid:0)R (cid:0)P\n(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)U(cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)L(cid:0)Q (cid:0)L(cid:0)P (cid:0)X (cid:0)P (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)Q (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)R (cid:0)\\ (cid:0)D (cid:0)O(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:21) (cid:0)(cid:24) (cid:0)(cid:15)(cid:0)(cid:25) (cid:0)(cid:23) (cid:0)(cid:22) (cid:0)(cid:3)(cid:0)Z (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)U(cid:0)R (cid:0)P (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)H (cid:0)[ (cid:0)W(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)V (cid:0)H (cid:0)T (cid:0)X (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)- (cid:0)D (cid:0)Q (cid:0)X (cid:0)D (cid:0)U(cid:0)\\\n(cid:0)(cid:20) (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)D (cid:0)I(cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)L(cid:0)Q (cid:0)L(cid:0)P (cid:0)X (cid:0)P (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)Q (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)R (cid:0)\\ (cid:0)D (cid:0)O(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)D (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)- (cid:0)D (cid:0)Q (cid:0)X (cid:0)D (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)U(cid:0)H (cid:0)G (cid:0)L(cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)D (cid:0)L(cid:0)Q (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)H (cid:0)D (cid:0)U(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)R (cid:0)\\ (cid:0)D (cid:0)O(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)D (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)G (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)\\ (cid:0)H (cid:0)D (cid:0)U(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)H\n(cid:0)U(cid:0)R (cid:0)\\ (cid:0)D (cid:0)O(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:24) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)U(cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)L(cid:0)Q (cid:0)L(cid:0)P (cid:0)X (cid:0)P (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)Q (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)R (cid:0)\\ (cid:0)D (cid:0)O(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:21) (cid:0)(cid:24) (cid:0)(cid:15)(cid:0)(cid:25) (cid:0)(cid:23) (cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)L(cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)$ (cid:0)S (cid:0)U(cid:0)L(cid:0)O(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)E (cid:0)O(cid:0)L(cid:0)J (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)1 (cid:0),(cid:0)+ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)U(cid:0)\\ (cid:0)(cid:16)(cid:0)E (cid:0)\\ (cid:0)(cid:16)(cid:0)F (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)E (cid:0)D (cid:0)V (cid:0)L(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)H (cid:0)D (cid:0)U(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)R (cid:0)\\ (cid:0)D (cid:0)O(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:8) (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)Q (cid:0)H (cid:0)W(cid:0)(cid:3)(cid:0)V (cid:0)D (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)H (cid:0)D (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)U(cid:0)R (cid:0)\\ (cid:0)D (cid:0)O(cid:0)W(cid:0)\\ (cid:0)(cid:16)(cid:0)E (cid:0)H (cid:0)D (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)G (cid:0)X (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)M(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R\n(cid:0)U(cid:0)H (cid:0)G (cid:0)X (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)(cid:24) (cid:0)(cid:19) (cid:0)(cid:8) (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)L(cid:0)U(cid:0)F (cid:0)X (cid:0)P (cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)O(cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)U(cid:0)R (cid:0)\\ (cid:0)D (cid:0)O(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)L(cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)U(cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)U(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)E (cid:0)X (cid:0)W(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)O(cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:8) (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)E (cid:0)O(cid:0)L(cid:0)J (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)H (cid:0)D (cid:0)U(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)R (cid:0)\\ (cid:0)D (cid:0)O(cid:0)W(cid:0)L(cid:0)H (cid:0)V\n(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)H (cid:0)Q (cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)U(cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)H (cid:0)U(cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)D (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)U(cid:0)R (cid:0)\\ (cid:0)D (cid:0)O(cid:0)W(cid:0)\\ (cid:0)(cid:16)(cid:0)E (cid:0)H (cid:0)D (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)G (cid:0)X (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)S (cid:0)L(cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)D (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)Y (cid:0)D (cid:0)O(cid:0)L(cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)D (cid:0)L(cid:0)P\n(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)G (cid:0)X (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)S (cid:0)L(cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)U(cid:0)\\ (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)E (cid:0)O(cid:0)L(cid:0)J (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)1 (cid:0),(cid:0)+ (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)Q (cid:0)F (cid:0)K (cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)(cid:3)(cid:0)U(cid:0)R (cid:0)\\ (cid:0)D (cid:0)O(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)H (cid:0)(cid:16)(cid:0)W(cid:0)L(cid:0)P (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)D (cid:0)V (cid:0)L(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)L(cid:0)[ (cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)\\ (cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)U(cid:0)R (cid:0)P (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)U(cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)K (cid:0)L(cid:0)H (cid:0)Y (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)H (cid:0)D (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)Q (cid:0)F (cid:0)K (cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H\n(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)Q (cid:0)F (cid:0)K (cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)D (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)‡ (cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)H (cid:0)U(cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)R (cid:0)U(cid:0)W(cid:0)V (cid:0)· (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K\n(cid:0)G (cid:0)H (cid:0)D (cid:0)G (cid:0)O(cid:0)L(cid:0)Q (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)2 (cid:0)F (cid:0)W(cid:0)R (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:26) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:28) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)H (cid:0)D (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)I(cid:0)I(cid:0)H (cid:0)U(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)L(cid:0)I(cid:0)L(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)Q (cid:0)F (cid:0)K (cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)\\ (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)\\ (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)U(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)\\ (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)K (cid:0)L(cid:0)H (cid:0)Y (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K\n(cid:0)E (cid:0)H (cid:0)Q (cid:0)F (cid:0)K (cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)2 (cid:0)F (cid:0)W(cid:0)R (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)Q (cid:0)F (cid:0)K (cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)Z (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)V (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)U(cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)W(cid:0)L(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)G (cid:0)X (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)3 (cid:0)K (cid:0)D (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)X (cid:0)G (cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)G\n(cid:0)S (cid:0)U(cid:0)R (cid:0)G (cid:0)X (cid:0)F (cid:0)W(cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)I(cid:0)L(cid:0)H (cid:0)O(cid:0)G (cid:0)V (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)X (cid:0)V (cid:0)H (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)K (cid:0)D (cid:0)G (cid:0)(cid:3) (cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)H (cid:0)Q (cid:0)F (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)D (cid:0)(cid:3) (cid:0)3 (cid:0)K (cid:0)D (cid:0)V (cid:0)H (cid:0)(cid:3) (cid:0)(cid:21) (cid:0)(cid:3) (cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)V (cid:0)W(cid:0)X (cid:0)G (cid:0)\\ (cid:0)(cid:3) (cid:0)D (cid:0)V (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)W(cid:0)R (cid:0)W(cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3) (cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)E (cid:0)H (cid:0)Q (cid:0)F (cid:0)K (cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)(cid:3) (cid:0)S (cid:0)D (cid:0)\\ (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3) (cid:0)L(cid:0)V\n(cid:0)(cid:7) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:21) (cid:0)(cid:21) (cid:0)(cid:24) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)E (cid:0)O(cid:0)L(cid:0)J (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)Q (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)1 (cid:0),(cid:0)+ (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)J (cid:0)U(cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)Z (cid:0)D (cid:0)U(cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)H (cid:0)U(cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)L(cid:0)] (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)G (cid:0)X (cid:0)F (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)W(cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:17)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)V (cid:0)H (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)G (cid:0)X (cid:0)H (cid:0)(cid:3) (cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)V (cid:0)L(cid:0)[ (cid:0)W(cid:0)\\ (cid:0)(cid:3) (cid:0)G (cid:0)D (cid:0)\\ (cid:0)V (cid:0)(cid:3) (cid:0)I(cid:0)R (cid:0)O(cid:0)O(cid:0)R (cid:0)Z (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)H (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)H (cid:0)D (cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)F (cid:0)D (cid:0)O(cid:0)H (cid:0)Q (cid:0)G (cid:0)D (cid:0)U(cid:0)(cid:3) (cid:0)\\ (cid:0)H (cid:0)D (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3) (cid:0)P (cid:0)X (cid:0)V (cid:0)W(cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)(cid:3) (cid:0)X (cid:0)S (cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)V (cid:0)(cid:3) (cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)J (cid:0)X (cid:0)O(cid:0)D (cid:0)W(cid:0)R (cid:0)U(cid:0)\\ (cid:0)(cid:3) (cid:0)V (cid:0)X (cid:0)E (cid:0)P (cid:0)L(cid:0)V (cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:15)\n(cid:0)P (cid:0)D (cid:0)Q (cid:0)X (cid:0)I(cid:0)D (cid:0)F (cid:0)W(cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)R (cid:0)U(cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)D (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)L(cid:0)W(cid:0)L(cid:0)D (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0),(cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)Y (cid:0)L(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)U(cid:0)R (cid:0)P (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)V (cid:0)W(cid:0)D (cid:0)E (cid:0)O(cid:0)L(cid:0)V (cid:0)K (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)H (cid:0)U(cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)O(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)G (cid:0)(cid:16)(cid:0)X (cid:0)S (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)Q (cid:0)F (cid:0)K (cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)F (cid:0)F (cid:0)X (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\\n(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)E (cid:0)O(cid:0)L(cid:0)J (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)S (cid:0)O(cid:0)D (cid:0)Q (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)H (cid:0)U(cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)O(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)Q (cid:0)F (cid:0)K (cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)M(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)1 (cid:0),(cid:0)+ (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)\\\n(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)O(cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)H (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)H (cid:0)U(cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)O(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:18)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)Q (cid:0)F (cid:0)K (cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)W(cid:0)H (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)L(cid:0)P (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)E (cid:0)H (cid:0)Q (cid:0)F (cid:0)K (cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)V (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)E (cid:0)O(cid:0)L(cid:0)J (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)1 (cid:0),(cid:0)+ (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)U(cid:0)R (cid:0)\\ (cid:0)D (cid:0)O(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:24) (cid:0)(cid:8) (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)H (cid:0)L(cid:0)Y (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)J (cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)H (cid:0)D (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)L(cid:0)[ (cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)\\ (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)H (cid:0)L(cid:0)S (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I\n(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)X (cid:0)H (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)(cid:24) (cid:0)(cid:22)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)’ (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)U(cid:0)H (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)Q (cid:0)W(cid:0)K (cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)V (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:26) (cid:0)(cid:15)(cid:0)(cid:24) (cid:0)(cid:22) (cid:0)(cid:26) (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)Q (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)E (cid:0)O(cid:0)L(cid:0)J (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)’ (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)Q (cid:0)L(cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)Q (cid:0)W(cid:0)K (cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)V (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:25) (cid:0)(cid:27) (cid:0)(cid:15)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:25) (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)Q (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)E (cid:0)O(cid:0)L(cid:0)J (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)6 (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)V (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H\n(cid:0)E (cid:0)H (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)J (cid:0)H (cid:0)Q (cid:0)H (cid:0)U(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)P (cid:0)L(cid:0)Q (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)V (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)R (cid:0)O(cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)$ (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)W(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)V (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:25) (cid:0)(cid:27) (cid:0)(cid:15)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:25) (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G\n(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)J (cid:0)U(cid:0)H (cid:0)J (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)L(cid:0)W(cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)O(cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)Y (cid:0)L(cid:0)R (cid:0)X (cid:0)V (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)L(cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)W(cid:0)D (cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)U(cid:0)R (cid:0)[ (cid:0)L(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:26) (cid:0)(cid:28) (cid:0)(cid:24) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I\n(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)U(cid:0)R (cid:0)[ (cid:0)L(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)H (cid:0)[ (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)Z (cid:0)H (cid:0)Q (cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)\\ (cid:0)H (cid:0)D (cid:0)U(cid:0)V (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)0 (cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)W(cid:0)W(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)( (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)X (cid:0)J (cid:0)X (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:20) (cid:0)(cid:27) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)O(cid:0)X (cid:0)V (cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)0 (cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)W(cid:0)W(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)3 (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)0 (cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)W(cid:0)W(cid:0)(cid:3)(cid:0)J (cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)F (cid:0)O(cid:0)X (cid:0)V (cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)W(cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)Z (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)0 (cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)W(cid:0)W(cid:0)(cid:3)(cid:0)(cid:11)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)‡ (cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)3 (cid:0)D (cid:0)W(cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)· (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)O(cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)H (cid:0)D (cid:0)W(cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)0 (cid:0)’ (cid:0)6 (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)Q (cid:0)(cid:16)(cid:0)H (cid:0)[ (cid:0)F (cid:0)O(cid:0)X (cid:0)V (cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)Y (cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:15)\n(cid:0)F (cid:0)R (cid:0)Q (cid:0)F (cid:0)H (cid:0)S (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)V (cid:0)V (cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)W(cid:0)D (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)N (cid:0)Q (cid:0)R (cid:0)Z (cid:0)(cid:16)(cid:0)K (cid:0)R (cid:0)Z (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)W(cid:0)D (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)N (cid:0)H (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)3 (cid:0)D (cid:0)W(cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)Q (cid:0)H (cid:0)F (cid:0)H (cid:0)V (cid:0)V (cid:0)D (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)X (cid:0)V (cid:0)H (cid:0)I(cid:0)X (cid:0)O(cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)D (cid:0)L(cid:0)P\n(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)3 (cid:0)D (cid:0)W(cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)X (cid:0)V (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)Q (cid:0)X (cid:0)I(cid:0)D (cid:0)F (cid:0)W(cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)D (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)G (cid:0)X (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)H (cid:0)D (cid:0)W(cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)0 (cid:0)’ (cid:0)6 (cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)Z (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)Z (cid:0)L(cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)I(cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)Y (cid:0)D (cid:0)O(cid:0)L(cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)D (cid:0)L(cid:0)P (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)3 (cid:0)D (cid:0)W(cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)2 (cid:0)Q (cid:0)(cid:3)(cid:0)2 (cid:0)F (cid:0)W(cid:0)R (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)H (cid:0)L(cid:0)Y (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:16)(cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)O(cid:0)H (cid:0)W(cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:28) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)O(cid:0)X (cid:0)V (cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)G\n(cid:0)$ (cid:0)X (cid:0)J (cid:0)X (cid:0)V (cid:0)W(cid:0)(cid:3) (cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:20) (cid:0)(cid:27) (cid:0)(cid:3) (cid:0)E (cid:0)H (cid:0)W(cid:0)Z (cid:0)H (cid:0)H (cid:0)Q (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)0 (cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)W(cid:0)W(cid:0)(cid:15)(cid:0)(cid:3) (cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3) (cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:17)(cid:0)(cid:3) (cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)0 (cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)W(cid:0)W(cid:0)(cid:3) (cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3) (cid:0)Q (cid:0)R (cid:0)(cid:3) (cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)I(cid:0)H (cid:0)H (cid:0)(cid:3) (cid:0)Z (cid:0)D (cid:0)V (cid:0)(cid:3) (cid:0)G (cid:0)X (cid:0)H (cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)S (cid:0)D (cid:0)\\ (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3) (cid:0)E (cid:0)\\ (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H\n(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)0 (cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)W(cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)N (cid:0)Q (cid:0)R (cid:0)Z (cid:0)O(cid:0)H (cid:0)G (cid:0)J (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)\\ (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)Z (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)’ (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)U(cid:0)H (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)Q (cid:0)W(cid:0)K (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)Q (cid:0)L(cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)Q (cid:0)W(cid:0)K (cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)R (cid:0)U(cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)U(cid:0)H (cid:0)G (cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:21) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:24) (cid:0)(cid:19) (cid:0)(cid:26) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:28) (cid:0)(cid:15)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:28) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)U(cid:0)H (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)E (cid:0)O(cid:0)L(cid:0)J (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)Y (cid:0)L(cid:0)R (cid:0)X (cid:0)V (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)R (cid:0)U(cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)O(cid:0)X (cid:0)V (cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)F (cid:0)H (cid:0)Q (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)2 (cid:0)W(cid:0)K (cid:0)H (cid:0)U (cid:0)(cid:3)(cid:0)6 (cid:0)L(cid:0)J (cid:0)Q (cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U (cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)Q (cid:0)W(cid:0)U (cid:0)D (cid:0)F (cid:0)W(cid:0)V\n(cid:0)(cid:3)\n(cid:0)1 (cid:0)’ (cid:0)$ (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)Q (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)U (cid:0)S (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)2 (cid:0)Q (cid:0)(cid:3)(cid:0)’ (cid:0)H (cid:0)F (cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:20) (cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)1 (cid:0)’ (cid:0)$ (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)Q (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)U(cid:0)S (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)L(cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)H (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I\n(cid:0)R (cid:0)Q (cid:0)F (cid:0)R (cid:0)O(cid:0)R (cid:0)J (cid:0)\\ (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)G (cid:0)U(cid:0)X (cid:0)J (cid:0)(cid:3) (cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)$ (cid:0)V (cid:0)(cid:3) (cid:0)S (cid:0)D (cid:0)U(cid:0)W(cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3) (cid:0)1 (cid:0)’ (cid:0)$ (cid:0)(cid:3) (cid:0)D (cid:0)O(cid:0)V (cid:0)R (cid:0)(cid:3) (cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)F (cid:0)D (cid:0)X (cid:0)V (cid:0)H (cid:0)(cid:3) (cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3) (cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3) (cid:0)’ (cid:0)U(cid:0)(cid:17)(cid:0)(cid:3) (cid:0)’ (cid:0)D (cid:0)Q (cid:0)L(cid:0)H (cid:0)O(cid:0)(cid:3) (cid:0)’ (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)9 (cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)+ (cid:0)R (cid:0)I(cid:0)I(cid:0)(cid:15)(cid:0)(cid:3) (cid:0)0 (cid:0)(cid:17)(cid:0)’ (cid:0)(cid:17)(cid:0)(cid:15)(cid:0)(cid:3) (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)E (cid:0)H (cid:0)F (cid:0)R (cid:0)P (cid:0)H (cid:0)(cid:3) (cid:0)D (cid:0)(cid:3) (cid:0)P (cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H\n(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)6 (cid:0)F (cid:0)L(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)(cid:3)(cid:0)$ (cid:0)G (cid:0)Y (cid:0)L(cid:0)V (cid:0)R (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)P (cid:0)L(cid:0)W(cid:0)W(cid:0)H (cid:0)H (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0)\\ (cid:0)H (cid:0)D (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)T (cid:0)X (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)V (cid:0)K (cid:0)(cid:3)(cid:0)I(cid:0)H (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)W(cid:0)R (cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)O(cid:0)\\\n(cid:0)U(cid:0)H (cid:0)Q (cid:0)H (cid:0)Z (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)H (cid:0)(cid:16)(cid:0)\\ (cid:0)H (cid:0)D (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)Q (cid:0)L(cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)D (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)L(cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:20) (cid:0)(cid:23) (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)Q (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)L(cid:0)V (cid:0)R (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)I(cid:0)H (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)K (cid:0)D (cid:0)U(cid:0)J (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)(cid:7) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)U(cid:0)H (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)Q (cid:0)W(cid:0)K (cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)Q (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)L(cid:0)V (cid:0)R (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)I(cid:0)H (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)K (cid:0)D (cid:0)U(cid:0)J (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:20) (cid:0)(cid:21) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)(cid:7) (cid:0)(cid:20) (cid:0)(cid:21) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)L(cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)Q (cid:0)W(cid:0)K (cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)- (cid:0)X (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)% (cid:0)L(cid:0)R (cid:0)3 (cid:0)K (cid:0)D (cid:0)U (cid:0)P (cid:0)D (cid:0): (cid:0)R (cid:0)U (cid:0)N (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3) (cid:0)( (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3) (cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)(cid:20) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)H (cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)D (cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)O(cid:0)O(cid:0)D (cid:0)E (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3) (cid:0)% (cid:0)L(cid:0)R (cid:0)3 (cid:0)K (cid:0)D (cid:0)U(cid:0)P (cid:0)D (cid:0): (cid:0)R (cid:0)U(cid:0)N (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\\n(cid:0)H (cid:0)Q (cid:0)J (cid:0)D (cid:0)J (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)% (cid:0)L(cid:0)R (cid:0)3 (cid:0)K (cid:0)D (cid:0)U(cid:0)P (cid:0)D (cid:0): (cid:0)R (cid:0)U(cid:0)N (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)U(cid:0)Y (cid:0)L(cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)R (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)U(cid:0)Y (cid:0)L(cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)R (cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)J (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)V (cid:0)L(cid:0)V (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)H (cid:0)U(cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)L(cid:0)] (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)G (cid:0)X (cid:0)F (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)V (cid:0)W(cid:0)U(cid:0)H (cid:0)Q (cid:0)J (cid:0)W(cid:0)K (cid:0)H (cid:0)Q (cid:0)(cid:3) (cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3) (cid:0)S (cid:0)D (cid:0)W(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)I(cid:0)R (cid:0)O(cid:0)L(cid:0)R (cid:0)(cid:30)(cid:0)(cid:3) (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)I(cid:0)\\ (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)O(cid:0)D (cid:0)U(cid:0)J (cid:0)H (cid:0)(cid:3) (cid:0)S (cid:0)K (cid:0)D (cid:0)U(cid:0)P (cid:0)D (cid:0)F (cid:0)H (cid:0)X (cid:0)W(cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3) (cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3) (cid:0)D (cid:0)(cid:3) (cid:0)S (cid:0)R (cid:0)W(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3) (cid:0)S (cid:0)U(cid:0)R (cid:0)G (cid:0)X (cid:0)F (cid:0)W(cid:0)(cid:3) (cid:0)S (cid:0)L(cid:0)S (cid:0)H (cid:0)O(cid:0)L(cid:0)Q (cid:0)H (cid:0)(cid:30)(cid:0)(cid:3) (cid:0)D (cid:0)V (cid:0)V (cid:0)L(cid:0)V (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)S (cid:0)U(cid:0)H (cid:0)S (cid:0)D (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)W(cid:0)H (cid:0)F (cid:0)K (cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O\n(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)Q (cid:0)F (cid:0)H (cid:0)U(cid:0)Q (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3) (cid:0)S (cid:0)U(cid:0)R (cid:0)G (cid:0)X (cid:0)F (cid:0)W(cid:0)V (cid:0)(cid:30)(cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)G (cid:0)U(cid:0)X (cid:0)J (cid:0)(cid:3) (cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)\\ (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:30)(cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)I(cid:0)\\ (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)H (cid:0)H (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)W(cid:0)D (cid:0)V (cid:0)N (cid:0)V (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)O(cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O\n(cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)Q (cid:0)H (cid:0)Z (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)S (cid:0)R (cid:0)X (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)% (cid:0)L(cid:0)R (cid:0)3 (cid:0)K (cid:0)D (cid:0)U(cid:0)P (cid:0)D (cid:0): (cid:0)R (cid:0)U(cid:0)N (cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)3 (cid:0)I(cid:0)L(cid:0)] (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)F (cid:0)L(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)V (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)W(cid:0)H (cid:0)Q (cid:0)V (cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)X (cid:0)O(cid:0)W(cid:0)L(cid:0)(cid:16)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)L(cid:0)S (cid:0)O(cid:0)L(cid:0)Q (cid:0)D (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)U(cid:0)X (cid:0)J (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H\n(cid:0)& (cid:0)R (cid:0)O(cid:0)O(cid:0)D (cid:0)E (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)L(cid:0)W(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)Z (cid:0)R (cid:0)(cid:3)(cid:0)\\ (cid:0)H (cid:0)D (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)W(cid:0)R (cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)Q (cid:0)H (cid:0)Z (cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)V (cid:0)H (cid:0)T (cid:0)X (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)Q (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)O(cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)U(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)O(cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:25) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)\\ (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)L(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)R\n(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)S (cid:0)L(cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)O(cid:0)L(cid:0)F (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)(cid:17)(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)Q (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)O(cid:0)O(cid:0)D (cid:0)E (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)% (cid:0)L(cid:0)R (cid:0)3 (cid:0)K (cid:0)D (cid:0)U(cid:0)P (cid:0)D (cid:0): (cid:0)R (cid:0)U(cid:0)N (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)Q (cid:0)W(cid:0)K (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)I(cid:0)H (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)M(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)Q (cid:0)H (cid:0)J (cid:0)R (cid:0)W(cid:0)L(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)X (cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)H (cid:0)X (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)Q (cid:0)W(cid:0)K (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)I(cid:0)H (cid:0)H (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)( (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)0 (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)S (cid:0)H (cid:0)Q (cid:0)V (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)\\ (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)O(cid:0)O(cid:0)D (cid:0)E (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)D (cid:0)V\n(cid:0)F (cid:0)R (cid:0)Q (cid:0)Y (cid:0)H (cid:0)U(cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)X (cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)U(cid:0)X (cid:0)F (cid:0)W(cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)R (cid:0)U(cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)K (cid:0)D (cid:0)U(cid:0)J (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)O(cid:0)O(cid:0)D (cid:0)E (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:27) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)G (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)U(cid:0)H (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)Q (cid:0)W(cid:0)K (cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)V (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)R (cid:0)O(cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)R (cid:0)U(cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)K (cid:0)D (cid:0)U(cid:0)J (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W\n(cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)O(cid:0)O(cid:0)D (cid:0)E (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)(cid:7) (cid:0)(cid:22) (cid:0)(cid:24) (cid:0)(cid:15)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)(cid:7) (cid:0)(cid:28) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3) (cid:0)G (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)Q (cid:0)L(cid:0)Q (cid:0)H (cid:0)(cid:3) (cid:0)P (cid:0)R (cid:0)Q (cid:0)W(cid:0)K (cid:0)V (cid:0)(cid:3) (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)Z (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G\n(cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)V (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)R (cid:0)O(cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)(cid:24) (cid:0)(cid:23)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)1 (cid:0)H (cid:0)W(cid:0)K (cid:0)H (cid:0)U (cid:0)O(cid:0)D (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:3) (cid:0)& (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)U (cid:0)(cid:3) (cid:0), (cid:0)Q (cid:0)V (cid:0)W(cid:0)L(cid:0)W(cid:0)X (cid:0)W(cid:0)H (cid:0)(cid:17)(cid:0)(cid:3) (cid:0)2 (cid:0)Q (cid:0)(cid:3) (cid:0)2 (cid:0)F (cid:0)W(cid:0)R (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)(cid:27) (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)H (cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)D (cid:0)(cid:3) (cid:0)’ (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)O(cid:0)O(cid:0)D (cid:0)E (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)1 (cid:0)H (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)O(cid:0)D (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:3) (cid:0)& (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0),(cid:0)Q (cid:0)V (cid:0)W(cid:0)L(cid:0)W(cid:0)X (cid:0)W(cid:0)H (cid:0)(cid:15)\n(cid:0)$ (cid:0)P (cid:0)V (cid:0)W(cid:0)H (cid:0)U(cid:0)G (cid:0)D (cid:0)P (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)‡ (cid:0)1 (cid:0). (cid:0),(cid:0)· (cid:0)(cid:12)(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)Z (cid:0)R (cid:0)U(cid:0)O(cid:0)G (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)O(cid:0)H (cid:0)D (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)S (cid:0)U(cid:0)H (cid:0)K (cid:0)H (cid:0)Q (cid:0)V (cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)2 (cid:0)Q (cid:0)F (cid:0)R (cid:0)G (cid:0)H (cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)V (cid:0)W(cid:0)L(cid:0)W(cid:0)X (cid:0)W(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)8 (cid:0)W(cid:0)U(cid:0)H (cid:0)F (cid:0)K (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)M(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)G (cid:0)H (cid:0)S (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)U(cid:0)H (cid:0)H\n(cid:0)\\ (cid:0)H (cid:0)D (cid:0)U(cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)’ (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)O(cid:0)O(cid:0)D (cid:0)E (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)V (cid:0)H (cid:0)T (cid:0)X (cid:0)H (cid:0)Q (cid:0)W(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)G (cid:0)L(cid:0)I(cid:0)L(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)$ (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)1 (cid:0)R (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)W(cid:0)R (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)’ (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)O(cid:0)O(cid:0)D (cid:0)E (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)X (cid:0)G (cid:0)\\\n(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)I(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)P (cid:0)L(cid:0)V (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)G (cid:0)U(cid:0)X (cid:0)J (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)E (cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)/ (cid:0)% (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)R (cid:0)W(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)/ (cid:0)% (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)D (cid:0)O(cid:0)R (cid:0)J (cid:0)X (cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)X (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)H (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)U(cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)I(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)O(cid:0)H (cid:0)F (cid:0)X (cid:0)O(cid:0)D (cid:0)U(cid:0)(cid:3)(cid:0)P (cid:0)H (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)L(cid:0)V (cid:0)P (cid:0)V (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)O(cid:0)\\ (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)I(cid:0)L(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)E (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)X (cid:0)G (cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)U(cid:0)R (cid:0)[ (cid:0)L(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:28) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)( (cid:0)X (cid:0)U(cid:0)R (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H\n(cid:0)D (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)L(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)S (cid:0)S (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)/ (cid:0)% (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)X (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)X (cid:0)G (cid:0)\\ (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)2 (cid:0)Q (cid:0)(cid:3)(cid:0)2 (cid:0)F (cid:0)W(cid:0)R (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)$ (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)1 (cid:0)R (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)’ (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)O(cid:0)O(cid:0)D (cid:0)E (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)1 (cid:0). (cid:0),(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)D (cid:0)U(cid:0)F (cid:0)K\n(cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)W(cid:0)H (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)’ (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)O(cid:0)O(cid:0)D (cid:0)E (cid:0)R (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)Z (cid:0)R (cid:0)(cid:3)(cid:0)\\ (cid:0)H (cid:0)D (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)2 (cid:0)F (cid:0)W(cid:0)R (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:27) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:25) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)(cid:24) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)( (cid:0)X (cid:0)U(cid:0)R (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)E (cid:0)X (cid:0)G (cid:0)J (cid:0)H (cid:0)W(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)L(cid:0)Q (cid:0)J\n(cid:0)I(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)’ (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)U(cid:0)H (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)Q (cid:0)W(cid:0)K (cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)K (cid:0)D (cid:0)U(cid:0)J (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:26) (cid:0)(cid:25) (cid:0)(cid:15)(cid:0)(cid:21) (cid:0)(cid:26) (cid:0)(cid:27) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:24) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:24) (cid:0)(cid:25) (cid:0)(cid:27) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V\n(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)V (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)R (cid:0)O(cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)’ (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)L(cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)Q (cid:0)W(cid:0)K (cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U\n(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)F (cid:0)K (cid:0)D (cid:0)U(cid:0)J (cid:0)H (cid:0)V (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)D (cid:0)P (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)(cid:7) (cid:0)(cid:21) (cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:22) (cid:0)(cid:25) (cid:0)(cid:21) (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)(cid:7) (cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:25) (cid:0)(cid:15)(cid:0)(cid:28) (cid:0)(cid:24) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3) (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3) (cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3) (cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)D (cid:0)P (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3) (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)L(cid:0)Q\n(cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)V (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)R (cid:0)O(cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)$ (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)W(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)V (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:25) (cid:0)(cid:28) (cid:0)(cid:24) (cid:0)(cid:15)(cid:0)(cid:28) (cid:0)(cid:20) (cid:0)(cid:27) (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V\n(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)J (cid:0)U(cid:0)H (cid:0)J (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)L(cid:0)W(cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)U(cid:0)H (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)O(cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)Y (cid:0)L(cid:0)R (cid:0)X (cid:0)V (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)L(cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)W(cid:0)D (cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)U(cid:0)R (cid:0)[ (cid:0)L(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:21) (cid:0)(cid:26) (cid:0)(cid:28) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:15)\n(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)U(cid:0)R (cid:0)X (cid:0)J (cid:0)K (cid:0)(cid:3)(cid:0)2 (cid:0)F (cid:0)W(cid:0)R (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:27) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:25) (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)$ (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)Z (cid:0)R (cid:0)U(cid:0)N (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)X (cid:0)F (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)( (cid:0)X (cid:0)U(cid:0)R (cid:0)S (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)L(cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)( (cid:0)X (cid:0)U(cid:0)R (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)V (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)M(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)H (cid:0)L(cid:0)J (cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)Q (cid:0)F (cid:0)\\\n(cid:0)I(cid:0)O(cid:0)X (cid:0)F (cid:0)W(cid:0)X (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)W(cid:0)Z (cid:0)H (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)8 (cid:0)Q (cid:0)L(cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)’ (cid:0)R (cid:0)O(cid:0)O(cid:0)D (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)( (cid:0)X (cid:0)U(cid:0)R (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)0 (cid:0)5 (cid:0), (cid:0)(cid:3)(cid:0)* (cid:0)O(cid:0)R (cid:0)E (cid:0)D (cid:0)O(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)$ (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)D (cid:0)F (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)0 (cid:0)5 (cid:0),(cid:0)(cid:3)(cid:0)* (cid:0)O(cid:0)R (cid:0)E (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)D (cid:0)O(cid:0)\\ (cid:0)V (cid:0)L(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)R (cid:0)U(cid:0)D (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)L(cid:0)E (cid:0)X (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)/ (cid:0)% (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)8 (cid:0)Q (cid:0)L(cid:0)W(cid:0)H (cid:0)G\n(cid:0)6 (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)’ (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)U(cid:0)H (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)Q (cid:0)W(cid:0)K (cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)V (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:28) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:25) (cid:0)(cid:21) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:21) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:23) (cid:0)(cid:24) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)D (cid:0)F (cid:0)W(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)’ (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)Q (cid:0)L(cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)Q (cid:0)W(cid:0)K (cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)V (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:20) (cid:0)(cid:27) (cid:0)(cid:15)(cid:0)(cid:28) (cid:0)(cid:22) (cid:0)(cid:21) (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:25) (cid:0)(cid:21) (cid:0)(cid:27) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)D (cid:0)F (cid:0)W(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)$ (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)W(cid:0)D (cid:0)O\n(cid:0)F (cid:0)R (cid:0)V (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:22) (cid:0)(cid:22) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:20) (cid:0)(cid:23) (cid:0)(cid:26) (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)D (cid:0)F (cid:0)W(cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)J (cid:0)J (cid:0)U(cid:0)H (cid:0)J (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)L(cid:0)W(cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)D (cid:0)F (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)O(cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)Y (cid:0)L(cid:0)R (cid:0)X (cid:0)V (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)L(cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)W(cid:0)D (cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)U(cid:0)R (cid:0)[ (cid:0)L(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)(cid:7) (cid:0)(cid:20) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)U (cid:0)H (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)( (cid:0)Y (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)8 (cid:0)Q (cid:0)F (cid:0)H (cid:0)U (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)W(cid:0)L(cid:0)H (cid:0)V\n(cid:0)(cid:3)\n(cid:0)5 (cid:0)H (cid:0)V (cid:0)H (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)Q (cid:0)H (cid:0)Z (cid:0)(cid:3)(cid:0)S (cid:0)K (cid:0)D (cid:0)U(cid:0)P (cid:0)D (cid:0)F (cid:0)H (cid:0)X (cid:0)W(cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)S (cid:0)R (cid:0)X (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)Q (cid:0)D (cid:0)W(cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)S (cid:0)U(cid:0)H (cid:0)G (cid:0)L(cid:0)F (cid:0)W(cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)$ (cid:0)O(cid:0)W(cid:0)K (cid:0)R (cid:0)X (cid:0)J (cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)W(cid:0)D (cid:0)N (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)R (cid:0)U(cid:0)W(cid:0)V\n(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)H (cid:0)U(cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)O(cid:0)L(cid:0)J (cid:0)H (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)V (cid:0)X (cid:0)U(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)V (cid:0)K (cid:0)(cid:3)(cid:0)S (cid:0)R (cid:0)V (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)L(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)(cid:3)(cid:0)S (cid:0)K (cid:0)D (cid:0)U(cid:0)P (cid:0)D (cid:0)F (cid:0)H (cid:0)X (cid:0)W(cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)S (cid:0)R (cid:0)X (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)H (cid:0)[ (cid:0)W(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)Q (cid:0)H (cid:0)H (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)F (cid:0)U(cid:0)H (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)W(cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)X (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)L(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)V (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)V (cid:0)X (cid:0)U(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)K (cid:0)D (cid:0)U(cid:0)P (cid:0)D (cid:0)F (cid:0)H (cid:0)X (cid:0)W(cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)S (cid:0)R (cid:0)X (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)E (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)X (cid:0)O(cid:0)D (cid:0)W(cid:0)R (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)D (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)U(cid:0)N (cid:0)H (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)F (cid:0)H (cid:0)S (cid:0)W(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)K (cid:0)L(cid:0)H (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)V (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)X (cid:0)H (cid:0)V\n(cid:0)V (cid:0)X (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)L(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)S (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)( (cid:0)Y (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)J (cid:0)H (cid:0)Q (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)X (cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)V (cid:0)X (cid:0)U(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)K (cid:0)L(cid:0)H (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)I(cid:0)L(cid:0)W(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)S (cid:0)R (cid:0)V (cid:0)L(cid:0)W(cid:0)L(cid:0)Y (cid:0)H\n(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)V (cid:0)K (cid:0)(cid:3)(cid:0)I(cid:0)O(cid:0)R (cid:0)Z (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)V (cid:0)X (cid:0)U(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)W(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)F (cid:0)H (cid:0)S (cid:0)W(cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:17)(cid:0)(cid:3)(cid:0),(cid:0)I(cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)V (cid:0)K\n(cid:0)U(cid:0)H (cid:0)V (cid:0)R (cid:0)X (cid:0)U(cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:3) (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)V (cid:0)X (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)L(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)V (cid:0)D (cid:0)W(cid:0)L(cid:0)V (cid:0)I(cid:0)\\ (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3) (cid:0)R (cid:0)Q (cid:0)J (cid:0)R (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)F (cid:0)D (cid:0)V (cid:0)K (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)Z (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3) (cid:0)E (cid:0)H (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)G (cid:0)X (cid:0)F (cid:0)H (cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)L(cid:0)Q (cid:0)X (cid:0)H (cid:0)(cid:3) (cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W\n(cid:0)S (cid:0)U(cid:0)R (cid:0)J (cid:0)U(cid:0)D (cid:0)P (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)W(cid:0)H (cid:0)P (cid:0)S (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)R (cid:0)E (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Y (cid:0)D (cid:0)L(cid:0)O(cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)D (cid:0)O(cid:0)W(cid:0)K (cid:0)R (cid:0)X (cid:0)J (cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)V (cid:0)X (cid:0)U(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:12)(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)U(cid:0)R (cid:0)X (cid:0)J (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)W(cid:0)H (cid:0)J (cid:0)L(cid:0)F (cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)L(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)O(cid:0)L(cid:0)Q (cid:0)T (cid:0)X (cid:0)L(cid:0)V (cid:0)K (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J (cid:0)K (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)D (cid:0)L(cid:0)Q\n(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)K (cid:0)D (cid:0)U(cid:0)P (cid:0)D (cid:0)F (cid:0)H (cid:0)X (cid:0)W(cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)S (cid:0)R (cid:0)X (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)F (cid:0)X (cid:0)U(cid:0)W(cid:0)D (cid:0)L(cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)L(cid:0)Q (cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)U(cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)2 (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)X (cid:0)V (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)L(cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)Q (cid:0)W(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)Z (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)H (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)N (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O\n(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)H (cid:0)D (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)W(cid:0)K (cid:0)R (cid:0)X (cid:0)J (cid:0)K (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)R (cid:0)V (cid:0)V (cid:0)L(cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)Q (cid:0)H (cid:0)Z (cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)H (cid:0)Q (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)W(cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)(cid:24) (cid:0)(cid:24)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0), (cid:0)7 (cid:0)( (cid:0)0 (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)4 (cid:0)8 (cid:0)$ (cid:0)1 (cid:0)7 (cid:0), (cid:0)7 (cid:0)$ (cid:0)7 (cid:0), (cid:0)9 (cid:0)( (cid:0)(cid:3)(cid:0)$ (cid:0)1 (cid:0)’ (cid:0)(cid:3)(cid:0)4 (cid:0)8 (cid:0)$ (cid:0)/ (cid:0), (cid:0)7 (cid:0)$ (cid:0)7 (cid:0), (cid:0)9 (cid:0)( (cid:0)(cid:3)(cid:0)’ (cid:0), (cid:0)6 (cid:0)& (cid:0)/ (cid:0)2 (cid:0)6 (cid:0)8 (cid:0)5 (cid:0)( (cid:0)(cid:3)(cid:0)$ (cid:0)% (cid:0)2 (cid:0)8 (cid:0)7 (cid:0)(cid:3)(cid:0)0 (cid:0)$ (cid:0)5 (cid:0). (cid:0)( (cid:0)7 (cid:0)(cid:3)(cid:0)5 (cid:0), (cid:0)6 (cid:0).\n(cid:0)(cid:3)\n(cid:0)1 (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)O(cid:0)L(cid:0)F (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0), (cid:0)7 (cid:0)( (cid:0)0 (cid:0)(cid:3)(cid:0)(cid:23) (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)& (cid:0)2 (cid:0)1 (cid:0)7 (cid:0)5 (cid:0)2 (cid:0)/ (cid:0)6 (cid:0)(cid:3)(cid:0)$ (cid:0)1 (cid:0)’ (cid:0)(cid:3)(cid:0)3 (cid:0)5 (cid:0)2 (cid:0)& (cid:0)( (cid:0)’ (cid:0)8 (cid:0)5 (cid:0)( (cid:0)6\n(cid:0)(cid:3)\n(cid:0)’ (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)Q (cid:0)W(cid:0)U (cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)3 (cid:0)U (cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U (cid:0)H (cid:0)V\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)Q (cid:0)D (cid:0)J (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)R (cid:0)Q (cid:0)V (cid:0)L(cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)V (cid:0)W(cid:0)D (cid:0)E (cid:0)O(cid:0)L(cid:0)V (cid:0)K (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)L(cid:0)Q (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)V (cid:0)\\ (cid:0)V (cid:0)W(cid:0)H (cid:0)P (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)5 (cid:0)X (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:22) (cid:0)D (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)H (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)G (cid:0)(cid:16)\n(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)H (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:28) (cid:0)(cid:22) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)‡ (cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)· (cid:0)(cid:12)(cid:0)(cid:12)(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)P (cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)R (cid:0)U(cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)V (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)P (cid:0)P (cid:0)D (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)L(cid:0)P (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)L(cid:0)I(cid:0)L(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)X (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)’ (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H\n(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)R (cid:0)X (cid:0)W(cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)P (cid:0)L(cid:0)W(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)O(cid:0)H (cid:0)V\n(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)P (cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)F (cid:0)X (cid:0)P (cid:0)X (cid:0)O(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)X (cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)H (cid:0)U(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)Q (cid:0)D (cid:0)J (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)L(cid:0)Q (cid:0)F (cid:0)L(cid:0)S (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)H (cid:0)F (cid:0)X (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)L(cid:0)Q (cid:0)F (cid:0)L(cid:0)S (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U\n(cid:0)S (cid:0)H (cid:0)U(cid:0)V (cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)V (cid:0)L(cid:0)P (cid:0)L(cid:0)O(cid:0)D (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)Q (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)U(cid:0)R (cid:0)S (cid:0)U(cid:0)L(cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)R (cid:0)Z (cid:0)(cid:3)(cid:0)W(cid:0)L(cid:0)P (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)F (cid:0)L(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)D (cid:0)U(cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0),(cid:0)Q (cid:0)(cid:3) (cid:0)D (cid:0)F (cid:0)F (cid:0)R (cid:0)U(cid:0)G (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3) (cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3) (cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3) (cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3) (cid:0)5 (cid:0)X (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:3) (cid:0)(cid:20) (cid:0)(cid:22) (cid:0)D (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)(cid:20) (cid:0)(cid:24) (cid:0)G (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)(cid:3) (cid:0)H (cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)Z (cid:0)D (cid:0)V (cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)P (cid:0)S (cid:0)O(cid:0)H (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)V (cid:0)X (cid:0)S (cid:0)H (cid:0)U(cid:0)Y (cid:0)L(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)S (cid:0)D (cid:0)U(cid:0)W(cid:0)L(cid:0)F (cid:0)L(cid:0)S (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V\n(cid:0)P (cid:0)D (cid:0)Q (cid:0)D (cid:0)J (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)K (cid:0)L(cid:0)H (cid:0)I(cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)H (cid:0)F (cid:0)X (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)& (cid:0)K (cid:0)L(cid:0)H (cid:0)I(cid:0)(cid:3)(cid:0)) (cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)V (cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)% (cid:0)D (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)Q (cid:0)D (cid:0)J (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W\n(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)V (cid:0)X (cid:0)U(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)U\n(cid:0)V (cid:0)X (cid:0)E (cid:0)P (cid:0)L(cid:0)W(cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)R (cid:0)U(cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)V (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)P (cid:0)P (cid:0)D (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)L(cid:0)P (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)L(cid:0)I(cid:0)L(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)X (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H\n(cid:0)& (cid:0)R (cid:0)P (cid:0)P (cid:0)L(cid:0)V (cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)/ (cid:0)L(cid:0)P (cid:0)L(cid:0)W(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)( (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)’ (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)Q (cid:0)W(cid:0)U (cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)3 (cid:0)U (cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U (cid:0)H (cid:0)V\n(cid:0)(cid:3)\n(cid:0),(cid:0)Q (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)Q (cid:0)D (cid:0)J (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)R (cid:0)J (cid:0)Q (cid:0)L(cid:0)] (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)Z (cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:15)\n(cid:0)F (cid:0)D (cid:0)Q (cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)V (cid:0)R (cid:0)O(cid:0)X (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)V (cid:0)X (cid:0)U(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)E (cid:0)M(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)\\ (cid:0)V (cid:0)W(cid:0)H (cid:0)P (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)H (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)V (cid:0)R (cid:0)O(cid:0)X (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)V (cid:0)X (cid:0)U(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)L(cid:0)Q (cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)I(cid:0)U(cid:0)D (cid:0)X (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)W(cid:0)H (cid:0)F (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:17)(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)X (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)I(cid:0)O(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)R (cid:0)X (cid:0)U(cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)L(cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)Q (cid:0)D (cid:0)J (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)M(cid:0)X (cid:0)G (cid:0)J (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)Q (cid:0)H (cid:0)I(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)S (cid:0)R (cid:0)V (cid:0)V (cid:0)L(cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)O(cid:0)D (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)L(cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)V (cid:0)W(cid:0)V (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)& (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0), (cid:0)Q (cid:0)W(cid:0)H (cid:0)U (cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)Q (cid:0)W(cid:0)U (cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)2 (cid:0)Y (cid:0)H (cid:0)U (cid:0)(cid:3)(cid:0)) (cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)S (cid:0)R (cid:0)U (cid:0)W(cid:0)L(cid:0)Q (cid:0)J\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)Q (cid:0)D (cid:0)J (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)K (cid:0)L(cid:0)H (cid:0)I(cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)H (cid:0)F (cid:0)X (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)& (cid:0)K (cid:0)L(cid:0)H (cid:0)I(cid:0)(cid:3)(cid:0)) (cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)(cid:3)(cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U\n(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)5 (cid:0)X (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:22) (cid:0)(cid:11)(cid:0)D (cid:0)(cid:12)(cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)I(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)G (cid:0)(cid:12)(cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)I(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:28) (cid:0)(cid:22) (cid:0)(cid:23) (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)R (cid:0)F (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23)\n(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)N (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)(cid:24) (cid:0)(cid:25)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)3 (cid:0)$ (cid:0)5 (cid:0)7 (cid:0)(cid:3)(cid:0), (cid:0), (cid:0)(cid:3)(cid:0)(cid:16)(cid:0)(cid:3)(cid:0)2 (cid:0)7 (cid:0)+ (cid:0)( (cid:0)5 (cid:0)(cid:3)(cid:0), (cid:0)1 (cid:0)) (cid:0)2 (cid:0)5 (cid:0)0 (cid:0)$ (cid:0)7 (cid:0), (cid:0)2 (cid:0)1\n(cid:0)(cid:3)\n(cid:0), (cid:0)7 (cid:0)( (cid:0)0 (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)/ (cid:0)( (cid:0)* (cid:0)$ (cid:0)/ (cid:0)(cid:3)(cid:0)3 (cid:0)5 (cid:0)2 (cid:0)& (cid:0)( (cid:0)( (cid:0)’ (cid:0), (cid:0)1 (cid:0)* (cid:0)6\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)Q (cid:0)W(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)M(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)Q (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)U(cid:0)H (cid:0)D (cid:0)W(cid:0)H (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)O(cid:0)H (cid:0)J (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)D (cid:0)L(cid:0)P (cid:0)V (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0), (cid:0)7 (cid:0)( (cid:0)0 (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)$ (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)5 (cid:0), (cid:0)6 (cid:0). (cid:0)(cid:3)(cid:0)) (cid:0)$ (cid:0)& (cid:0)7 (cid:0)2 (cid:0)5 (cid:0)6\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)X (cid:0)V (cid:0)L(cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)V (cid:0)K (cid:0)(cid:3)(cid:0)I(cid:0)O(cid:0)R (cid:0)Z (cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)P (cid:0)S (cid:0)D (cid:0)F (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)Q (cid:0)X (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)\\ (cid:0)R (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V\n(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)R (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)W(cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)$ (cid:0)Q (cid:0)Q (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:16)(cid:0). (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)V (cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)\\ (cid:0)H (cid:0)D (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)’ (cid:0)H (cid:0)F (cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H\n(cid:0)& (cid:0)R (cid:0)P (cid:0)P (cid:0)L(cid:0)V (cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)0 (cid:0)D (cid:0)U(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:28) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)‡ (cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:16)(cid:0). (cid:0)· (cid:0)(cid:12)(cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)5 (cid:0)L(cid:0)V (cid:0)N (cid:0)(cid:3)(cid:0)) (cid:0)D (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)W(cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:16)(cid:0). (cid:0)(cid:3)(cid:0)V (cid:0)K (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)D (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)U(cid:0)H (cid:0)I(cid:0)X (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)Q (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)X (cid:0)V (cid:0)L(cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)Q (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)Z (cid:0)D (cid:0)U(cid:0)G (cid:0)(cid:16)\n(cid:0)O(cid:0)R (cid:0)R (cid:0)N (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3) (cid:0)4 (cid:0)X (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3) (cid:0)5 (cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3) (cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)) (cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3) (cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:16)(cid:0)4 (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)$ (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)U(cid:0)L(cid:0)V (cid:0)N (cid:0)V (cid:0)(cid:3) (cid:0)G (cid:0)H (cid:0)V (cid:0)F (cid:0)U(cid:0)L(cid:0)E (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:3) (cid:0)) (cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3) (cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:16)(cid:0). (cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3) (cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3) (cid:0)D (cid:0)G (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3) (cid:0)D (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V\n(cid:0)E (cid:0)X (cid:0)V (cid:0)L(cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)I(cid:0)X (cid:0)W(cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)D (cid:0)F (cid:0)W(cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)R (cid:0)X (cid:0)W(cid:0)F (cid:0)R (cid:0)P (cid:0)H (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)P (cid:0)D (cid:0)W(cid:0)W(cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3) (cid:0)D (cid:0)V (cid:0)(cid:3) (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)I(cid:0)R (cid:0)U(cid:0)Z (cid:0)D (cid:0)U(cid:0)G (cid:0)(cid:16)(cid:0)O(cid:0)R (cid:0)R (cid:0)N (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3) (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3) (cid:0)P (cid:0)D (cid:0)G (cid:0)H (cid:0)(cid:17)(cid:0)(cid:3) (cid:0)7 (cid:0)K (cid:0)H (cid:0)V (cid:0)H (cid:0)(cid:3) (cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3) (cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)R (cid:0)Q (cid:0)O(cid:0)\\ (cid:0)(cid:3) (cid:0)U(cid:0)L(cid:0)V (cid:0)N (cid:0)V (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H\n(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)$ (cid:0)G (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)V (cid:0)N (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)Q (cid:0)W(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)N (cid:0)Q (cid:0)R (cid:0)Z (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)Q (cid:0)W(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)H (cid:0)P (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)P (cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)V (cid:0)R (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)H (cid:0)O(cid:0)\\\n(cid:0)D (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)X (cid:0)V (cid:0)L(cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:18)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)V (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)$ (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)O(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)F (cid:0)X (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)F (cid:0)H (cid:0)S (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)L(cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)5 (cid:0)L(cid:0)V (cid:0)N (cid:0)(cid:3)(cid:0)) (cid:0)D (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)Y (cid:0)L(cid:0)R (cid:0)X (cid:0)V (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V\n(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:22) (cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:16)(cid:0). (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)6 (cid:0)H (cid:0)U (cid:0)L(cid:0)R (cid:0)X (cid:0)V (cid:0)(cid:3)(cid:0)$ (cid:0)G (cid:0)Y (cid:0)H (cid:0)U (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)( (cid:0)Y (cid:0)H (cid:0)Q (cid:0)W(cid:0)V\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)O(cid:0)H (cid:0)D (cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)U(cid:0)X (cid:0)J (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)/ (cid:0)% (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)Q (cid:0)W(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)J (cid:0)R (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)Y (cid:0)D (cid:0)U(cid:0)L(cid:0)R (cid:0)X (cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)V (cid:0)N (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)O(cid:0)D (cid:0)F (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G\n(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)X (cid:0)O(cid:0)D (cid:0)W(cid:0)R (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)W(cid:0)K (cid:0)R (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)X (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)6 (cid:0)$ (cid:0)( (cid:0)V (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)O(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)U(cid:0)X (cid:0)J (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)U(cid:0)X (cid:0)J (cid:0)(cid:3)(cid:0)X (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)E (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0),(cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V\n(cid:0)S (cid:0)R (cid:0)V (cid:0)V (cid:0)L(cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)$ (cid:0)( (cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)W(cid:0)U(cid:0)L(cid:0)E (cid:0)X (cid:0)W(cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)U(cid:0)X (cid:0)J (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)E (cid:0)X (cid:0)W(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)P (cid:0)L(cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)H (cid:0)[ (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)H (cid:0)Y (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)L(cid:0)G (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)H (cid:0)D (cid:0)W(cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:16)(cid:0)U(cid:0)H (cid:0)O(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)D (cid:0)W(cid:0)K (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)O(cid:0)R (cid:0)Q (cid:0)J (cid:0)(cid:16)(cid:0)W(cid:0)H (cid:0)U(cid:0)P\n(cid:0)K (cid:0)H (cid:0)D (cid:0)O(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)S (cid:0)O(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)$ (cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)J (cid:0)L(cid:0)Y (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)Q (cid:0)(cid:16)(cid:0)W(cid:0)R (cid:0)O(cid:0)H (cid:0)U(cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)V (cid:0)H (cid:0)(cid:16)(cid:0)O(cid:0)L(cid:0)P (cid:0)L(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)[ (cid:0)L(cid:0)F (cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)’ (cid:0)/ (cid:0)7 (cid:0)(cid:12)(cid:0)(cid:17)(cid:0)(cid:3)(cid:0): (cid:0)K (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)Z (cid:0)R (cid:0)(cid:3)(cid:0)’ (cid:0)/ (cid:0)7 (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)F (cid:0)F (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)D (cid:0)P (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)V (cid:0)H (cid:0)(cid:16)(cid:0)O(cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)V (cid:0)H (cid:0)(cid:16)\n(cid:0)O(cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)L(cid:0)G (cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)R (cid:0)(cid:3)(cid:0)K (cid:0)L(cid:0)J (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)V (cid:0)D (cid:0)I(cid:0)H (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)) (cid:0)X (cid:0)U(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)H (cid:0)D (cid:0)W(cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)R (cid:0)Z (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)O(cid:0)R (cid:0)Z (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)V (cid:0)H (cid:0)(cid:16)(cid:0)O(cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)Y (cid:0)L(cid:0)R (cid:0)X (cid:0)V (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)X (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)D (cid:0)I(cid:0)H (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0),(cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)6 (cid:0)$ (cid:0)( (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)W(cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)6 (cid:0)$ (cid:0)( (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)E (cid:0)V (cid:0)H (cid:0)U(cid:0)Y (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)X (cid:0)U(cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)Y (cid:0)R (cid:0)O(cid:0)Y (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)U(cid:0)X (cid:0)J (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)8 (cid:0)(cid:17)(cid:0)6 (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)R (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)’ (cid:0)U(cid:0)X (cid:0)J (cid:0)(cid:3)(cid:0)$ (cid:0)G (cid:0)P (cid:0)L(cid:0)Q (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)) (cid:0)’ (cid:0)$ (cid:0)(cid:12)(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)( (cid:0)X (cid:0)U(cid:0)R (cid:0)S (cid:0)H (cid:0)D (cid:0)Q\n(cid:0)0 (cid:0)H (cid:0)G (cid:0)L(cid:0)F (cid:0)L(cid:0)Q (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)$ (cid:0)J (cid:0)H (cid:0)Q (cid:0)F (cid:0)\\ (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)( (cid:0)0 (cid:0)$ (cid:0)(cid:12)(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)X (cid:0)O(cid:0)D (cid:0)W(cid:0)R (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)W(cid:0)K (cid:0)R (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)V (cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)X (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)X (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)L(cid:0)Q (cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)U(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)U(cid:0)R (cid:0)O(cid:0)O(cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)V (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:17)(cid:0)(cid:3)(cid:0),(cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V\n(cid:0)D (cid:0)O(cid:0)V (cid:0)R (cid:0)(cid:3) (cid:0)S (cid:0)R (cid:0)V (cid:0)V (cid:0)L(cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)W(cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3) (cid:0)E (cid:0)H (cid:0)(cid:3) (cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)$ (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)V (cid:0)H (cid:0)(cid:3) (cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3) (cid:0)G (cid:0)H (cid:0)O(cid:0)D (cid:0)\\ (cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)K (cid:0)D (cid:0)O(cid:0)W(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3) (cid:0)G (cid:0)U(cid:0)X (cid:0)J (cid:0)(cid:3) (cid:0)F (cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)F (cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)H (cid:0)(cid:3) (cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)V (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G\n(cid:0)Q (cid:0)H (cid:0)J (cid:0)D (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)L(cid:0)P (cid:0)S (cid:0)D (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)X (cid:0)O(cid:0)W(cid:0)L(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)K (cid:0)L(cid:0)H (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)X (cid:0)O(cid:0)D (cid:0)W(cid:0)R (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)D (cid:0)O(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)$ (cid:0)G (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)6 (cid:0)$ (cid:0)( (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)I(cid:0)L(cid:0)U(cid:0)P (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)U(cid:0)X (cid:0)J (cid:0)(cid:16)(cid:0)U(cid:0)H (cid:0)O(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)X (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)D (cid:0)O\n(cid:0)V (cid:0)W(cid:0)X (cid:0)G (cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)P (cid:0)R (cid:0)G (cid:0)L(cid:0)I(cid:0)\\ (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)V (cid:0)W(cid:0)X (cid:0)G (cid:0)\\ (cid:0)(cid:3) (cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)D (cid:0)E (cid:0)D (cid:0)Q (cid:0)G (cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)I(cid:0)X (cid:0)U(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)G (cid:0)H (cid:0)Y (cid:0)H (cid:0)O(cid:0)R (cid:0)S (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)G (cid:0)U(cid:0)X (cid:0)J (cid:0)(cid:3) (cid:0)F (cid:0)D (cid:0)Q (cid:0)G (cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3) (cid:0)D (cid:0)O(cid:0)W(cid:0)R (cid:0)J (cid:0)H (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3) (cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3) (cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3) (cid:0)L(cid:0)P (cid:0)S (cid:0)D (cid:0)F (cid:0)W(cid:0)(cid:3) (cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3) (cid:0)E (cid:0)X (cid:0)V (cid:0)L(cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)G\n(cid:0)S (cid:0)U(cid:0)R (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)V (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)F (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)6 (cid:0)$ (cid:0)( (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)X (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)V (cid:0)R (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)X (cid:0)W(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)W(cid:0)L(cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)K (cid:0)\\ (cid:0)V (cid:0)L(cid:0)F (cid:0)L(cid:0)D (cid:0)Q (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)K (cid:0)H (cid:0)D (cid:0)O(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)V (cid:0)W(cid:0)L(cid:0)W(cid:0)X (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)Y (cid:0)H (cid:0)V (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)P (cid:0)L(cid:0)Q (cid:0)L(cid:0)V (cid:0)K (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U\n(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)W(cid:0)U(cid:0)D (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)U(cid:0)W(cid:0)L(cid:0)F (cid:0)L(cid:0)S (cid:0)D (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)G (cid:0)D (cid:0)P (cid:0)D (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)X (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)H (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)Y (cid:0)H (cid:0)V (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)E (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)W(cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)V (cid:0)X (cid:0)U(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)H (cid:0)Q (cid:0)F (cid:0)H\n(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)6 (cid:0)$ (cid:0)( (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)W(cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)O(cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)K (cid:0)R (cid:0)O(cid:0)G (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)I(cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)W(cid:0)L(cid:0)P (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)Q (cid:0)Q (cid:0)H (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)S (cid:0)U(cid:0)L(cid:0)Q (cid:0)F (cid:0)L(cid:0)S (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)Y (cid:0)H (cid:0)V (cid:0)W(cid:0)L(cid:0)J (cid:0)D (cid:0)W(cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)R (cid:0)I(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)O(cid:0)R (cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)V (cid:0)W(cid:0)X (cid:0)G (cid:0)\\ (cid:0)(cid:3) (cid:0)W(cid:0)H (cid:0)V (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)/ (cid:0)% (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)P (cid:0)E (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3) (cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3) (cid:0)D (cid:0)W(cid:0)H (cid:0)] (cid:0)R (cid:0)O(cid:0)L(cid:0)] (cid:0)X (cid:0)P (cid:0)D (cid:0)E (cid:0)(cid:3) (cid:0)(cid:11)(cid:0)5 (cid:0)R (cid:0)F (cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)3 (cid:0)’ (cid:0)(cid:16)(cid:0)/ (cid:0)(cid:20) (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)K (cid:0)L(cid:0)E (cid:0)L(cid:0)W(cid:0)R (cid:0)U(cid:0)(cid:12)(cid:0)(cid:3) (cid:0)L(cid:0)V (cid:0)(cid:3) (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)Q (cid:0)W(cid:0)O(cid:0)\\ (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)Y (cid:0)H (cid:0)V (cid:0)W(cid:0)L(cid:0)J (cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)W(cid:0)Z (cid:0)R (cid:0)(cid:3) (cid:0)6 (cid:0)$ (cid:0)( (cid:0)V\n(cid:0)R (cid:0)E (cid:0)V (cid:0)H (cid:0)U(cid:0)Y (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)O(cid:0)L(cid:0)Q (cid:0)L(cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)Z (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)O(cid:0)D (cid:0)X (cid:0)Q (cid:0)F (cid:0)K (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)$ (cid:0)X (cid:0)J (cid:0)X (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)( (cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)Z (cid:0)D (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0)Q (cid:0)H (cid:0)[ (cid:0)W(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)H (cid:0)S (cid:0)V (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0), (cid:0)7 (cid:0)( (cid:0)0 (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)8 (cid:0)1 (cid:0)5 (cid:0)( (cid:0)* (cid:0), (cid:0)6 (cid:0)7 (cid:0)( (cid:0)5 (cid:0)( (cid:0)’ (cid:0)(cid:3)(cid:0)6 (cid:0)$ (cid:0)/ (cid:0)( (cid:0)6 (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)( (cid:0)4 (cid:0)8 (cid:0), (cid:0)7 (cid:0)< (cid:0)(cid:3)(cid:0)6 (cid:0)( (cid:0)& (cid:0)8 (cid:0)5 (cid:0), (cid:0)7 (cid:0), (cid:0)( (cid:0)6 (cid:0)(cid:3)(cid:0)$ (cid:0)1 (cid:0)’ (cid:0)(cid:3)(cid:0)8 (cid:0)6 (cid:0)( (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)3 (cid:0)5 (cid:0)2 (cid:0)& (cid:0)( (cid:0)( (cid:0)’ (cid:0)6\n(cid:0)(cid:3)\n(cid:0)1 (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)O(cid:0)L(cid:0)F (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)(cid:24) (cid:0)(cid:26)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0), (cid:0)7 (cid:0)( (cid:0)0 (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)’ (cid:0)( (cid:0)) (cid:0)$ (cid:0)8 (cid:0)/ (cid:0)7 (cid:0)6 (cid:0)(cid:3)(cid:0)8 (cid:0)3 (cid:0)2 (cid:0)1 (cid:0)(cid:3)(cid:0)6 (cid:0)( (cid:0)1 (cid:0), (cid:0)2 (cid:0)5 (cid:0)(cid:3)(cid:0)6 (cid:0)( (cid:0)& (cid:0)8 (cid:0)5 (cid:0), (cid:0)7 (cid:0), (cid:0)( (cid:0)6\n(cid:0)(cid:3)\n(cid:0)1 (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)O(cid:0)L(cid:0)F (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0), (cid:0)7 (cid:0)( (cid:0)0 (cid:0)(cid:3)(cid:0)(cid:23) (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)0 (cid:0), (cid:0)1 (cid:0)( (cid:0)(cid:3)(cid:0)6 (cid:0)$ (cid:0)) (cid:0)( (cid:0)7 (cid:0)< (cid:0)(cid:3)(cid:0)’ (cid:0), (cid:0)6 (cid:0)& (cid:0)/ (cid:0)2 (cid:0)6 (cid:0)8 (cid:0)5 (cid:0)( (cid:0)6\n(cid:0)(cid:3)\n(cid:0)1 (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)O(cid:0)L(cid:0)F (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0), (cid:0)7 (cid:0)( (cid:0)0 (cid:0)(cid:3)(cid:0)(cid:24) (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)2 (cid:0)7 (cid:0)+ (cid:0)( (cid:0)5 (cid:0)(cid:3)(cid:0), (cid:0)1 (cid:0)) (cid:0)2 (cid:0)5 (cid:0)0 (cid:0)$ (cid:0)7 (cid:0), (cid:0)2 (cid:0)1\n(cid:0)(cid:3)\n(cid:0)’ (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)U(cid:0)H (cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)Q (cid:0)W(cid:0)K (cid:0)V (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:11)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)5 (cid:0)X (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:25) (cid:0)D (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:11)(cid:0)I(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)R (cid:0)S (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)D (cid:0)W(cid:0)H (cid:0)G\n(cid:0)D (cid:0)(cid:3)(cid:0)‡ (cid:0)5 (cid:0)X (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)E (cid:0)(cid:24) (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:3)(cid:0)W(cid:0)U(cid:0)D (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)U(cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)· (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)H (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0),(cid:0)W(cid:0)H (cid:0)P (cid:0)(cid:3)(cid:0)(cid:23) (cid:0)(cid:19) (cid:0)(cid:27) (cid:0)(cid:11)(cid:0)D (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)J (cid:0)X (cid:0)O(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)6 (cid:0)(cid:16)(cid:0). (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0), (cid:0)7 (cid:0)( (cid:0)0 (cid:0)(cid:3)(cid:0)(cid:25) (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)( (cid:0); (cid:0)+ (cid:0), (cid:0)% (cid:0), (cid:0)7 (cid:0)6\n(cid:0)(cid:3)\n(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)O(cid:0)O(cid:0)R (cid:0)Z (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)F (cid:0)X (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:0)( (cid:0)[ (cid:0)K (cid:0)L(cid:0)E (cid:0)L(cid:0)W (cid:0)(cid:3)\n(cid:0)1 (cid:0)X (cid:0)P (cid:0)E (cid:0)H (cid:0)U (cid:0)’ (cid:0)H (cid:0)V (cid:0)F (cid:0)U(cid:0)L(cid:0)S (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)’ (cid:0)R (cid:0)F (cid:0)X (cid:0)P (cid:0)H (cid:0)Q (cid:0)W\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:17)(cid:0)(cid:20) (cid:0)(cid:13) (cid:0)(cid:3) (cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)3 (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)D (cid:0)U(cid:0)E (cid:0)D (cid:0)Q (cid:0)H (cid:0)V (cid:0)(cid:16)(cid:0)2 (cid:0)[ (cid:0)O(cid:0)H (cid:0)\\ (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:21)\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:17)(cid:0)(cid:21) (cid:0)(cid:13) (cid:0)(cid:3) (cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)3 (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)D (cid:0)U(cid:0)E (cid:0)D (cid:0)Q (cid:0)H (cid:0)V (cid:0)(cid:16)(cid:0)2 (cid:0)[ (cid:0)O(cid:0)H (cid:0)\\ (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:21)\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:22) (cid:0)(cid:21) (cid:0)(cid:17)(cid:0)(cid:20) (cid:0)(cid:13) (cid:0)(cid:3) (cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)3 (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:28) (cid:0)(cid:19) (cid:0)(cid:25) (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)D (cid:0)U(cid:0)E (cid:0)D (cid:0)Q (cid:0)H (cid:0)V (cid:0)(cid:16)(cid:0)2 (cid:0)[ (cid:0)O(cid:0)H (cid:0)\\ (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:21)\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:22) (cid:0)(cid:21) (cid:0)(cid:17)(cid:0)(cid:21) (cid:0)(cid:13) (cid:0)(cid:3) (cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)& (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)3 (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:28) (cid:0)(cid:19) (cid:0)(cid:25) (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)D (cid:0)U(cid:0)E (cid:0)D (cid:0)Q (cid:0)H (cid:0)V (cid:0)(cid:16)(cid:0)2 (cid:0)[ (cid:0)O(cid:0)H (cid:0)\\ (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:21)\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:20) (cid:0)(cid:17)(cid:0),(cid:0)1 (cid:0)6 (cid:0)(cid:3) (cid:0),(cid:0)Q (cid:0)O(cid:0)L(cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0); (cid:0)% (cid:0)5 (cid:0)/ (cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)’ (cid:0)R (cid:0)F (cid:0)X (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)(cid:11)(cid:0)G (cid:0)R (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)S (cid:0)S (cid:0)H (cid:0)D (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)’ (cid:0)D (cid:0)W(cid:0)D (cid:0)(cid:3)(cid:0)) (cid:0)L(cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)F (cid:0)D (cid:0)X (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0); (cid:0)% (cid:0)5 (cid:0)/ (cid:0)(cid:3)(cid:0)W(cid:0)D (cid:0)J (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)G (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)O(cid:0)L(cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0); (cid:0)% (cid:0)5 (cid:0)/ (cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)F (cid:0)X (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:12)\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:20) (cid:0)(cid:17)(cid:0)6 (cid:0)& (cid:0)+ (cid:0)(cid:3) (cid:0),(cid:0)Q (cid:0)O(cid:0)L(cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0); (cid:0)% (cid:0)5 (cid:0)/ (cid:0)(cid:3)(cid:0)7 (cid:0)D (cid:0)[ (cid:0)R (cid:0)Q (cid:0)R (cid:0)P (cid:0)\\ (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)W(cid:0)H (cid:0)Q (cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)6 (cid:0)F (cid:0)K (cid:0)H (cid:0)P (cid:0)D (cid:0)(cid:3)(cid:0)’ (cid:0)R (cid:0)F (cid:0)X (cid:0)P (cid:0)H (cid:0)Q (cid:0)W\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:20) (cid:0)(cid:17)(cid:0)& (cid:0)$ (cid:0)/ (cid:0)(cid:3) (cid:0),(cid:0)Q (cid:0)O(cid:0)L(cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0); (cid:0)% (cid:0)5 (cid:0)/ (cid:0)(cid:3)(cid:0)7 (cid:0)D (cid:0)[ (cid:0)R (cid:0)Q (cid:0)R (cid:0)P (cid:0)\\ (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)W(cid:0)H (cid:0)Q (cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)& (cid:0)D (cid:0)O(cid:0)F (cid:0)X (cid:0)O(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)Q (cid:0)N (cid:0)E (cid:0)D (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)’ (cid:0)R (cid:0)F (cid:0)X (cid:0)P (cid:0)H (cid:0)Q (cid:0)W\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:20) (cid:0)(cid:17)(cid:0)’ (cid:0)( (cid:0)) (cid:0)(cid:3) (cid:0),(cid:0)Q (cid:0)O(cid:0)L(cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0); (cid:0)% (cid:0)5 (cid:0)/ (cid:0)(cid:3)(cid:0)7 (cid:0)D (cid:0)[ (cid:0)R (cid:0)Q (cid:0)R (cid:0)P (cid:0)\\ (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)W(cid:0)H (cid:0)Q (cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)’ (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)Q (cid:0)N (cid:0)E (cid:0)D (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)’ (cid:0)R (cid:0)F (cid:0)X (cid:0)P (cid:0)H (cid:0)Q (cid:0)W\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:20) (cid:0)(cid:17)(cid:0)/ (cid:0)$ (cid:0)% (cid:0)(cid:3) (cid:0),(cid:0)Q (cid:0)O(cid:0)L(cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0); (cid:0)% (cid:0)5 (cid:0)/ (cid:0)(cid:3)(cid:0)7 (cid:0)D (cid:0)[ (cid:0)R (cid:0)Q (cid:0)R (cid:0)P (cid:0)\\ (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)W(cid:0)H (cid:0)Q (cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)/ (cid:0)D (cid:0)E (cid:0)H (cid:0)O(cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)Q (cid:0)N (cid:0)E (cid:0)D (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)’ (cid:0)R (cid:0)F (cid:0)X (cid:0)P (cid:0)H (cid:0)Q (cid:0)W\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:20) (cid:0)(cid:17)(cid:0)3 (cid:0)5 (cid:0)( (cid:0)(cid:3) (cid:0),(cid:0)Q (cid:0)O(cid:0)L(cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0); (cid:0)% (cid:0)5 (cid:0)/ (cid:0)(cid:3)(cid:0)7 (cid:0)D (cid:0)[ (cid:0)R (cid:0)Q (cid:0)R (cid:0)P (cid:0)\\ (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)W(cid:0)H (cid:0)Q (cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)Q (cid:0)N (cid:0)E (cid:0)D (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)’ (cid:0)R (cid:0)F (cid:0)X (cid:0)P (cid:0)H (cid:0)Q (cid:0)W\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:23) (cid:0)(cid:3) (cid:0)& (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)3 (cid:0)D (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)D (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)’ (cid:0)D (cid:0)W(cid:0)D (cid:0)(cid:3)(cid:0)) (cid:0)L(cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)O(cid:0)L(cid:0)Q (cid:0)H (cid:0)(cid:3)(cid:0); (cid:0)% (cid:0)5 (cid:0)/ (cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)F (cid:0)X (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)K (cid:0)L(cid:0)E (cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:20) (cid:0)(cid:17)(cid:0),(cid:0)1 (cid:0)6 (cid:0)(cid:12)\n(cid:0)(cid:3)\n(cid:0)(cid:13) (cid:0)(cid:3)(cid:0)) (cid:0)L(cid:0)O(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)(cid:24) (cid:0)(cid:27)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)6 (cid:0), (cid:0)* (cid:0)1 (cid:0)$ (cid:0)7 (cid:0)8 (cid:0)5 (cid:0)( (cid:0)6\n(cid:0)(cid:3)\n(cid:0),(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)F (cid:0)R (cid:0)U(cid:0)G (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:28) (cid:0)(cid:22) (cid:0)(cid:23) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)X (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)X (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)K (cid:0)D (cid:0)O(cid:0)I(cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G\n(cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)H (cid:0)X (cid:0)Q (cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)G (cid:0)X (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)W(cid:0)K (cid:0)R (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)G (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)/ (cid:0),(cid:0); (cid:0)7 (cid:0)( (cid:0)(cid:3)(cid:0)% (cid:0),(cid:0)2 (cid:0)7 (cid:0)( (cid:0)& (cid:0)+ (cid:0)1 (cid:0)2 (cid:0)/ (cid:0)2 (cid:0)* (cid:0)< (cid:0)(cid:3)(cid:0)+ (cid:0)2 (cid:0)/ (cid:0)’ (cid:0),(cid:0)1 (cid:0)* (cid:0)6 (cid:0)(cid:15)(cid:0)(cid:3)(cid:0),(cid:0)1 (cid:0)& (cid:0)(cid:17)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)5 (cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:12)\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)’ (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:29)(cid:0)(cid:3)(cid:0)1 (cid:0)R (cid:0)Y (cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:21) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)% (cid:0)\\ (cid:0)(cid:29) (cid:0)(cid:18)(cid:0)V (cid:0)(cid:18)(cid:0)(cid:3)(cid:0)% (cid:0)$ (cid:0)6 (cid:0)7 (cid:0),(cid:0)$ (cid:0)$ (cid:0)1 (cid:0)(cid:3)(cid:0)9 (cid:0)$ (cid:0)1 (cid:0)(cid:3)(cid:0)’ (cid:0)( (cid:0)5 (cid:0)(cid:3)(cid:0)% (cid:0)$ (cid:0)$ (cid:0)1\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)% (cid:0)D (cid:0)V (cid:0)W(cid:0)L(cid:0)D (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)Y (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)% (cid:0)D (cid:0)D (cid:0)Q\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)3 (cid:0)U(cid:0)H (cid:0)V (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)& (cid:0)K (cid:0)L(cid:0)H (cid:0)I(cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)H (cid:0)F (cid:0)X (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:11)(cid:0)3 (cid:0)U(cid:0)L(cid:0)Q (cid:0)F (cid:0)L(cid:0)S (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)H (cid:0)F (cid:0)X (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:12)\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)’ (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:29)(cid:0)(cid:3)(cid:0)1 (cid:0)R (cid:0)Y (cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:21) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)% (cid:0)\\ (cid:0)(cid:29) (cid:0)(cid:18)(cid:0)V (cid:0)(cid:18)(cid:0)(cid:3)(cid:0)5 (cid:0)2 (cid:0)% (cid:0)( (cid:0)5 (cid:0)7 (cid:0)(cid:3)(cid:0)1 (cid:0)(cid:17)(cid:0)(cid:3)(cid:0): (cid:0)( (cid:0),(cid:0)1 (cid:0)* (cid:0)$ (cid:0)5 (cid:0)7 (cid:0)( (cid:0)1\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)5 (cid:0)R (cid:0)E (cid:0)H (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)1 (cid:0)(cid:17)(cid:0)(cid:3)(cid:0): (cid:0)H (cid:0)L(cid:0)Q (cid:0)J (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)Q\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)9 (cid:0)L(cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)V (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)& (cid:0)K (cid:0)L(cid:0)H (cid:0)I(cid:0)(cid:3)(cid:0)) (cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:11)(cid:0)3 (cid:0)U(cid:0)L(cid:0)Q (cid:0)F (cid:0)L(cid:0)S (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)) (cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)F (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:12)\n(cid:0)(cid:3)\n(cid:0)(cid:24) (cid:0)(cid:28)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)( (cid:0)[ (cid:0)K (cid:0)L(cid:0)E (cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:17)(cid:0)(cid:20)\n(cid:0)(cid:3)\n(cid:0)& (cid:0)( (cid:0)5 (cid:0)7 (cid:0), (cid:0)) (cid:0), (cid:0)& (cid:0)$ (cid:0)7 (cid:0), (cid:0)2 (cid:0)1 (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)& (cid:0)+ (cid:0), (cid:0)( (cid:0)) (cid:0)(cid:3)(cid:0)( (cid:0); (cid:0)( (cid:0)& (cid:0)8 (cid:0)7 (cid:0), (cid:0)9 (cid:0)( (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)) (cid:0), (cid:0)& (cid:0)( (cid:0)5\n(cid:0)8 (cid:0)1 (cid:0)’ (cid:0)( (cid:0)5 (cid:0)(cid:3)(cid:0)6 (cid:0)( (cid:0)& (cid:0)7 (cid:0), (cid:0)2 (cid:0)1 (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)7 (cid:0)+ (cid:0)( (cid:0)(cid:3)(cid:0)6 (cid:0)$ (cid:0)5 (cid:0)% (cid:0)$ (cid:0)1 (cid:0)( (cid:0)6 (cid:0)(cid:16)(cid:0)2 (cid:0); (cid:0)/ (cid:0)( (cid:0)< (cid:0)(cid:3)(cid:0)$ (cid:0)& (cid:0)7 (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:21)\n(cid:0)(cid:3)\n(cid:0),(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)% (cid:0)D (cid:0)V (cid:0)W(cid:0)L(cid:0)D (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)Y (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)% (cid:0)D (cid:0)D (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:0)(cid:20) (cid:0)(cid:17) (cid:0),(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)Y (cid:0)L(cid:0)H (cid:0)Z (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)4 (cid:0)X (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:16)(cid:0)4 (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)[ (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)% (cid:0)L(cid:0)R (cid:0)W(cid:0)H (cid:0)F (cid:0)K (cid:0)Q (cid:0)R (cid:0)O(cid:0)R (cid:0)J (cid:0)\\ (cid:0)(cid:3)(cid:0)+ (cid:0)R (cid:0)O(cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)F (cid:0)(cid:17)(cid:0)(cid:30)\n(cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:21) (cid:0)(cid:17) (cid:0)% (cid:0)D (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)P (cid:0)\\ (cid:0)(cid:3)(cid:0)N (cid:0)Q (cid:0)R (cid:0)Z (cid:0)O(cid:0)H (cid:0)G (cid:0)J (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)W(cid:0)U(cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)P (cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)Q (cid:0)H (cid:0)F (cid:0)H (cid:0)V (cid:0)V (cid:0)D (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)N (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)G (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)J (cid:0)K (cid:0)W\n(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)L(cid:0)U(cid:0)F (cid:0)X (cid:0)P (cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)G (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)L(cid:0)V (cid:0)O(cid:0)H (cid:0)D (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:30)\n(cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:22) (cid:0)(cid:17) (cid:0)% (cid:0)D (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)P (cid:0)\\ (cid:0)(cid:3)(cid:0)N (cid:0)Q (cid:0)R (cid:0)Z (cid:0)O(cid:0)H (cid:0)G (cid:0)J (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)L(cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)\n(cid:0)U(cid:0)H (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)V (cid:0)K (cid:0)(cid:3)(cid:0)I(cid:0)O(cid:0)R (cid:0)Z (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:30)\n(cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:23) (cid:0)(cid:17) (cid:0),(cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)R (cid:0)Q (cid:0)V (cid:0)L(cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)V (cid:0)W(cid:0)D (cid:0)E (cid:0)O(cid:0)L(cid:0)V (cid:0)K (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)L(cid:0)Q (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)5 (cid:0)X (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:22) (cid:0)D (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)H (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)G (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)H (cid:0)(cid:12)(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U\n(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)5 (cid:0)X (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:22) (cid:0)D (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)I(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)G (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)I(cid:0)(cid:12)(cid:0)(cid:12)(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)D (cid:0)(cid:12) (cid:0)’ (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)X (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)P (cid:0)\\ (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)S (cid:0)H (cid:0)U(cid:0)Y (cid:0)L(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O\n(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)O(cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)R (cid:0)O(cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)V (cid:0)L(cid:0)G (cid:0)L(cid:0)D (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)G (cid:0)H (cid:0)(cid:3)(cid:0)N (cid:0)Q (cid:0)R (cid:0)Z (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)P (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)R (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)U(cid:0)W(cid:0)L(cid:0)F (cid:0)X (cid:0)O(cid:0)D (cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q\n(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)S (cid:0)D (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:30)\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)E (cid:0)(cid:12) (cid:0)’ (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3) (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)F (cid:0)D (cid:0)X (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3) (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)E (cid:0)H (cid:0)(cid:3) (cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)P (cid:0)\\ (cid:0)(cid:3) (cid:0)V (cid:0)X (cid:0)S (cid:0)H (cid:0)U(cid:0)Y (cid:0)L(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H\n(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)V (cid:0)X (cid:0)U(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)D (cid:0)U(cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)O(cid:0)L(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)S (cid:0)D (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)S (cid:0)R (cid:0)V (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)F (cid:0)R (cid:0)U(cid:0)G (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)J (cid:0)H (cid:0)Q (cid:0)H (cid:0)U(cid:0)D (cid:0)O(cid:0)O(cid:0)\\\n(cid:0)D (cid:0)F (cid:0)F (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)F (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)L(cid:0)Q (cid:0)F (cid:0)L(cid:0)S (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:30)\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)F (cid:0)(cid:12) (cid:0)( (cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)\\ (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)R (cid:0)X (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H\n(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)E (cid:0)D (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:30)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)G (cid:0)(cid:12) (cid:0)’ (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3) (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3) (cid:0)R (cid:0)F (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)G (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3) (cid:0)P (cid:0)R (cid:0)V (cid:0)W(cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)F (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)I(cid:0)L(cid:0)V (cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)T (cid:0)X (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)X (cid:0)U(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)V (cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)T (cid:0)X (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)Q (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)N (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O\n(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:30)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)(cid:3)\n(cid:0)(cid:24) (cid:0)(cid:17) (cid:0),(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)E (cid:0)D (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)P (cid:0)\\ (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)G (cid:0)L(cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)G (cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)L(cid:0)W(cid:0)W(cid:0)H (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)% (cid:0)R (cid:0)D (cid:0)U(cid:0)G\n(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)’ (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)V (cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)Y (cid:0)D (cid:0)O(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)Q (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:12)(cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)D (cid:0)(cid:12) (cid:0)$ (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)F (cid:0)L(cid:0)H (cid:0)Q (cid:0)F (cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)D (cid:0)N (cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)N (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)H (cid:0)O(cid:0)\\\n(cid:0)D (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)R (cid:0)U(cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)P (cid:0)P (cid:0)D (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:30)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)E (cid:0)(cid:12) (cid:0)$ (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)I(cid:0)U(cid:0)D (cid:0)X (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)Z (cid:0)K (cid:0)H (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3) (cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:15)(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)Y (cid:0)R (cid:0)O(cid:0)Y (cid:0)H (cid:0)V (cid:0)(cid:3) (cid:0)P (cid:0)D (cid:0)Q (cid:0)D (cid:0)J (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)H (cid:0)P (cid:0)S (cid:0)O(cid:0)R (cid:0)\\ (cid:0)H (cid:0)H (cid:0)V (cid:0)(cid:3) (cid:0)Z (cid:0)K (cid:0)R (cid:0)(cid:3) (cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3) (cid:0)D (cid:0)(cid:3) (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)U(cid:0)R (cid:0)O(cid:0)H (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3) (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O\n(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)’ (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:29)(cid:0)(cid:3)(cid:0)1 (cid:0)R (cid:0)Y (cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:21) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)% (cid:0)\\ (cid:0)(cid:29) (cid:0)(cid:18)(cid:0)V (cid:0)(cid:18)(cid:0)(cid:3)(cid:0)% (cid:0)$ (cid:0)6 (cid:0)7 (cid:0),(cid:0)$ (cid:0)$ (cid:0)1 (cid:0)(cid:3)(cid:0)9 (cid:0)$ (cid:0)1 (cid:0)(cid:3)(cid:0)’ (cid:0)( (cid:0)5 (cid:0)(cid:3)(cid:0)% (cid:0)$ (cid:0)$ (cid:0)1\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)% (cid:0)D (cid:0)V (cid:0)W(cid:0)L(cid:0)D (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)Y (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)% (cid:0)D (cid:0)D (cid:0)Q\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)3 (cid:0)U(cid:0)H (cid:0)V (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)& (cid:0)K (cid:0)L(cid:0)H (cid:0)I(cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)H (cid:0)F (cid:0)X (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:11)(cid:0)3 (cid:0)U(cid:0)L(cid:0)Q (cid:0)F (cid:0)L(cid:0)S (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)H (cid:0)F (cid:0)X (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:12)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)( (cid:0)[ (cid:0)K (cid:0)L(cid:0)E (cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:20) (cid:0)(cid:17)(cid:0)(cid:21)\n(cid:0)(cid:3)\n(cid:0)& (cid:0)( (cid:0)5 (cid:0)7 (cid:0), (cid:0)) (cid:0), (cid:0)& (cid:0)$ (cid:0)7 (cid:0), (cid:0)2 (cid:0)1 (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)& (cid:0)+ (cid:0), (cid:0)( (cid:0)) (cid:0)(cid:3)(cid:0)) (cid:0), (cid:0)1 (cid:0)$ (cid:0)1 (cid:0)& (cid:0), (cid:0)$ (cid:0)/ (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)) (cid:0), (cid:0)& (cid:0)( (cid:0)5\n(cid:0)8 (cid:0)1 (cid:0)’ (cid:0)( (cid:0)5 (cid:0)(cid:3)(cid:0)6 (cid:0)( (cid:0)& (cid:0)7 (cid:0), (cid:0)2 (cid:0)1 (cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)7 (cid:0)+ (cid:0)( (cid:0)(cid:3)(cid:0)6 (cid:0)$ (cid:0)5 (cid:0)% (cid:0)$ (cid:0)1 (cid:0)( (cid:0)6 (cid:0)(cid:16)(cid:0)2 (cid:0); (cid:0)/ (cid:0)( (cid:0)< (cid:0)(cid:3)(cid:0)$ (cid:0)& (cid:0)7 (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:21)\n(cid:0)(cid:3)\n(cid:0),(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)5 (cid:0)R (cid:0)E (cid:0)H (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)1 (cid:0)(cid:17)(cid:0)(cid:3)(cid:0): (cid:0)H (cid:0)L(cid:0)Q (cid:0)J (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:0)(cid:20) (cid:0)(cid:17) (cid:0),(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)Y (cid:0)L(cid:0)H (cid:0)Z (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)4 (cid:0)X (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:16)(cid:0)4 (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)[ (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)% (cid:0)L(cid:0)R (cid:0)W(cid:0)H (cid:0)F (cid:0)K (cid:0)Q (cid:0)R (cid:0)O(cid:0)R (cid:0)J (cid:0)\\ (cid:0)(cid:3)(cid:0)+ (cid:0)R (cid:0)O(cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)F (cid:0)(cid:17)(cid:0)(cid:30)\n(cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:21) (cid:0)(cid:17) (cid:0)% (cid:0)D (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)P (cid:0)\\ (cid:0)(cid:3)(cid:0)N (cid:0)Q (cid:0)R (cid:0)Z (cid:0)O(cid:0)H (cid:0)G (cid:0)J (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)G (cid:0)R (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)W(cid:0)U(cid:0)X (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)P (cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)Q (cid:0)H (cid:0)F (cid:0)H (cid:0)V (cid:0)V (cid:0)D (cid:0)U(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)N (cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)G (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)J (cid:0)K (cid:0)W\n(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)L(cid:0)U(cid:0)F (cid:0)X (cid:0)P (cid:0)V (cid:0)W(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)G (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)L(cid:0)V (cid:0)O(cid:0)H (cid:0)D (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:30)\n(cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:22) (cid:0)(cid:17) (cid:0)% (cid:0)D (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)P (cid:0)\\ (cid:0)(cid:3)(cid:0)N (cid:0)Q (cid:0)R (cid:0)Z (cid:0)O(cid:0)H (cid:0)G (cid:0)J (cid:0)H (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)L(cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)\n(cid:0)U(cid:0)H (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)V (cid:0)K (cid:0)(cid:3)(cid:0)I(cid:0)O(cid:0)R (cid:0)Z (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:30)\n(cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:23) (cid:0)(cid:17) (cid:0),(cid:0)(cid:3)(cid:0)D (cid:0)P (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)R (cid:0)Q (cid:0)V (cid:0)L(cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)V (cid:0)W(cid:0)D (cid:0)E (cid:0)O(cid:0)L(cid:0)V (cid:0)K (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)L(cid:0)Q (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)5 (cid:0)X (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:22) (cid:0)D (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)H (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)G (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)H (cid:0)(cid:12)(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U\n(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)5 (cid:0)X (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:22) (cid:0)D (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)I(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)G (cid:0)(cid:16)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)I(cid:0)(cid:12)(cid:0)(cid:12)(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)D (cid:0)(cid:12) (cid:0)’ (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)X (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)P (cid:0)\\ (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)S (cid:0)H (cid:0)U(cid:0)Y (cid:0)L(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O\n(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)O(cid:0)D (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)V (cid:0)R (cid:0)O(cid:0)L(cid:0)G (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)E (cid:0)V (cid:0)L(cid:0)G (cid:0)L(cid:0)D (cid:0)U(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)G (cid:0)H (cid:0)(cid:3)(cid:0)N (cid:0)Q (cid:0)R (cid:0)Z (cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)P (cid:0)H (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)R (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)W(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)D (cid:0)U(cid:0)W(cid:0)L(cid:0)F (cid:0)X (cid:0)O(cid:0)D (cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)G (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q\n(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)S (cid:0)D (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:30)\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)E (cid:0)(cid:12) (cid:0)’ (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3) (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)F (cid:0)D (cid:0)X (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3) (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)E (cid:0)H (cid:0)(cid:3) (cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)X (cid:0)Q (cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)P (cid:0)\\ (cid:0)(cid:3) (cid:0)V (cid:0)X (cid:0)S (cid:0)H (cid:0)U(cid:0)Y (cid:0)L(cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)W(cid:0)R (cid:0)(cid:3) (cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H\n(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)V (cid:0)X (cid:0)U(cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)D (cid:0)U(cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)O(cid:0)L(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)S (cid:0)D (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)H (cid:0)[ (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)S (cid:0)R (cid:0)V (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)F (cid:0)R (cid:0)U(cid:0)G (cid:0)D (cid:0)Q (cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)J (cid:0)H (cid:0)Q (cid:0)H (cid:0)U(cid:0)D (cid:0)O(cid:0)O(cid:0)\\\n(cid:0)D (cid:0)F (cid:0)F (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)D (cid:0)F (cid:0)F (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)L(cid:0)Q (cid:0)F (cid:0)L(cid:0)S (cid:0)O(cid:0)H (cid:0)V (cid:0)(cid:30)\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)F (cid:0)(cid:12) (cid:0)( (cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)D (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)P (cid:0)\\ (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)F (cid:0)O(cid:0)X (cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)R (cid:0)X (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)X (cid:0)U(cid:0)H\n(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)G (cid:0)X (cid:0)U(cid:0)H (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)E (cid:0)D (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:30)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)G (cid:0)(cid:12) (cid:0)’ (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3) (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3) (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3) (cid:0)R (cid:0)F (cid:0)F (cid:0)X (cid:0)U(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3) (cid:0)G (cid:0)X (cid:0)U(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3) (cid:0)P (cid:0)R (cid:0)V (cid:0)W(cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)F (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)I(cid:0)L(cid:0)V (cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)T (cid:0)X (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)X (cid:0)U(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)V (cid:0)F (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)T (cid:0)X (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)F (cid:0)D (cid:0)V (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)Q (cid:0)X (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)N (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O\n(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:30)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)(cid:3)\n(cid:0)(cid:24) (cid:0)(cid:17) (cid:0),(cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)L(cid:0)V (cid:0)F (cid:0)O(cid:0)R (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)E (cid:0)D (cid:0)V (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)P (cid:0)\\ (cid:0)(cid:3)(cid:0)P (cid:0)R (cid:0)V (cid:0)W(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)H (cid:0)Y (cid:0)D (cid:0)O(cid:0)X (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)G (cid:0)L(cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)X (cid:0)G (cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)P (cid:0)L(cid:0)W(cid:0)W(cid:0)H (cid:0)H (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)% (cid:0)R (cid:0)D (cid:0)U(cid:0)G\n(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)’ (cid:0)L(cid:0)U(cid:0)H (cid:0)F (cid:0)W(cid:0)R (cid:0)U(cid:0)V (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)V (cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)Y (cid:0)D (cid:0)O(cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)Q (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:12)(cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)D (cid:0)(cid:12) (cid:0)$ (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)I(cid:0)L(cid:0)F (cid:0)L(cid:0)H (cid:0)Q (cid:0)F (cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)Z (cid:0)H (cid:0)D (cid:0)N (cid:0)Q (cid:0)H (cid:0)V (cid:0)V (cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)Z (cid:0)K (cid:0)L(cid:0)F (cid:0)K (cid:0)(cid:3)(cid:0)D (cid:0)U(cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)D (cid:0)V (cid:0)R (cid:0)Q (cid:0)D (cid:0)E (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)O(cid:0)L(cid:0)N (cid:0)H (cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)D (cid:0)G (cid:0)Y (cid:0)H (cid:0)U(cid:0)V (cid:0)H (cid:0)O(cid:0)\\\n(cid:0)D (cid:0)I(cid:0)I(cid:0)H (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)E (cid:0)L(cid:0)O(cid:0)L(cid:0)W(cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)F (cid:0)R (cid:0)U(cid:0)G (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)F (cid:0)H (cid:0)V (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)V (cid:0)X (cid:0)P (cid:0)P (cid:0)D (cid:0)U(cid:0)L(cid:0)] (cid:0)H (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:30)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)\n(cid:0)(cid:3) (cid:0)(cid:11)(cid:0)E (cid:0)(cid:12) (cid:0)$ (cid:0)Q (cid:0)\\ (cid:0)(cid:3) (cid:0)I(cid:0)U(cid:0)D (cid:0)X (cid:0)G (cid:0)(cid:15)(cid:0)(cid:3) (cid:0)Z (cid:0)K (cid:0)H (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)Q (cid:0)R (cid:0)W(cid:0)(cid:3) (cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:15)(cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)Y (cid:0)R (cid:0)O(cid:0)Y (cid:0)H (cid:0)V (cid:0)(cid:3) (cid:0)P (cid:0)D (cid:0)Q (cid:0)D (cid:0)J (cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)R (cid:0)U(cid:0)(cid:3) (cid:0)R (cid:0)W(cid:0)K (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)H (cid:0)P (cid:0)S (cid:0)O(cid:0)R (cid:0)\\ (cid:0)H (cid:0)H (cid:0)V (cid:0)(cid:3) (cid:0)Z (cid:0)K (cid:0)R (cid:0)(cid:3) (cid:0)K (cid:0)D (cid:0)Y (cid:0)H (cid:0)(cid:3) (cid:0)D (cid:0)(cid:3) (cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)L(cid:0)I(cid:0)L(cid:0)F (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3) (cid:0)U(cid:0)R (cid:0)O(cid:0)H (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)(cid:3) (cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3) (cid:0)U(cid:0)H (cid:0)J (cid:0)L(cid:0)V (cid:0)W(cid:0)U(cid:0)D (cid:0)Q (cid:0)W(cid:0)¶(cid:0)V (cid:0)(cid:3) (cid:0)L(cid:0)Q (cid:0)W(cid:0)H (cid:0)U(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3) (cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)U(cid:0)R (cid:0)O(cid:0)(cid:3) (cid:0)R (cid:0)Y (cid:0)H (cid:0)U(cid:0)(cid:3) (cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O\n(cid:0)U(cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)’ (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:29)(cid:0)(cid:3)(cid:0)1 (cid:0)R (cid:0)Y (cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:21) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)% (cid:0)\\ (cid:0)(cid:29) (cid:0)(cid:18)(cid:0)V (cid:0)(cid:18)(cid:0)(cid:3)(cid:0)5 (cid:0)2 (cid:0)% (cid:0)( (cid:0)5 (cid:0)7 (cid:0)(cid:3)(cid:0)1 (cid:0)(cid:17)(cid:0)(cid:3)(cid:0): (cid:0)( (cid:0),(cid:0)1 (cid:0)* (cid:0)$ (cid:0)5 (cid:0)7 (cid:0)( (cid:0)1\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)5 (cid:0)R (cid:0)E (cid:0)H (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)1 (cid:0)(cid:17)(cid:0)(cid:3)(cid:0): (cid:0)H (cid:0)L(cid:0)Q (cid:0)J (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)Q\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)9 (cid:0)L(cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)V (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)& (cid:0)K (cid:0)L(cid:0)H (cid:0)I(cid:0)(cid:3)(cid:0)) (cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:11)(cid:0)3 (cid:0)U(cid:0)L(cid:0)Q (cid:0)F (cid:0)L(cid:0)S (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)) (cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)F (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:12)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)( (cid:0)[ (cid:0)K (cid:0)L(cid:0)E (cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:21) (cid:0)(cid:17)(cid:0)(cid:20)\n(cid:0)(cid:3)\n(cid:0)& (cid:0)( (cid:0)5 (cid:0)7 (cid:0), (cid:0)) (cid:0), (cid:0)& (cid:0)$ (cid:0)7 (cid:0), (cid:0)2 (cid:0)1 (cid:0)6 (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)& (cid:0)+ (cid:0), (cid:0)( (cid:0)) (cid:0)(cid:3)(cid:0)( (cid:0); (cid:0)( (cid:0)& (cid:0)8 (cid:0)7 (cid:0), (cid:0)9 (cid:0)( (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)) (cid:0), (cid:0)& (cid:0)( (cid:0)5\n(cid:0)8 (cid:0)1 (cid:0)’ (cid:0)( (cid:0)5 (cid:0)(cid:3)(cid:0)6 (cid:0)( (cid:0)& (cid:0)7 (cid:0), (cid:0)2 (cid:0)1 (cid:0)(cid:3)(cid:0)(cid:28) (cid:0)(cid:19) (cid:0)(cid:25) (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)7 (cid:0)+ (cid:0)( (cid:0)(cid:3)(cid:0)6 (cid:0)$ (cid:0)5 (cid:0)% (cid:0)$ (cid:0)1 (cid:0)( (cid:0)6 (cid:0)(cid:16)(cid:0)2 (cid:0); (cid:0)/ (cid:0)( (cid:0)< (cid:0)(cid:3)(cid:0)$ (cid:0)& (cid:0)7 (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:21)\n(cid:0)(cid:3)\n(cid:0),(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)% (cid:0)D (cid:0)V (cid:0)W(cid:0)L(cid:0)D (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)Y (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)% (cid:0)D (cid:0)D (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)K (cid:0)L(cid:0)H (cid:0)I(cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)H (cid:0)F (cid:0)X (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)[ (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)% (cid:0)L(cid:0)R (cid:0)W(cid:0)H (cid:0)F (cid:0)K (cid:0)Q (cid:0)R (cid:0)O(cid:0)R (cid:0)J (cid:0)\\ (cid:0)(cid:3)(cid:0)+ (cid:0)R (cid:0)O(cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)F (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)(cid:11)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)‡ (cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)· (cid:0)(cid:12)(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:28) (cid:0)(cid:19) (cid:0)(cid:25) (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)D (cid:0)U(cid:0)E (cid:0)D (cid:0)Q (cid:0)H (cid:0)V (cid:0)(cid:16)(cid:0)2 (cid:0)[ (cid:0)O(cid:0)H (cid:0)\\\n(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:27) (cid:0)(cid:3)(cid:0)8 (cid:0)(cid:17)(cid:0)6 (cid:0)(cid:17)(cid:0)& (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:22) (cid:0)(cid:24) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:0)(cid:11)(cid:0)L(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)4 (cid:0)X (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:16)(cid:0)4 (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)T (cid:0)X (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)‡ (cid:0)5 (cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)· (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)S (cid:0)O(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I\n(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:22) (cid:0)(cid:11)(cid:0)D (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)G (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:28) (cid:0)(cid:22) (cid:0)(cid:23) (cid:0)(cid:30)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)(cid:3)\n(cid:0)(cid:11)(cid:0)L(cid:0)L(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)L(cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)$ (cid:0)(cid:3)(cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)L(cid:0)J (cid:0)L(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)U(cid:0)L(cid:0)W(cid:0)W(cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:28) (cid:0)(cid:19) (cid:0)(cid:25) (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)U(cid:0)Q (cid:0)L(cid:0)V (cid:0)K (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)6 (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)P (cid:0)L(cid:0)V (cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)I(cid:0)I(cid:0)(cid:3)(cid:0)X (cid:0)S (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)H (cid:0)V (cid:0)W(cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)’ (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:29)(cid:0)(cid:3)(cid:0)1 (cid:0)R (cid:0)Y (cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:21) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)% (cid:0)\\ (cid:0)(cid:29) (cid:0)(cid:18)(cid:0)V (cid:0)(cid:18)(cid:0)(cid:3)(cid:0)% (cid:0)$ (cid:0)6 (cid:0)7 (cid:0),(cid:0)$ (cid:0)$ (cid:0)1 (cid:0)(cid:3)(cid:0)9 (cid:0)$ (cid:0)1 (cid:0)(cid:3)(cid:0)’ (cid:0)( (cid:0)5 (cid:0)(cid:3)(cid:0)% (cid:0)$ (cid:0)$ (cid:0)1\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)% (cid:0)D (cid:0)V (cid:0)W(cid:0)L(cid:0)D (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)Y (cid:0)D (cid:0)Q (cid:0)(cid:3)(cid:0)G (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)% (cid:0)D (cid:0)D (cid:0)Q\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)3 (cid:0)U(cid:0)H (cid:0)V (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)& (cid:0)K (cid:0)L(cid:0)H (cid:0)I(cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)H (cid:0)F (cid:0)X (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:11)(cid:0)3 (cid:0)U(cid:0)L(cid:0)Q (cid:0)F (cid:0)L(cid:0)S (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)H (cid:0)F (cid:0)X (cid:0)W(cid:0)L(cid:0)Y (cid:0)H (cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:12)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)( (cid:0)[ (cid:0)K (cid:0)L(cid:0)E (cid:0)L(cid:0)W(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:21) (cid:0)(cid:17)(cid:0)(cid:21)\n(cid:0)(cid:3)\n(cid:0)& (cid:0)( (cid:0)5 (cid:0)7 (cid:0), (cid:0)) (cid:0), (cid:0)& (cid:0)$ (cid:0)7 (cid:0), (cid:0)2 (cid:0)1 (cid:0)6 (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)& (cid:0)+ (cid:0), (cid:0)( (cid:0)) (cid:0)(cid:3)(cid:0)) (cid:0), (cid:0)1 (cid:0)$ (cid:0)1 (cid:0)& (cid:0), (cid:0)$ (cid:0)/ (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)) (cid:0), (cid:0)& (cid:0)( (cid:0)5\n(cid:0)8 (cid:0)1 (cid:0)’ (cid:0)( (cid:0)5 (cid:0)(cid:3)(cid:0)6 (cid:0)( (cid:0)& (cid:0)7 (cid:0), (cid:0)2 (cid:0)1 (cid:0)(cid:3)(cid:0)(cid:28) (cid:0)(cid:19) (cid:0)(cid:25) (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)7 (cid:0)+ (cid:0)( (cid:0)(cid:3)(cid:0)6 (cid:0)$ (cid:0)5 (cid:0)% (cid:0)$ (cid:0)1 (cid:0)( (cid:0)6 (cid:0)(cid:16)(cid:0)2 (cid:0); (cid:0)/ (cid:0)( (cid:0)< (cid:0)(cid:3)(cid:0)$ (cid:0)& (cid:0)7 (cid:0)(cid:3)(cid:0)2 (cid:0)) (cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:21)\n(cid:0)(cid:3)\n(cid:0),(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)5 (cid:0)R (cid:0)E (cid:0)H (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)1 (cid:0)(cid:17)(cid:0)(cid:3)(cid:0): (cid:0)H (cid:0)L(cid:0)Q (cid:0)J (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)Q (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)K (cid:0)L(cid:0)H (cid:0)I(cid:0)(cid:3)(cid:0)) (cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)/ (cid:0)L(cid:0)[ (cid:0)W(cid:0)H (cid:0)(cid:3)(cid:0)% (cid:0)L(cid:0)R (cid:0)W(cid:0)H (cid:0)F (cid:0)K (cid:0)Q (cid:0)R (cid:0)O(cid:0)R (cid:0)J (cid:0)\\ (cid:0)(cid:3)(cid:0)+ (cid:0)R (cid:0)O(cid:0)G (cid:0)L(cid:0)Q (cid:0)J (cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0),(cid:0)Q (cid:0)F (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)(cid:11)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)‡ (cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)· (cid:0)(cid:12)(cid:0)(cid:15)(cid:0)(cid:3)(cid:0)F (cid:0)H (cid:0)U(cid:0)W(cid:0)L(cid:0)I(cid:0)\\ (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)S (cid:0)X (cid:0)U(cid:0)V (cid:0)X (cid:0)D (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:28) (cid:0)(cid:19) (cid:0)(cid:25) (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)D (cid:0)U(cid:0)E (cid:0)D (cid:0)Q (cid:0)H (cid:0)V (cid:0)(cid:16)(cid:0)2 (cid:0)[ (cid:0)O(cid:0)H (cid:0)\\\n(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:27) (cid:0)(cid:3)(cid:0)8 (cid:0)(cid:17)(cid:0)6 (cid:0)(cid:17)(cid:0)& (cid:0)(cid:17)(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:22) (cid:0)(cid:24) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)D (cid:0)W(cid:0)(cid:29)\n(cid:0)(cid:3)\n(cid:0)(cid:11)(cid:0)L(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)4 (cid:0)X (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)) (cid:0)R (cid:0)U(cid:0)P (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:19) (cid:0)(cid:16)(cid:0)4 (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)I(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)T (cid:0)X (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)H (cid:0)U(cid:0)L(cid:0)R (cid:0)G (cid:0)(cid:3)(cid:0)H (cid:0)Q (cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)S (cid:0)W(cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:22) (cid:0)(cid:19) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)(cid:3)(cid:0)(cid:11)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)‡ (cid:0)5 (cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)· (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)O(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)P (cid:0)S (cid:0)O(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)W(cid:0)K (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I\n(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:22) (cid:0)(cid:11)(cid:0)D (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:24) (cid:0)(cid:11)(cid:0)G (cid:0)(cid:12)(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)W(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:28) (cid:0)(cid:22) (cid:0)(cid:23) (cid:0)(cid:30)(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G\n(cid:0)(cid:3)\n(cid:0)(cid:11)(cid:0)L(cid:0)L(cid:0)(cid:12)(cid:0)(cid:3)(cid:0)7 (cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)I(cid:0)R (cid:0)U(cid:0)P (cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)5 (cid:0)H (cid:0)S (cid:0)R (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)I(cid:0)D (cid:0)L(cid:0)U(cid:0)O(cid:0)\\ (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)H (cid:0)V (cid:0)H (cid:0)Q (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)L(cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)P (cid:0)D (cid:0)W(cid:0)H (cid:0)U(cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)S (cid:0)H (cid:0)F (cid:0)W(cid:0)V (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)I(cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)F (cid:0)R (cid:0)Q (cid:0)G (cid:0)L(cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)V (cid:0)X (cid:0)O(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)R (cid:0)S (cid:0)H (cid:0)U(cid:0)D (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)V (cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)$ (cid:0)(cid:3)(cid:0)V (cid:0)L(cid:0)J (cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)L(cid:0)J (cid:0)L(cid:0)Q (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)R (cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)L(cid:0)V (cid:0)(cid:3)(cid:0)Z (cid:0)U(cid:0)L(cid:0)W(cid:0)W(cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)W(cid:0)H (cid:0)P (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)L(cid:0)U(cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)6 (cid:0)H (cid:0)F (cid:0)W(cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)(cid:28) (cid:0)(cid:19) (cid:0)(cid:25) (cid:0)(cid:3)(cid:0)K (cid:0)D (cid:0)V (cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)H (cid:0)Q (cid:0)(cid:3)(cid:0)S (cid:0)U(cid:0)R (cid:0)Y (cid:0)L(cid:0)G (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)Z (cid:0)L(cid:0)O(cid:0)O(cid:0)(cid:3)(cid:0)E (cid:0)H (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)W(cid:0)D (cid:0)L(cid:0)Q (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)E (cid:0)\\ (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)S (cid:0)D (cid:0)Q (cid:0)\\ (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)I(cid:0)X (cid:0)U(cid:0)Q (cid:0)L(cid:0)V (cid:0)K (cid:0)H (cid:0)G (cid:0)(cid:3)(cid:0)W(cid:0)R (cid:0)(cid:3)(cid:0)W(cid:0)K (cid:0)H\n(cid:0)6 (cid:0)H (cid:0)F (cid:0)X (cid:0)U(cid:0)L(cid:0)W(cid:0)L(cid:0)H (cid:0)V (cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)( (cid:0)[ (cid:0)F (cid:0)K (cid:0)D (cid:0)Q (cid:0)J (cid:0)H (cid:0)(cid:3)(cid:0)& (cid:0)R (cid:0)P (cid:0)P (cid:0)L(cid:0)V (cid:0)V (cid:0)L(cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)R (cid:0)U(cid:0)(cid:3)(cid:0)L(cid:0)W(cid:0)V (cid:0)(cid:3)(cid:0)V (cid:0)W(cid:0)D (cid:0)I(cid:0)I(cid:0)(cid:3)(cid:0)X (cid:0)S (cid:0)R (cid:0)Q (cid:0)(cid:3)(cid:0)U(cid:0)H (cid:0)T (cid:0)X (cid:0)H (cid:0)V (cid:0)W(cid:0)(cid:17)\n(cid:0)(cid:3)\n(cid:0)’ (cid:0)D (cid:0)W(cid:0)H (cid:0)(cid:29)(cid:0)(cid:3)(cid:0)1 (cid:0)R (cid:0)Y (cid:0)H (cid:0)P (cid:0)E (cid:0)H (cid:0)U(cid:0)(cid:3)(cid:0)(cid:20) (cid:0)(cid:21) (cid:0)(cid:15)(cid:0)(cid:3)(cid:0)(cid:21) (cid:0)(cid:19) (cid:0)(cid:21) (cid:0)(cid:23) (cid:0)% (cid:0)\\ (cid:0)(cid:29) (cid:0)(cid:18)(cid:0)V (cid:0)(cid:18)(cid:0)(cid:3)(cid:0)5 (cid:0)2 (cid:0)% (cid:0)( (cid:0)5 (cid:0)7 (cid:0)(cid:3)(cid:0)1 (cid:0)(cid:17)(cid:0)(cid:3)(cid:0): (cid:0)( (cid:0),(cid:0)1 (cid:0)* (cid:0)$ (cid:0)5 (cid:0)7 (cid:0)( (cid:0)1\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)5 (cid:0)R (cid:0)E (cid:0)H (cid:0)U(cid:0)W(cid:0)(cid:3)(cid:0)1 (cid:0)(cid:17)(cid:0)(cid:3)(cid:0): (cid:0)H (cid:0)L(cid:0)Q (cid:0)J (cid:0)D (cid:0)U(cid:0)W(cid:0)H (cid:0)Q\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)9 (cid:0)L(cid:0)F (cid:0)H (cid:0)(cid:3)(cid:0)3 (cid:0)U(cid:0)H (cid:0)V (cid:0)L(cid:0)G (cid:0)H (cid:0)Q (cid:0)W(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)& (cid:0)K (cid:0)L(cid:0)H (cid:0)I(cid:0)(cid:3)(cid:0)) (cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U\n(cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:11)(cid:0)3 (cid:0)U(cid:0)L(cid:0)Q (cid:0)F (cid:0)L(cid:0)S (cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)) (cid:0)L(cid:0)Q (cid:0)D (cid:0)Q (cid:0)F (cid:0)L(cid:0)D (cid:0)O(cid:0)(cid:3)(cid:0)D (cid:0)Q (cid:0)G (cid:0)(cid:3)(cid:0)$ (cid:0)F (cid:0)F (cid:0)R (cid:0)X (cid:0)Q (cid:0)W(cid:0)L(cid:0)Q (cid:0)J (cid:0)(cid:3)(cid:0)2 (cid:0)I(cid:0)I(cid:0)L(cid:0)F (cid:0)H (cid:0)U(cid:0)(cid:12)\n(cid:0)(cid:3)\n(cid:0)(cid:3)\n(cid:0)(cid:3)"
        },
        {
          "title": "View 10-K",
          "url": "https://ir.lixte.com/sec-filings/all-sec-filings/content/0001493152-24-010427/0001493152-24-010427.pdf",
          "content": ""
        }
      ]
    },
    {
      "section_name": "Presentations",
      "links": [
        {
          "title": "View Presentation",
          "url": "https://d1io3yog0oux5.cloudfront.net/_dc5892ca2b7f04aeb93d8225863bdadd/lixte/db/1159/10981/pdf/Lixte+Corporate+Presentation+August+2024.pdf",
          "content": ""
        }
      ]
    },
    {
      "section_name": "Investor Events",
      "links": [
        {
          "title": "View Event",
          "url": "https://ir.lixte.com/news-events/ir-calendar/detail/20241219-2024-annual-meeting-of-stockholders",
          "content": ""
        }
      ]
    }
  ]
}